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Loss of muscle mass and function, termed sarcopenia, occurs commonly with 
advancing age. This loss of strength can have a profound impacts on an 
individual’s life expectancy and quality of life. Population genetic studies can 
provide information on underlying biological mechanisms, but little was known 
about the genetic contributions to sarcopenia.  
By using data from multi-national community based studies of 256,523 individuals 
of European ancestry aged 60 years or older I have identified 15 genomic risk 
loci for muscle weakness with age. I have shown that the genetic contributions to 
muscle weakness in later life have novel characteristics not seen in studies of 
muscle strength at younger ages. I have also shown that for a section of the older 
population meeting the criteria for sarcopenia, there is a substantial auto-immune 
component separate from diagnosed autoimmune conditions, such as 
Rheumatoid arthritis. Analysis of sex-specific cohorts has highlighted that the 
underlying genetics contributing to muscle weakness with age differ between the 
sexes. Additional research on the shared pathways between age-related traits 
and muscle weakness with age has shown that diabetes, rheumatoid arthritis and 
life courses traits, for example birth weight, share at least some of the same 
biological pathways. Biological pathways implicated included transcription 
regulation, processing of misfolded proteins, cell growth and development. 
In conclusion I have identified several common genetic variants associated with 
sarcopenia in humans, which has highlighted an autoimmune component and 
several shared casual pathways with traits ranging from life-course and growth 
traits through to later life conditions such as Rheumatoid arthritis and diabetes. 
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These findings should inform efforts to prevent and treat muscle loss with 
advancing age, and may more personalised approaches to intervention.    
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1.1 The ageing process 
Ageing has been described as the accumulation of molecular and cellular 
damage over time (D. Harman 1981; Denham Harman 1992). In the multicellular 
organisms, such as humans, this process is characterised by a gradual decrease 
in physical and mental capacity, an increased risk of multi-morbidity and then 
finally death (López-Otín et al. 2013). Benjamin Gompertz described aging as a 
process leading to an exponential increase in mortality over time (Gompertz 
1825). The Gompertz model as the “law of mortality” has been superseded by an 
appreciation that other models exist across a range of different species (O. R. 
Jones et al. 2014), however it’s simple intrinsic message that for much of the 
adult human lifespan, age-specific mortality rates increase exponentially is still 
relevant (Kirkwood 2015). 
One of the hallmarks of human ageing is the progressive loss of muscle, and the 
increased risk of associated musculoskeletal disorders of ageing, such as frailty. 
Musculoskeletal (MSK) ageing itself has been defined by Dawson et al, as 
comprising of four components; osteoporosis, osteoarthritis, sarcopenia and 
frailty (Dawson and Dennison 2016). These conditions have been shown to have 
a substantial impact on individual mobility, pain and disability (Leveille 2004; Blyth 
and Noguchi 2017). Osteoarthritis and Osteoporosis have been intensively 
analysed in the UK Biobank dataset (Zengini et al. 2018; Kemp et al. 2017), 
however lesser studied components such as sarcopenia and frailty are just as 




Sarcopenia has been characterised as the age-related loss of skeletal muscle 
mass and function (Cruz-Jentoft et al. 2010, 2019). Sarcopenia, as defined by the 
Foundation for the National Institutes of Health criteria (grip strength less than 26 
Kg in men and under 16 Kg in women) (S. A. Studenski et al. 2014) has been 
estimated to increase UK healthcare costs by £2.5 billion (Pinedo-Villanueva et 
al. 2019). In addition, sarcopenia has been associated with a higher risk of all-
cause mortality (Beaudart et al. 2017) and functional decline (Beaudart et al. 
2017). As increasing life expectancy results in a larger aging population, with 
increased risks of multi-morbidity, hospitalisation, and premature death, later life 
conditions such as frailty and sarcopenia have become more common and of 
greater impact to the health system. 
In this chapter I will discuss the background to the musculoskeletal system ageing 
process, alongside the underlying mechanisms. I will outline the relationship 
between loss muscle mass and reduced function, and how these components of 
sarcopenia relate to frailty and health in older adults, and the methods for defining 
these conditions. The impact of these age related conditions will also be 
discussed. Finally I will outline the specific aims of my thesis, which included 




1.2 Sarcopenia and dynapenia 
The name sarcopenia (Greek ‘sarcx’ or flesh and ‘penia’ or loss) was proposed 
in 1989 by Rosenberg (I. H. Rosenberg 1997). However it is only since 2016 that 
sarcopenia has been recognised as an independent condition by the International 
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Classification of Diseases, with an ICD-10 code of M62.84 (“ICD-10 
Version:2019” n.d.). 
The health burden of musculoskeletal disorders such as sarcopenia, rheumatoid 
arthritis, osteoarthritis and frailty are substantial with the conditions associated 
with incident disability and an increased risk of co-morbidities (Choong and 
Brooks 2012; Duffield et al. 2017).  
Low muscle strength in mid-life has been shown to be strongly predictive of later 
life disability (T. Rantanen 2003) with musculoskeletal (MSK) disorders being a 
major cause of Years Lived with Disability (YLDs) (Vos et al. 2012), and a 
recognised global health burden, whose full impact is often underestimated (Hoy 
et al. 2015).The Milan EXPO survey highlighted that it is physical performance 
rather than muscle mass that decreases more rapidly with age. Individuals older 
than 75 years have approximately 60% of their muscle strength and 30% of their 
function (Francesco Landi et al. 2017). 
Sarcopenic individuals over the age of 80, have a substantially higher mortality 
risk (HR: 2.32, 95% CI:1.01-5.43) when compared to controls without sarcopenia 
(F. Landi et al. 2013). In addition the economic impact of sarcopenia is 
substantial, with a recent estimate of the cost of hospitalisations in the US for 





1.2.1 European Working Group on Sarcopenia in Older People 
The European Working Group on Sarcopenia in Older People (EWGSOP) 
published their first definition of Sarcopenia in 2010 (Cruz-Jentoft et al. 2010), 
followed by a revised version in 2019 (Cruz-Jentoft et al. 2019). This allowed the 
characterisation of sarcopenia as a syndrome with progressive generalised loss 
of skeletal muscle and function, which increased risk of physical disability, a 
lowered quality of life, and multi-morbidities resulting in death. 
In the original definition, sarcopenia was diagnosed by low muscle mass (Skeletal 
Mass Index – SMI 7.26 Kg/m2 for males and 5.5 kg/m2 for females), plus the 
presence of either/or low muscle strength (handgrip strength - < 30 Kg for males 
and < 20 Kg for females) and low physical performance (Figure 1-1). 
The low muscle mass measured by dual-energy X-ray absorptiometry (DEXA) 
had a cut-off derived from 2 standard deviations below the mean Skeletal Mass 
Index (SMI) based on measurements from 229 non-Hispanic white men and 
women aged 18-40 years of age who were participants in the Rosetta study 
(1986-1992) (Cruz-Jentoft et al. 2010; Baumgartner et al. 1998). While low grip 
strength, a clinical predictor of loss of muscle function, was defined based on 2 
standard deviations below the mean based measured in 1,030 (469 mean and 
561 women) participants from the InCHIANTI study by isometric dynamometry 





Figure 1-1 : EWGSOP (2010) flowchart for defining sarcopenia 
 
* Comorbidity and individual circumstances must also be considered, Adapted 






Figure 1-2 : EWGSOP2 (2019) flowchart for defining sarcopenia 




The European Working Group on Sarcopenia in Older People was revised in 
2019 (Cruz-Jentoft et al. 2019), with the introduction of the SARC-F questionnaire 
(Malmstrom et al. 2016; Gülistan Bahat et al. 2018) (discussed in more detail in 
section 1.4.2 1.2.4 Additional definitions of sarcopenia) and expanded on the 
concepts of probable sarcopenia and severe sarcopenia (Figure 1-2). The 
original 2010 definition included the categorisation of sarcopenia into 
“Presarcopenia”, “Sarcopenia” and “Severe sarcopenia” (Cruz-Jentoft et al. 2010) 
as shown in Table 1-1: 
Table 1-1 : EWGSOP1 Stages of sarcopenia 
Stage Muscle Mass Muscle Strength Performance 
 CT / MRI / DEXA / 
BIA / Total 
potassium 
Handgrip strength / 
Knee flexion / Peak 
expiratory flow 
SPPB / Usual gait 
speed / Timed get up 
and go test / Stair climb 
test 
Presarcopenia Low   
Sarcopenia Low Low Low 
Severe 
sarcopenia 
Low Low Low 
EWGSOP1 (2010) definition, sarcopenia can be characterised by the loss of muscle mass and 
either muscle strength or performance (Cruz-Jentoft et al. 2010). CT=Computed tomography; 
MRI=Magnetic resonance imaging; DEXA=Dual energy X-ray absorptiometry; BIA= 
Bioimpedance analysis 
 
Under the EWGSOP1 definition, pre-sarcopenia is characterised by low muscle 
mass without any particular loss of function or performance. This is identified by 
accurate measurement of muscle mass loss, such as by Dual-energy X-ray 
absorptiometry (DEXA) or Bioimpedance analysis (BIA). Sarcopenia itself 




strength (for example of handgrip strength via a Dynameter, or Knee flexion) or 
a low score on tests measuring physical performance (for example the Short 
Physical Performance Battery – SPPB (JM et al. 1994)), see Table 1-2. 
Table 1-2 : Measurements of muscle mass and function in research and practice 
Variable  Research  Clinical practice  
Muscle mass  Computed tomography (CT)  BIA  
Magnetic resonance imaging (MRI)  DXA  
Dual energy X-ray absorptiometry (DEXA)  Anthropometry  
Bioimpedance analysis (BIA)  
Total or partial body potassium per fat-free soft tissue  
Muscle 
strength  
Handgrip strength  Handgrip strength  
Knee flexion/extension  
Peak expiratory flow  
Physical 
performance  
Short Physical Performance Battery (SPPB)  SPPB  
Usual gait speed  
Usual gait speed  Get-up-and-go test  
Timed get-up-and-go test  
Stair climb power test  
(Cruz-Jentoft et al. 2010) 
The EWGSOP updated the original definition of sarcopenia at a meeting in early 
2018, releasing their new definition in 2019. This was to reflect the substantial 
additional clinical evidence and scientific feedback from the initial EWGSOP 
definition of 2010 (Cruz-Jentoft et al. 2019).  
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Four areas were mentioned specifically: 
1) Recognition that although sarcopenia is still a condition associated with 
ageing and older people, that it can begin earlier in life and that it has 
multifactorial causes (Sayer et al. 2004, 2008). 
2) Low muscle strength and functional has been shown to be more important 
component of sarcopenia than the loss of muscle mass. 
3) Muscle mass and muscle quality can be difficult to measure accurately. 
4) Clearer diagnostic criteria and cut-offs were required for use in the 
mainstream medical practice. 
The updated 2019 definition, EWGSOP2, instead of “pre-sarcopenia” identifies 
“probable sarcopenia” as reduced handgrip strength and/or increased time on the 
five times chair stand test (> 15 seconds). The additional observation of a low 
Skeletal Mass Index is required to confirm sarcopenia. Severe sarcopenia is once 
again indicated by a combination of the three metrics of low muscle strength, 
quantity and physical performance (Cruz-Jentoft et al. 2019). 
 
1.2.2 Foundation for the National Institutes of Health 
In 2012 the Foundation for the National Institutes of Health (FNIH) sarcopenia 
project published a series of guidelines for their definition of sarcopenia (S. A. 
Studenski et al. 2014). The primary outcome selected for sarcopenia was mobility 
impairment, as measured by gait speed. A gait speed of less than or equal to 0.8 
m/s was used as the primary cut-point due to its impact on overall survival (S. 
Studenski et al. 2011) and disability (Abellan Van Kan et al. 2009). 
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The FNIH aggregated data from nine cohorts (26,625 participants; mean age – 
male: 75.2 years, mean age – female: 78.6 years) in order to derive their cut-
points for sarcopenia.  
For both the low grip strength and appendicular lean mass (ALM), Classification 
and Regression Trees (CART), or decision tree analysis was used to recursively 
partition participants into mutually exclusive groups. These groups are defined by 
a predictor cut-point range within which participants have similar outcome 
probabilities (Breiman et al. 1984). The outcomes used for the FNIH definition 
being prevalence of slowness and then maximum grip strength. 
Cross validation was used to select the cut-points for both the grip and lean mass 
CART analyses. The pooled data was randomly partitioned into 10 equally sized 
mutually exclusive subsets. Each of these subsets, containing 90% of the data, 
were analysed by the decision tree. The prediction error from each of the subsets 
was calculated and the tree pruned in order to select the nodes with the smallest 
prediction error (Alley et al. 2014; Cawthon et al. 2014) - Figure 1-3. 
The grip strength cut-offs used pooled data from 9,897 men and 10,950 women 
(Alley et al. 2014), while for the low appendicular lean mass data from 7,582 men 




Figure 1-3 : Classification tree for FNIH gait speed and grip strength 
(Alley et al. 2014) 
 
 
The odds ratio of mobility impairment, as measured by low gait speed, for males 
with a grip strength of less than 26 Kg was 7.6 (CI 95% 6.1-9.5) when compared 
to men with normal grip strength (≥ 32 Kg). For women the odds ratio for low gait 
speed with a low grip strength of less than 16 Kg was 4.4 (CI 95% 3.9-5.0). 
For ALM the odds ratio of weakness, as measured by low grip strength, was 6.9 
(CI 95% 5.4-8.9) for men and 3.6 (CI 95% 2.9-4.3) for women. 
The definition proposes a gait speed of less than 0.8 m/s with less than 26Kg grip 
strength for men and less than 16 Kg for women, in addition to a low lean 
appendicular muscle mass (adjusted for BMI) of less than 0.789 for men and less 




Table 1-3 : FNIH cut-points for Weakness and Low Lean Mass in Men and 
Women 
Cutpoint Men Women 
Weakness 
Recommended: grip strength (GSMAX) <26 kg <16 kg 
Alternate: grip strength adjusted for BMI 
(GSMAXBMI) 
<1.0 <0.56 
Appendicular lean body mass 
Recommended: ALM adjusted for BMI (ALMBMI) <0.789 <0.512 
Alternate: ALM <19.75 kg <15.02 kg 
Notes: ALM = appendicular lean mass; BMI = body mass index. (S. A. Studenski et al. 2014) 
 
1.2.3 International definitions of sarcopenia 
 
In 2014 the Asian Working Group for Sarcopenia (AWGS) published a report on 
specific diagnostic cut-offs for the definition of sarcopenia in Asian populations 
(L.-Y. K. L.-K. Y. Chen et al. 2014).  
Recommended cut-offs for lean muscle mass derived from DEXA were 7.0 Kg/m2 
for men and 5.4 Kg/m2 for women. Bio-impedance analysis (BIA) suggested 7.0 
Kg/m2 for men and 5.7 Kg/m2 for women. In addition a gait speed of less than 
0.8 m/s and low handgrip strength (less than 26 Kg for men and less than 18 Kg 
for women) were also found to indicate sarcopenia in Asian participants. As the 
published work highlights there is a wide range of ethnicities in Asia, when 
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compared to the single northern European lineage which is often the focus of 
diagnostic criteria (L.-Y. K. L.-K. Y. Chen et al. 2014), and the AWGS 
acknowledge these limitations in proposing their definitions for sarcopenia 
(Figure 1-4). 
 
Figure 1-4 : AWGS (2014) flowchart for defining sarcopenia 
Adapted from (L.-Y. K. L.-K. Y. Chen et al. 2014) 
There is currently no single recognised set of definitive criteria for sarcopenia, 
with definitions being provided by a number of consortia. As noted by the AWGS 
in their 2014 definition, the proposed cut-offs for defining sarcopenia for the Asian 
population follows similar methodology for measuring physical performance but 
provides different cut-offs to the definitions for the European population 
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(EWGSOP/FNIH). This reflects the differences in ethnicity, body size, lifestyles 
and cultural background (L.-Y. K. L.-K. Y. Chen et al. 2014). Woo et al, 2014, 
noted that overall observations of anthropometric measures (BMI, ASM/height2, 
and grip strength) in a diverse set of studies on community dwelling adults over 
65 years of age with Asian participants (Beijing Chinese, Singapore Chinese, 
Hong Kong Chinese, Japanese, Malays and Indians) were significantly lower 
when compared to similar studies with participants of European ancestry (J. Woo 
et al. 2014), however gait speed was equivalent. Global variation in grip strength 
has been investigated regarding a consensus definition of sarcopenia by Dodds 
et al. They found that although developed regions closely followed the normative 
grip data from a cohort of 12 British studies (Dodds et al. 2014), this was not the 
case for developing regions (Figure 1-5) (Dodds et al. 2016). 
 
Figure 1-5 : Grip strength mean values by UN region 
(Dodds et al. 2016) 





1.2.4 Additional definitions of sarcopenia 
 
The SARC-F (Malmstrom et al. 2016) incorporates five observations in order to 
score the likelihood of sarcopenia: ability to climb stairs, rising from a chair, lifting 
and carrying strength, assistance in walking and finally the number of falls in the 
past year. A combined score of equal to or greater than 4 is predictive of 
sarcopenia and adverse outcomes. 
Evaluation of the screening ability of the SARC-F for sarcopenia, found that 
although sensitivity is poor, its specificity is high (Ida, Kaneko, and Murata 2018; 
Gülistan Bahat et al. 2018). This allows for the selection of patients who would 
benefit from a more rigorous assessment and possible confirmation of a 
sarcopenia diagnosis, however the low sensitivity means that SARC-F is not 
reliable enough on its own to act as a screening tool. 
SARC-F is concerned primarily with muscle function and doesn’t take muscle 
mass into consideration. Extensions to the SARC-F questionnaire have 
increased its performance as a screening tool by including calf circumference 
measurements (Barbosa-Silva et al. 2016), or as part of a more comprehensive 
algorithm as with the EWGSOP2 definition (Cruz-Jentoft et al. 2019). SARC-F 
combined with calf circumference (SARC-CalF) has been proposed as a suitable 
enhancement to the stand alone SARC-F questionnaire in order to improve 
screening performance (Barbosa-Silva et al. 2016).  
An additional sarcopenia definition proposed by the International Working Group 
on Sarcopenia (IWGS) was also considered for inclusion in this study.  In 2009 
the IWGS met in Rome, Italy in order to provide a consensus definition of 
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sarcopenia (Fielding et al. 2011), which was published in 2011. The IWGS 
specified that sarcopenia should be considered in older patients who are long-
term bedridden, cannot independently rise from a chair or who have a gait speed 
of less than 1 m/s. They defined sarcopenia as a gait speed of less than 1 m/s 
and low appendicular muscle mass of ≤ 5.67 Kg/m2 in women and ≤ 7.23 kg/m2 
in men (Fielding et al. 2011).  
The IWGS definition was developed for use in clinical settings, such as hospital 
or care homes. By contrast the EWGSOP definition in 2010 focused on any 
community dwelling individual over the age of 65. A study by Lee et al comparing 
the two definitions for diagnosing sarcopenia in 408 individuals over the age of 
65 recruited as part of the I-Lan Longitudinal Ageing Study (ILAS), found that 
agreement between the two definitions was only fair (kappa = 0.448 by relative 
appendicular skeletal muscle index and kappa = 0.471 by Skeletal Mass Index) 
(W.-J. Lee et al. 2013). Although the comparison focused almost exclusively on 
the loss of muscle mass, the discrepancy between the IWGS and EWGSOP 
definitions, as well as EWGSOP focus on community diagnosis, made the 




1.2.5 Prevalence and impact 
A systematic review by Mayhew et al, 2019 found that the prevalence of 
sarcopenia in community-dwelling older adults varied across a wide range (9.9% 
to 40.4%) depending on the sarcopenia definition (Mayhew et al. 2019) - Figure 
1-6. 
 
Figure 1-6 : Sarcopenia prevalence estimates 
(Mayhew et al. 2019). 
 
Prevalence of sarcopenia under the EWGSOP combined low grip strength and 
low Skeletal Muscle Index (SMI), of European ancestry and between the ages of 
60 and 70, in the UK Biobank is 12.7% for females and 4.3% for males. A recent 
review of sarcopenia prevalence in community dwelling adults over 60, based on 
a number of different definitions returned an estimate of 10% (95% CI: 8-13%) 
for females and 10% (95% Ci: 8-12%) for males (Shafiee et al. 2017). It should 
be noted that out of the 35 studies included in the analysis (n=58404 individuals; 
32642 male, 25762 female) 21 studies were from Asian populations while 14 
studies were categorised as Non-Asian. Sarcopenia was defined using one of 
EWGSOP, AWGS or IWGS criteria (depending on the study population) and so 
accounted for regional differences. The Health and Retirement study (HRS) 
however has a sarcopenia prevalence of 39% in females and 27% in males in 
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the over 60 age group. It should be noted that HRS has substantially older cohort 
compared to UK Biobank. 
Sarcopenia of older adults in nursing homes has also been investigated and 
found to be extremely prevalent. In a meta-analysis of 12 studies (2685 
participants) using the EWGSOP1 definition of sarcopenia, an estimated pooled 
prevalence was 41% (I2=96%, 95% CI 32%-51%, Figure 1-7). 
 
Figure 1-7 : Prevalence of EWGSOP1 sarcopenia in nursing homes. 
 (Shen et al. 2019) 
Data from a study of geriatric inpatients (Sarcopenia in Geriatric Elderly - SAGE) 
between April 2013 and May 2015 (Jens Reiss et al. 2016) has been used to 
compare the prevalence of sarcopenia as defined by both EWGSOP versions 1 
and 2 (J. Reiss et al. 2019). The study found that the overall prevalence of 
sarcopenia diagnosed using EWGSOP2 was significantly lower than EWGSOP1, 
18.1% versus 27.7% of participants. This discrepancy was mainly due to sex-
specific differences, with sarcopenia prevalence in women found to be 22.1% 
(EWGSOP1) against 17.4% (EWGSOP2), however in men the percentage 
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meeting the definition of sarcopenia was 37.9% for EWGSOP1 and only 19.4% 
for EWGSOP2.  
Of greater concern was the lack of overlap between the individuals defined as 
sarcopenic under EWGSOP1 compared to EWGSOP2. From the 19 women 
defined as having sarcopenia under EWGSOP1, 10 individuals did not reach the 
EWGSOP2 criteria and of the 15 women meeting the EWGSOP2 definition, 6 did 
not reach the EWGSOP1 cut-offs. With the males a similar pattern was observed 
with 11 out of the 22 men meeting the EWGSOP1 definition, but being judged as 
non-sarcopenic by the EWGSOP2 algorithm.  However there were no new males 
diagnosed with sarcopenia under the EWGSOP2 definition (J. Reiss et al. 2019). 
The small, non-representative nature of the study should be taken into account, 
however it does highlight the variability in prevalence depending on the algorithm 
and definitions used.  
A study of sarcopenia prevalence in community dwelling men (Uppsala 
Longitudinal Study of Adult Men, ULSAM; N=287 males, aged 85-89 years) found 
that the definition used, EWGSOP1 or EWGSOP2, resulted in different 
individuals being identified as sarcopenic, despite the overall prevalence of 20% 





1.2.6 Overlap between frailty and sarcopenia 
 
The Rapid Geriatric Assessment, comprising of the SARC-F (Jean Woo, Leung, 
and Morley 2014), FRAIL (J. E. Morley, Malmstrom, and Miller 2012), Simplified 
Nutritional Appetite Questionnaire (SNAQ) (Rolland et al. 2012) and Rapid 
Cognitive Screen (RCS) (Malmstrom et al. 2015) tools, was used to screen 
11,344 individuals over the age of 65 in Missouri, USA between 2015 and 2019. 
The study found that most individuals who screened positive for sarcopenia or 
frailty, also returned positive for the other condition, highlighting the large overlap 
between the two conditions (Sanford et al. 2020), see Figure 1-8. 
 
Figure 1-8 : Overlap between sarcopenia and frailty 





Frailty is a heterogenous phenotype (Junius-Walker et al. 2018) with symptoms 
including loss of muscle mass and function, unintentional weight loss, exhaustion, 
cognitive impairment and decline in motivation. A combination of these traits can 
be measured using indices such as the Fried index of frailty (L. P. Fried et al. 
2001) to provide a definitive phenotype. Frailty is often characterized by a state 
of increased vulnerability following a stressor event, with implications for multiple 
adverse outcomes, such as falls or additional co-morbidities (Clegg et al. 2013). 
The Rockwood scale is a 7 point Clinical Frailty Scale originally developed to 
categorise frailty for 2305 participants of the Canadian Study of Health and Aging 
(CSHA) over a 5 year time frame (Rockwood et al. 2005). A number of tools were 
used in order to assign participants to a category including the CSHA Frailty Index 
(derived from a count of 70 deficits), CSHA Function Scale (based on daily living 
activities and the ability to maintain independence) and clinical history of falls, co-
morbidity, cognitive impairment or dementia. 
The methodology used to create the CSHA Frailty Index has been developed into 
a standardised process (Searle et al. 2008). Williams et al used these methods 
to produce a list of frailty indices (FIs) derived from 49 self-reported questionnaire 
items in the UK Biobank data, concluding that FIs provided a valid measure of 
frailty with the UK Biobank participant. Survival analysis showed that a 0.1 FI 
increment was associated with a 65% increase in mortality risk (hazard ratio = 
1.65, 95% confidence interval: 1.62-1.68) (D. M. Williams et al. 2019). 
Frailty measured by five criteria (weight loss, exhaustion, grip strength, low 
physical activity and slow walking pace) was also measured in the entire UK 
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Biobank (493,737 healthy community volunteers, age range 37-73 years) by 
Hanlon et al. The study found that 16,538 (3%) met the criteria for frail, 185,360 
(38%) for pre-frail and 291,839 (59%) as not frail (Hanlon et al. 2018). It should 
be noted that the UK Biobank is a community based study of predominately 
young healthy volunteers. Analysis has shown that UK Biobank participants were 
more likely to be female and older than the general population, and to live in less 
socioeconomically deprived areas. At age 70-74 rates of all-cause mortality were 
55.5% lower in women and 46.2% lower in men compare to the general 
population of the same age range. There is also a “healthy volunteer” selection 
bias within the UK Biobank compared to the general population (Fry et al. 2017). 
However despite this bias previous studies have found that results from analyses 
in UK Biobank are generalizable to the population, especially in the context of 
prospective analysis of incident disease (Fry et al. 2017). 
The Fried frailty phenotype and Rockwood frailty index should be regarded as 
complementary measures of frailty, rather than overlapping metrics, as they 





Table 1-4 : Characteristics of Fried frailty phenotype and Rockwood frailty index 
Frailty phenotype (Fried) Frailty Index (Rockwood) 
Signs, symptoms  Diseases, activities of daily living, results of a 
clinical evaluation  
Requires clinical assessment for 
measurements such as grip strength.  
Possible to obtain using existing records, for 
example electronic frailty index 
Categorical variable  Continuous variable  
Pre-defined set of criteria  Unspecified set of criteria  
Frailty as a pre-disability syndrome  Frailty as an accumulation of deficits  
Meaningful results potentially restricted to 
non-disabled older persons  
Meaningful results in every individual, 
independently of functional status or age  
(Adapted from Cesari et al, 2014) 
 
1.3.1 Prevalence 
A systematic review and meta-analysis of frailty in community-dwelling older 
adults worldwide, using mainly the Fried criteria for frailty, found that frailty rates 
were significantly higher in women (44.8 cases per 1000 person years, 95% CI 
36.7-61.3; heterogeneity between studies I2=97.7%) than men (24.3 cases per 
1000 person years, 95% CI 19.6-30.1; I2=8.94%). The meta-analysis involved 
101,259 participants in which 73.3% were women (Ofori-Asenso et al. 2019). 
A systematic review of frailty in community dwelling older adults has placed the 
prevalence at 17.4% in middle (US$1006-US$3955) and low (≤ US$1005) 




Figure 1-9 : Frailty prevalence for men and women by age 
(Hoogendijk et al. 2019) 
Prevalence in the Longitudinal Aging Study Amsterdam wave F (2005-6) based on either frailty 





1.4 Measuring the Musculoskeletal ageing process 
 
1.4.1 Grip strength  
Because the strength of both upper and lower limbs can be used as a proxy for 
overall muscle function (Aadahl et al. 2011; Bohannon et al. 2012), the most 
convenient and currently recommended clinical measure is provided by 
maximum grip strength using a handheld dynamometer (Beaudart et al. 2019) - 
Figure 1-10.  
 
Figure 1-10 : Hydraulic type dynamometer (Jamar) 
(S. H. Lee and Gong 2020)  
Handgrip strength has been found to be a strong indicator of mortality, across a 
range of studies of community dwelling adults (mixed ancestry), with a hazard 
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ratio of 1.67 (95% confidence interval 1.45-1.93) when comparing the weakest to 
strongest quartiles from 14 studies (N=53,476) (Cooper, Kuh, and Hardy 2010). 
The 2010 European Working Group on Sarcopenia in Older People (EWGSOP) 
used grip strength as measured by a hand dynameter as its preferred measure 
of muscle strength (Cruz-Jentoft et al. 2010).  
 
Figure 1-11 : Grip strength across life course from 12 British studies 
(Dodds et al. 2014) : 49,964 participants, age range 4-90 years 
 
A study in 2014 by Dodds et al, on handgrip strength within the British population 
used 12 general population studies (N=49,964) with a wide age range (4-90 
years). Peak mean grip was observed for both sexes at the age of 32 (51.9 Kg 
for males and 31.4 Kg for females) and this was used to calculate the prevalence 
of weak grip strength at different age range - Figure 1-11. Weak grip strength was 
defined as either a T-score of -2 (32 Kg or less for males and 19 Kg or less for 
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females) or -2.5 (27 Kg or less for males and 16 Kg or less for females) - Figure 
1-12. 
 
Figure 1-12 : Prevalence of low grip strength in 12 British studies 
(Dodds et al. 2014) 
 
23% of males and 26.6% of females had a grip strength lower than the weakest 
grip strength definition of a T-score of -2.5 by the age of 80, with the cut-offs of 
27Kg for males and 16Kg females being roughly equivalent to the more 
stringent FNIH definition of low grip strength in the context of sarcopenia (26Kg 
for males, 16 Kg for females). 
 
1.4.2 Appendicular Lean Muscle mass 
Appendicular lean muscle mass is a commonly used metric for healthy aging and 
physical performance decline with age (Ian Janssen, Heymsfield, and Ross 2002; 
Goodpaster et al. 2006).   
Dual-energy x-ray absorptiometry (DEXA) is used clinically to measure body 
composition, with estimates of lean muscle mass being derived from the raw data 
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(J. Kim et al. 2002). Computed tomography (CT)(Georgiou et al. 2020), 
bioimpedance analysis (BIA) (Scafoglieri et al. 2017) and magnetic resonance 




1.4.3 Short Physical Performance Battery 
 
The Short Physical Performance Battery (SPPB) is a series of physical tests used 
to gauge balance and muscle strength. SPPB has been shown to be suitable for 
diagnosing older adults with severe sarcopenia when used in isolation (Phu et al. 
2020), and has been proposed for diagnostic use due to it being easy to 
administer. It consists of a series of balance tests in the following positions; side 
by side (feet touching), semi tandem (one foot slightly in front of the other but still 
overlapping) and tandem (heel of one foot directly in front of the toes of the other 
foot). The positions have to be maintained for 10 seconds. Gait speed along an 
8 foot course, and the ability to rise from a chair are also tested. Tests are scored 
on a scale of 0-4 based on quartiles of results from the original SPPB paper 
(Guralnik et al. 1994).  
A meta-analysis of studies using SPPB to predict all-cause mortality (17 studies, 
n= 16,534, mean age 76 ± 3 years) found that a score of less than 10 is predictive, 
with the lowest class of score between 0-3 having a very high increased risk of 
mortality (OR 3.25, 95% CI 2.86-3.79) (Pavasini et al. 2016). 
1.4.4 Gait speed 
A recent cohort study of 904 participants from New Zealand, over almost five 
decades, found that a slower gait speed in mid-life (45 years of age) is associated 
with accelerated biological aging, including neurocognitive functions (Rasmussen 
et al. 2019). This included key sarcopenia indicators such as low grip strength 
(Beta=0.36, 95% CI, 0.25-0.46) and poor performance on the chair-stand test 
(Beta=0.34, 95% CI, 0.27-0.40). 
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Gait speed is a good predictor of loss of physical function with age (Abellan Van 




1.5 Musculoskeletal system and ageing 
 
Over the age of 70 years, individuals have an average rate of muscle mass loss 
of around 0.5-1% per year, with the majority of over 70 year olds retaining only 
80% of their muscle mass compared to individuals in the 20-30 years age bracket 
(Mitchell et al. 2012). There is a reduction in muscle fibre numbers and fibre size 
with age, with the Type 2a (fast-twitch) myofibres being the most affected (W. J. 
Evans and Lexell 1995). Studies on the variability of the morphology of the Type 
2 and Type 1 fibres have shown that in older individuals Type 2 fibres exhibit a 
significantly wider range of cross-sectional area, when compared to younger 
individuals – something not seen to such an extent with the Type 1 fibres (J Lexell 
and Taylor 1991; W. J. Evans and Lexell 1995). However there is enormous 
variability between individuals, and the factors that affect individual susceptibility 
to loss of muscle function are not fully understood. 
Sarcopenia, the age related loss of muscle mass and function and dynapenia, 
the age-associated loss of muscle function independent of atrophy are thought to 
be caused by a number of factors. Identification of suitable biomarkers has 
implicated a multifactorial pathogenesis for sarcopenia, with the involvement of a 
diverse set of pathways including the neuromuscular junction, endocrine system, 
growth factors, protein synthesis and lysis, behaviour mediated pathways, 




1.5.1 Muscle fibres 
Myofibres (skeletal muscle fibres - Figure 1-13 : Structure of muscle fibre, (Betts 
et al., n.d.)) are post-mitotic multinucleated cells formed during embryonic and 
foetal development from the fusion of myoblasts (Mintz and Baker 1967), and 
continue to regenerate damaged muscle by a similar fusion mechanism 
throughout life by myoblasts produced from the muscle satellite cells (Zammit 
2008). With advancing age muscle re-growth is reduced by the lower potential for 
satellite cells to proliferate, differentiate into myoblasts and fuse with the 
diminished myofibre (Suetta et al. 2013). 
 
 
Figure 1-13 : Structure of muscle fibre 
(Betts et al., n.d.) 
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Myofibres are categorised into various types based on their characteristic 
response to stimuli, metabolism, contractile cycle and expression of specific 
proteins, in particular the heavy myosin protein (Figure 1-13) (Schiaffino and 
Reggiani 2011). 
Table 1-5 : Basic types of muscle fibres in Humans 
 Slow-twitch Fast-twitch 
Fiber type Type 1 Type 2A Type 2X 
Contraction speed Slowest Fast Fast 
Fatigue endurance Highest Low Low 
Metabolism Oxidative Oxidative Glycolytic 
Indicative Mysosin MYH7 MYH2 MYH1 
Adapted from (Talbot and Maves 2016); Intermediate types with characteristics falling between 
the main categories exist, for example Type 1C co-express MYH7 and MYH2 heavy chain Myosin. 
 
Aging muscle is characterised by the atrophy of muscle fibres, cell death of the 
muscle fibre and alterations to the grouping of muscle fibre types (Doherty 2003). 
 
Figure 1-14 : Structure of skeletal muscle 
(Betts et al., n.d.)  
Muscle fibres are grouped together with a motor neuron and form the basic unit 
of a mammalian skeletal muscle, the motor unit (Sherrington 1925). Each muscle 
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fibre within the motor unit is innervated by an axon from the alpha motor neuron 
and all muscle fibres are of the same phenotype, for example Type 1 or 2A. Motor 
units are organised into fascicle (Figure 1-14), with motor units of the same type 
rarely being adjacent to one another (Edström and Larsson 1987).  
In older individuals the cross-sectional area (CSA) of Type 2 fibres are 
significantly smaller when compared to younger individuals (approximately 35% 
smaller; P < 0.001, measurements from five cross sectional of 375 Type 2 fibres 
from 20 individuals, age 19 to 84 years), while the CSA of the Type 1 fibres 
between the young and older individuals showed only a 6% decrease (J Lexell 
and Taylor 1991). The study authors also observed that aged fibres had a highly 
significant variation in the mean CSA for both Type 1 and 2 fibres, with an 
increased number of both atrophied and enlarged (hypotrophied) dysfunctional 
fibres. 
 
1.5.2 Satellite cells 
 
Skeletal muscle satellite cells are essential for muscle growth and development. 
They are stem cells providing the reserve of myoblasts for myofibre regeneration 
in the adult, and reside in niches on the surface of the muscle fibre underneath 




Figure 1-15 : Skeletal muscle satellite cells 
(Relaix and Zammit 2012) 
The reduced capacity of skeletal muscle in older adults to repair itself appears to 
be correlated with a loss of satellite cell function, such as their ability to migrate 
to the site of injury (Collins-Hooper et al. 2012) or respond to signalling molecules 
correctly (JV 2012). In a small study (N=105, number of cases=6) sarcopenic 
men have been shown to have a lower Satellite cell (SC) density and lower SC 
to muscle fibre ratio than controls (Patel et al. 2015). 
1.5.3 Denervation and re-innervation 
 
Denervation and re-innervation of muscle fibres has been shown to increase with 
age  (Rowan et al. 2012), alongside the loss of functioning motor units (McNeil et 
al. 2005). Neuron cell death leads to denervation of the motor unit, with re-
innervation achieved by axonal sprouting from nearby motor neurons. This 
results in absorption of the orphaned muscle fibres into an enlarged motor unit 
(Gordon, Hegedus, and Tam 2004). This process of adaptive axonal sprouting 
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breaks down with extreme age leading to the loss of the motor unit, atrophy of 
the muscle fibres (Rowan et al. 2012) and a subsequent reduction in overall 
muscle function. 
The underlying mechanisms for this loss of motor neurons are not fully 
understood with a number of possible causes including dysregulation of 
mitochondria and oxidative stress, inflammation and neurodegeneration of motor 
neurons and the attending Schwann cells (Gonzalez-Freire et al. 2014). 
1.5.4 Neuromuscular Junction 
Innervation of the muscle fibres occurs at the Neuromuscular Junctions (NMJ; 
Figure 1-16) where the motor neuron forms a pretzel-like structure against the 
muscle fibre cell. This structure is covered by the terminal Schwann cell and these 
cells have a role in regenerating the neuronal connection when denervation 
occurs (Son and Thompson 1995; Reynolds and Woolf 1992), as do the Schwann 
cells forming the remaining endoneurial tube from an axon undergoing a dying-
back (Wallerian degeneration (Conforti, Gilley, and Coleman 2014)) event 




Figure 1-16 : Structure of the Neuromuscular Junction 
(L. Li, Xiong, and Mei 2018): tSC -Terminal Schwann Cells, AChR – Acetylcholine receptors 
 
In ageing mammals the postsynaptic site has been observed to fragment into 
numerous, unconnected sections resulting in decreased Acetylcholine receptor 
(AChR) density. Additionally the AChR clusters increasingly are not contacted by 
an axon, or the terminal axons were misshapen. Finally innervation of the same 
NMJ by multiple axons is also observed and associated with lower motor unit 
function from fibre atrophy (Valdez et al. 2010; Hepple and Rice 2016).  
Neuromuscular junction dysfunction could be the result of an increased 
breakdown of Agrin, a protein responsible for activation of MuSK (muscle-specific 
tyrosine kinase), itself involved in the stabilization of the acetylcholine receptor 





1.5.5 Muscle morphology 
The structure of skeletal muscle undergoes changes with age. The intermingling 
of fibres from different motor units seen in young adulthood, gives way to 
increasing grouping of fibres of the same type which alters the functionality of the 
muscle (Figure 1-17) (Hepple and Rice 2016). 
 
Figure 1-17 : Morphology of ageing muscle 
(Hepple and Rice 2016) 
 
The loss of muscle function due to age has been shown to be related to the 
changes in the population balance of the fibres, with reduced numbers of Type 2 




1.5.6 Muscle-lipid system 
Lipids are stored in skeletal muscle as either adipocytes or intramyocellular lipid 
droplets (Engelke et al. 2018). Adipocytes can be located in between the muscle 
groups as perimuscular adipose tissue or within the muscle groups as 
intramuscular adipose tissue (Figure 1-18) 
 
 
Figure 1-18 : Muscle-lipid system 
(Engelke et al. 2018); Cross section of the thigh muscle. Blue outlines the muscle fascia. Green 
outlines a single muscle Fascicle. Adipose tissue includes intramuscular (red) and perimuscular 
(yellow) 
Accumulation of intramuscular fat increases with age resulting in progressive loss 
of strength (Delmonico et al. 2009). The infiltration of lipids into the skeletal 
muscle (myosteatosis) may be due to a number of mechanisms, including a 
shared origin of osteoblasts and adipocytes from the mesenchymal progenitors 




1.5.7 Immune response 
 
Aging is associated with a chronic state of low-grade inflammation characterised 
by increased levels of pro-inflammatory mediators such as C-reactive protein 
(CRP), tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) (Paik et al. 2013; 
Puzianowska-Kuźnicka et al. 2016). Sarcopenic individuals have shown 
increased levels of TNF-α and IL-6 when compared to matched controls of similar 
age (age > 60) (Bian et al. 2017).  
Aged tissues accumulate senescent cells, cells that have ceased to divide due to 
damage or stress. These cells release a range of cytokines, growth factors and 
proteases cumulatively referred to as the Senescence-associated secretory 
phenotype (SASP) (Neves et al. 2015). 
IL-6 is a component of the SASP (Coppé et al. 2008) and is involved in the 
transition of muscle satellite cells to an active state. In healthy skeletal muscle 
this promotes myogenesis (Serrano et al. 2008) upon acute tissue stress, for 
example in response to exercise. However chronic IL-6 signalling due to the pro-
inflammatory state and accumulation of senescent cells observed in older 
individuals can have a detrimental effect (J. Wang et al. 2017). 
C-reactive protein (CRP) is a biomarker for systemic inflammation, and has also 
been seen to have increased levels in individuals with sarcopenia (Fujikawa et 
al. 2017) and in particular sarcopenic obesity – a combination of decreased 
muscle mass and function alongside infiltration of fat cells into muscle tissue and 
overall high fat mass (Stenholm et al. 2008). 
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1.5.8 Protein turnover 
 
Protein synthesis and breakdown in skeletal muscle is thought to be due to the 
interaction of three distinct systems – ubiquitin-proteasome pathway, calpain 
system and the autophagy mechanism (Tipton, Hamilton, and Gallagher 2018). 
One of the best characterised protein synthesis pathways in muscle is the PI3-
Kinase/AKT/mTOR cascade (Bodine et al. 2001) (Figure 1-19).  
 
 
Figure 1-19 : Aging and skeletal muscle protein synthesis and degradation 
(Gomes et al. 2017) 
 
The mTOR cascade has been shown to regulate skeletal muscle mass (Yoon 
2017), and there are two distinct mTOR complexes, mTORC1 and mTORC2 
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(Laplante and Sabatini 2012). mTORC1 in particular has been linked to 
sarcopenia (H. Tang et al. 2019) and neuromuscular dysfunction in ageing 
skeletal muscle (H. Tang et al. 2019). This makes a dysfunctional mTOR pathway 
as a possible candidate for the development of sarcopenia in later life. 
A study on the transcriptional markers of Unfolded Protein Response (UPR) 
pathway in older adults (75 ± 5 years) compared to young adults (27 ± 5 years) 
showed that after exercise the activation of the pathway was significantly lower 
in the older participants (Hart et al. 2019).  
1.5.9 Oxidative stress 
 
Endogenous reactive oxygen species (ROS) have a central role in the free radical 
theory of aging (Denham Harman 1992; Kregel and Zhang 2007). Accumulation 
of ROS and their secondary products increases in skeletal muscle with age, with 




Mitochondria dysfunction has been postulated as a possible underlying causative 
mechanism in sarcopenia and weakness associated with skeletal muscle and 
age (Alway, Mohamed, and Myers 2017). 
Sarcopenic skeletal muscle has fewer mitochondria and reduced mitochondrial 
respiratory complex activity. In addition intracellular levels of NAD+, a major 
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regulator of oxidative mitochondrial metabolism (Cantó, Menzies, and Auwerx 
2015), are lower in sarcopenic muscle (Migliavacca et al. 2019). 
 
1.5.11 Central Nervous System 
Age related changes to the nervous system can lead to reduced muscle strength 
by atrophy of the grey and white matter of the brain, domaminergic degeneration 
or loss of volume of subcortical structure such as the nasal ganglia and cingulate 
cortex which have an important role in mediating movement (Manini, Hong, and 
Clark 2013; B. C. Clark 2019). 
 
1.5.12 Vasculature 
The microvasculature of the skeletal muscles is reduced with age (Ryan et al. 
2006) and reduced levels of physical activity (Hedman et al. 2002). Studies of 
sarcopenic older adults has shown that they have a lower capillary-to-muscle 
fibre ratio (Patel et al. 2015). Skeletal muscle satellite cells, which are essential 
for repair and regeneration of myofibres, have been shown to be spatially located 
at a further distance from the muscle fibre capillaries in older men (average age 
67 years) when compare to younger controls (average age 24 years) (Nederveen 





Bone is a highly dynamic tissue with an estimated turnover of the entire human 
skeleton every ten years (W. C. Lee et al. 2017), through a cycle of resorption 
and bone formation.  
The tissue comprises of two main components, a range of specialised and 
precursor cells (Table 1-6), and the extracellular matrix (ECM).  
Table 1-6 : Bone cell types 
Cell type Function 
Mesenchymal stem cells Multipotent stem cells able to differentiate into mesodermal 
lineage, for example osteoblasts (Ullah, Subbarao, and 
Rho 2015). 
Pre-osteoblasts Osteoblast-committed progenitor cells actively proliferate 
before differentiation. 
Osteoblasts Specialised cuboidal bone-matrix secreting cells, with a 
large Golgi apparatus and increased rough endoplasmic 
reticulum. Crucial for bone formation and remodelling 
(Neve, Corrado, and Cantatore 2011). 
Osteocytes Embedded in the bone matrix and metabolically quiescent 
– respond to strain and stress on the matrix. 
Osteoclasts Osteoclast precursors derived from circulating 
mononuclear monocyte macrophages. Multinucleated 
Osteoclasts formed from the fusion of precursors are 
essential for bone resorption and repair (Schell et al. 2006). 
Bone lining cells (BLC) Post-mitotic flat osteoblast lineage cells, can be reactivated 
as functional osteoblasts and pre-osteoblasts (Matic et al. 
2016). 
 
Osteoporosis can be defined as “systemic skeletal disease characterized by low 
bone mass and microarchitectural deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture” (“Consensus Development 
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Conference: Diagnosis, Prophylaxis, and Treatment of Osteoporosis” 1993). 
There is evidence that sarcopenia and osteoporosis share common underlying 
mechanisms such as increased inflammation, and sensitivity to anabolic 
hormone secretion (Cruz-Jentoft et al. 2010; Reginster et al. 2016). 
Osteoblasts are responsible for secretion of certain hormone and signalling 
molecules related to skeletal muscle mass, such as osteocalcin (A. J. Lee, 
Hodges, and Eastell 2000).  
 
1.5.14 Hormones and signalling molecules 
 
Muscle cells secrete a wide range of signalling molecules termed myokines (B. 
K. Pedersen et al. 2003). They can be characterised as cytokines and other 
peptides that are expressed and released by the muscle fibres, often in response 
to muscle contraction, and exert either paracrine or endocrine effects (Bente 
Klarlund Pedersen et al. 2007). 
 These include the interleukins interleukin-6 (IL-6), interleukin-7 (IL-7) and 
interleukin-15 (IL-15); insulin-like growth factor 1 (IGF-1); Myostatin, follistatin 
and decorin; as well as additional myokines such as osteoglycin (OGN)(Guo et 
al. 2017). 
Testosterone has been shown to decrease in males with age (androgen 
deficiency), with a corresponding increase in luteinising hormone (LH), follicle-
stimulating hormone (FSH) and sex hormone-binding globulin (SHBG) (John E. 
Morley et al. 1997). Testosterone can induce an increase in muscle mass by 
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hypertrophy of myofibres (Sinha-Hikim et al. 2002) and upregulating the 
proliferation of satellite cells (Bhasin et al. 2003). 
Specific muscle force (maximum voluntary force per cross-sectional area) 
declines significantly in post-menopausal women, with the decline in men 
delayed until a later age (over 60 years of age) and only reaching the level seen 
in post-menopausal women, after the age of 75. Hormone replacement therapy 
(either sequential oestrogen / progestin or oestrogen alone) has been shown to 
reduce this muscle weakness (Phillips et al. 1993). A cross-sectional study of 144 
women aged 30-70 found that prevalence of sarcopenia (as defined by 
appendicular lean mass adjusted by the square of the participant’s height or ALM 
index ≤ 5.67 Kg/m2, International Working Group on Sarcopenia (Fielding et al. 
2011)) in early (n=31, 50 ± 3 years) and late (n=30, 50 ± 4 years) perimenopausal, 
and early (n=26, 55 ± 3 years) and late (n=27, 62 ± 4 years) postmenopausal as 
3%, 30%, 27% and 32%. This is compared to the control group of premenopausal 
women (n=30, 38 ± 6 years) with a prevalence of 7%. Measured Follicle 
Stimulating Hormone (FSH) was found to be negatively correlated with ALM index 
(r = -0.28, p = 0.003), while oestradiol was not significantly correlated (r = 0.088, 
p= 0.34) (Park et al. 2020). Sex hormone-binding globulin (SHBG) regulates the 
amounts of biologically active testosterone and oestradiol by binding to them with 
different affinities (Laurent et al. 2016). 
Insulin-like Growth Factor-1 (IGF-1) is secreted by many tissues including the 
liver and skeletal muscle and has no specific target tissue after entering the 
bloodstream, despite this tissues capable of producing their own IGF-1 seem to 




IGF-1 and growth hormone (GH or somatotropin, GH1) form part of the GH/IGF-
1 axis which amongst a wide range of pleiotropic effects, promotes growth. Levels 
of GH and IGF-1 decline after reaching adulthood to low levels in the over 60s in 
humans (Zadik et al. 1985; Junnila et al. 2013), a period referred to as the 
“somatopause”(Lombardi et al. 2005; Bartke 2008). Decreased GH/IGF-1 has 
been linked to extended longevity in a range of organisms including humans 
(Fontana, Partridge, and Longo 2010). IGF-1 is a regulator of the 
PI3K/AKT/mTOR pathway, via its receptor. 
Higher systemic levels of GDF11 (Growth Differentiation Factor 11, a member of 
the Transforming Growth Factor β – TGFβ family) have been shown to impair 
satellite cell proliferation and so inhibit muscle fibre regeneration (Y. S. Lee and 
Lee 2013). Myostatin (GDF8) and GDF11 both bind to activing type II receptors 
and activate the SMAD 2/3 pathway (Trendelenburg et al. 2009; Paul Oh et al. 
2002), which in turn is an important regulator of muscle mass in adult humans 
(Sartori et al. 2009). GDF11 levels have been shown to increase with age in both 
humans and mice and inhibits the regeneration of skeletal muscle (Egerman et 
al. 2015). 
Loss of the bone derived hormone Osteocalcin has been shown in the female 
mouse model (homozygous negative Ocn -/-) to result in decreased skeletal 
muscle mass (in particular the hindlimb muscle). The decrease in muscle mass 
appears to be the result of loss of cross-sectional area from the myofibers, via 
signalling of the Gprc6a receptor (Oury et al. 2011) and dysregulation of protein 
synthesis, however it should be noted that muscle function appeared to be 
maintained (Mera et al. 2016).  In older mice exogenous osteocalcin treatment 
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1.6 Genetics of associated traits 
 
Previous studies have investigated the genetics of measurements used to define 
sarcopenia including maximal grip strength and appendicular lean muscle mass. 
Additional work is underway within the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium for metrics such as the Short 
Physical Performance Battery. 
A Genome-Wide Association Study (GWAS) is a methodology for testing variants 
across the genomes from many participants in order to discover genotype-
phenotype associations with a given trait. The variant or genotype data being 
commonly provided by SNP (Single Nucleotide Polymorphisms) arrays 
containing millions of oligonucleotide probes specific for certain variants or alleles 
– further details are available in Chapter 2 - Methods.  
Significant associations between the genotype and phenotype identify genomic 
risk loci, often covering a region with multiple variants due to the variants being 
inherited together (Linkage Disequilibrium). GWAS have successfully identified 
risk loci for a wide range of traits and diseases (Tam et al. 2019). 
 
1.6.1 Maximal grip strength 
 
Twin/Sibling studies with young adult, middle aged (59-69) or extreme age (over 
90) participants  have shown grip strength to be a highly heritable trait with h2 
between 30-65% (Matteini et al. 2010; Reed et al. 1991; Silventoinen et al. 2008). 
70 
 
Linear grip strength has been investigated in the UK Biobank (UKB) dataset by 
both Tikkanen (2018) and Willems (2017). Willems utilised data from the May 
2015 imputed interim genotyping release, restricting the analysis to biallelic 
Single Nucleotide Variants (SNVs) with a Minor Allele Frequency (MAF) ≥ 1% 
from 142,035 UKB participants self-identifying as having white ancestry. 
Replication was undertaken with 53,145 European individuals from the CHARGE 
consortium (Willems et al. 2017). 
By contrast Tikkanen used the full UKB July 2017 imputed genotyping release 
with only unrelated individuals who clustered by principal component analysis 
with European ancestry and self-reported as white British descent. Genetic 
markers with a minor allele count of equal to or less than 30 and/or a low 
imputation quality (<0.8) were excluded. The initial discovery Genome Wide 
Association Study (GWAS) was carried out on a random sub-sample of 223,315 
UKB participants, replication was undertaken using the remaining 111,610 
individuals and then a meta-analysis was undertaken with both datasets for the 
Mendelian Randomization and pathway analysis (Tikkanen et al. 2018). 
Willems et al, identified 16 genomic loci (a region containing a number of genetic 
variants or polymorphisms, often in linkage disequilibrium, which shows 
significant association with the trait of interest) associated with maximal hand grip 
strength. These included variants proximal to TGFA (rs958685 - Transforming 
Growth Factor Alpha, involved in cell proliferation, differentiation and 
development), POLD3 (rs72979233 - DNA Polymerase Delta 3, Accessory 
Subunit, involved in DNA replication and repair), ERP27 (rs11614333 - 
Endoplasmic Reticulum Protein 27, part of the Unfolded Protein Response of the 
ER) and HOXB3 (rs2288278 - Homeobox B3 part of the cell development 
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pathways). The study also highlighted the HLA (rs78325334) region. Fifteen of 
the 16 loci had MAF of over 5%, with only one significant locus close to DEC1 
(MAF=3%) having a MAF of less, and so a high prevalence in the general 
population. The authors highlighted the possible roles for the proximal genes in 
the structure and function of skeletal muscle (ACTG1 encodes a component of 
the costmere, part of the Z-disc of the sarcomere) and cell growth (TGFA – 
Transforming Growth Factor Alpha). 
Tikkanen identified 101 loci associated with maximal grip strength in their 
discovery dataset (N = 223,315, P < 5 * 10-8), and achieved replication for 64 of 
these (N = 111,610, P < 0.01). The most significant associations in the discovery 
analysis where seen for FTO (rs1421085), ATXN2L (rs12928404), SLC39A8 
(rs13107325) and ADCY3 (rs10203386). Although 7 of the loci are located on 
chromosome 6, only two are within the HLA region, defined as between the start 
of the MOG gene GRCh37 Chr6:29624758 and the end of the COL11A2 gene 
GRCh37 Chr6:33160276. These were HLA-DRB1 (rs2760975) and PRRC2A 
(rs2260051), although only PRRC2A was significant in both the discovery and 
replication datasets. 
The study implicated the FTO locus, rs1421085 (long associated with 
obesity(Loos and Yeo 2014)) and a possible regulatory variant, rs12928404, 
close to ATXNL2L and ATP2A1. ATP2A1 is a SERCA Ca(2+) ATPase, an 
intracellular pump embedded in the sarcoplasmic reticula of muscle cells 
(Hovnanian 2007; Winther et al. 2013) and is known to be involved in Brody 
disease, a rare inherited disorder of skeletal muscle function where exercise 
induces uncontrollable muscle relaxation, stiffness or cramps (Odermatt et al. 
1996). ATP2A1 was identified by the gene-based analysis as the most significant 
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gene for grip strength. It should be noted that rs12928404 is an eQTL for TUFM 
in a number of tissues. TUFM encodes a protein product with a mitochondrial 
import signal (Christian and Spremulli 2012) and is involved in protein synthesis. 
Tikkanen concluded that grip strength shared biological pathways with frailty and 
that in addition to genes related directly to muscle function, neuro-development 
and maintenance was also linked to maximal grip strength. 
 
1.6.2 Lean muscle mass 
 
A 2017 meta-analysis of lean muscle mass analysed 38,292 participants of 
European ancestry from 20 cohorts in the discovery set, with whole body lean 
mass measured by either dual energy X-ray absorptiometry (DEXA, 21,074 
participants) or bioelectrical impedance (BIA, 17,218 participants) (Zillikens et al. 
2017). In a similar manner appendicular lean muscle mass was estimated from 
15 cohorts with 28,330 participants (6 cohorts using BIA, the majority measured 
with DEXA). 
Replication was analysed using 33 studies with 63,475 participants (47,227 of 
European ancestry and 16,248 African American, South Asian or Korean 
ancestry) for whole body lean muscle mass and for appendicular lean muscle 
mass  
Five variants were associated with whole body lean mass and were replicated, 
rs2943656 (IRS1 - Insulin Receptor Substrate 1), rs9991501 (HSD17B11- 
Hydroxysteroid 17-Beta Dehydrogenase 11), rs2287926 (VCAN – Versican), 
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rs4842924 (ADAMTSL3 - ADAMTS Like 3) and rs9936385 (FTO - FTO Alpha-
Ketoglutarate Dependent Dioxygenase). The variants for IRS1, VCAN and 
ADAMTSL3 were replicated in the appendicular lean muscle mass cohort 
(Zillikens et al. 2017). ADAMTSL3 has previously been associated with height (H. 
L. Allen et al. 2010) and Zillikens et al proposed that the variants at this genomic 
risk locus could be directly involved in muscle mass via growth and development 
pathways rather than height, since their analysis adjusted for height. VCAN is 
involved in chondrocyte differentiation and joint development (Choocheep et al. 
2010), IRS1 is part of the insulin signalling pathway and is highly expressed in 
skeletal muscle (Long et al. 2011), while FTO is required for myogenesis (X. 
Wang et al. 2017). 
 
1.7 Biomarkers associated with sarcopenia 
 
Age related biomarkers have been analysed in the UK Biobank cohort (396,707), 
using the EWGSOP2 definition of sarcopenia (Cruz-Jentoft et al. 2019). Under 
the revised definition low grip strength (<26 kg in men and <16 kg in women) and 
low muscle mass (appendicular lean muscle mass (kg) divided by height (m) as 
measured by bioimpedance; < 7.0 kg/m2 for men and < 5.5 kg/m2 for women) is 
categorised as sarcopenia. The addition of self-reported slow gait speed was 
used as a proxy for a gait speed of less than or equal to 0.8 m/s, as EWGSOP2 
defines participants with all three criteria as having severe sarcopenia. 
For the biomarker analysis both those with severe sarcopenia (3 criteria) and 
confirmed sarcopenia (2 criteria) were analysed together to give a prevalence of 
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0.9% in female participants (n=209,722, cases=1,990, mean age 55.8 ± 8 years) 
and 0.1% in male participants (n=186,935, cases=112, mean age 60.6 ± 7.4 
years) (Petermann-Rocha, Gray, et al. 2020). 
Out of the initial 33 biomarkers, 20 were associated with sarcopenia in women 
and 18 in men (Figure 1-20). Overall the results highlight the complex 
multifactorial nature of muscle loss and weakness with age. IGF-1 (GH/IGF-1 
axis) was associated with sarcopenia in this study, and have previously been 
linked to muscle wastage (Giovannini et al. 2008). Higher levels of sex hormone-
binding globulin (SHBG) were also associated with sarcopenia in the analysis 
and has previously been observed alongside reduced appendicular skeletal 
muscle mass in older men (Baumgartner et al. 1999). Lower levels of 
testosterone were associated with sarcopenia in the female participants, although 
the coefficient is inconclusive in the male participants. This could be due to the 
low average age of the participants and the earlier and more profound onset of 





Figure 1-20 : Association between age-related biomarkers and sarcopenia 
(Petermann-Rocha, Gray, et al. 2020) 
 
Biomarkers of renal function, derived from the turnover of muscle mass such as 
lower creatinine and higher cystatin C were also observed to be associated with 
sarcopenia. Inflammatory markers such as rheumatoid factor and C-reactive 
protein (CRP) were also associated, which highlights a possible role of the 
immune system in the development of sarcopenia and age-related loss of 






Current understanding of sarcopenia and muscle weakness directly related to 
age is that there is a multifactorial pathogenesis (Figure 1-21) with a diverse set 
of interacting pathways resulting in a pathological end state.  
Various studies have shown the extreme range of muscle fibre cross-sectional 
area in aged muscle, in particular in Type 2 fibres (J Lexell and Taylor 1991) and 
the accumulating presence of both atrophied and hypotrophic fibres (Jan Lexell, 
Taylor, and Sjöström 1988). Age related denervation and re-innervation of the 
neuromuscular junction (NMJ) is only one possible cause of this dysfunction and 
associated muscle wasting (Tintignac, Brenner, and Rüegg 2015) and reasons 
include oxidative stress and inflammation (J. Wang et al. 2017), and incomplete 
or misconfiguration of the NMJ during a re-innervation (Hepple and Rice 2016). 
My work aims to understand some of the inheritable causes to the underlying 
mechanisms responsible for loss of muscle mass and function, and in turn 
sarcopenia. In addition this thesis will provide evidence for the genetic 
contribution to sarcopenia and loss of muscle function with age, which will provide 
plausible pathways to explain the variability in muscle function between older 











1.9 Aims and objectives 
There have been previous large scale studies of grip strength (Willems et al. 2017; 
Tikkanen et al. 2018), however these have been across all age ranges and of the 
continuous trait of grip strength. The focus of my thesis is older individuals and using 
the defined cut-offs for low grip strength derived from sarcopenia definitions, as 
proxies for whole body loss of muscle function. 
In the course of my research I have investigated low strength in older adults in order 
to identify mechanisms that result in some older individuals having a higher 
susceptibility to physical weakness / frailty than others. I hypothesize that these 
specific pathways that result in weakness with age are distinct from overall strength 
across the life course. 
Previous studies using the diagnostic criteria from the definitions of the sarcopenia 
have been unable to robustly identify significant risk loci, although sample size was 
undoubtedly a factor. 
By using the definitions of low grip strength and lean muscle mass provided by 
international sarcopenia consortia I have found evidence that sarcopenia does have a 
multifactorial pathogenesis with multiple routes to the pathogenic state and that it does 





1.9.1 Chapter Aims 
 
Chapter 3: HLA and sarcopenia; to identify alleles of the HLA locus that are associated 
with Sarcopenia and Dynapenia in older adults. 
In the first results chapter I have investigated the HLA region and HLA haplotypes, 
and their relationship to sarcopenia. I have shown how different measures of 
sarcopenia, either low grip strength or appendicular lean muscle mass, or both metrics 
taken together, are associated with different sets of HLA haplotypes. I also show how 
combinations of HLA types can increase risk of meeting the definition of sarcopenia.  
Chapter 4: GWAS meta-analysis of 22 CHARGE cohorts for dynapenia, as 
characterised by low grip strength, in order to identify genomic risk loci associated with 
dynapenia 
In this results chapter I use data from 256,523 individuals of European ancestry aged 
60 years or older from 22 international cohorts in order identify 15 genomic risk loci 
associated with muscle weakness. These loci are involved in growth and development 
of the musculo-skeletal system, control of the immune system, regulation of 
transcription and protein metabolism. 
Chapter 5: Sex-stratified analysis of GWAS meta-analysis of 22 CHARGE cohorts for 
dynapenia. By investigating sex stratified subsets of the meta-analysis I show that the 
genomic risk loci for muscle weakness with age has distinct loci for each sex.   
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Chapter 6: Mendelian Randomisation analysis of meta-analysis against a range of 
traits associated with aging and frailty to investigate possible relationships and causal 
mechanisms. 
In my final results chapter I show that there are shared casual pathways between 
muscle weakness with age and traits such as age of menarche, birth weight, and 










2.1 UK Biobank study 
 
The UK Biobank is a large population based prospective cohort with extensive 
baseline data captured during recruitment including physical measurements, 
biochemical assays and genomic information (Sudlow et al. 2015). The number of 
participants, general composition reflecting the UK population - although with a healthy 
volunteer bias, and age range (40-70 years) made the UK Biobank the most 
appropriate available source of data given the overall aim of the thesis, which is 
studying the effect of inheritable factors in low muscle function with age.  
Integration of the study with national health records and subsequent additional 
measures such as Magnetic Resonance Imaging (MRI) of participants and monitoring 
of physical activity, has increased the utility of the study and allowed researchers 
unprecedented access to a large population based cohort with comprehensive 
phenotyping (Bycroft et al. 2018). 
Recruitment to the UK Biobank study throughout the period 2006 – 2009, involved 
mailed invitations to 9.2 million potential participants, aged between the ages of 40 to 
69 years and living within approximately 25 miles of one the 22 study assessment 
centres. With a response rate of 5.47%, 503,325 individuals were recruited to take part 




Figure 2-1: UK Biobank assessment centres 
www.ukbiobank.ac.uk 
Genetic data derived from the two microarray panels used by UK Biobank was 
available on 488,377 UK Biobank participants after genotype calling and quality control 
performed centrally by the UK Biobank team (Bycroft et al. 2018). 
For the main focus of my thesis I analysed participants over the age of 60 at baseline, 
and whose genotypes clustered by principal component analysis of the 1000 genomes 
data, into a group identified as European ancestry (Thompson et al. 2019a) (clustering 
of populations is explained in further in detail in section 2.1.3). Those participants of 
European ancestry form the largest ancestral group within the UK Biobank and the 
constituent studies available through the CHARGE consortium, and so give the 
greatest statistical power. This is especially important given the stratification of the 
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cohorts into older individuals in order to separate age-related sarcopenia and muscle 
weakness from cachexia, or loss of muscle function and mass due to a chronic non-




2.1.1 Description of cohort 
9,238,453 individuals registered with the National Health Service (NHS), were 
selected for inclusion in the UK Biobank on the criteria of aged between 40 and 69 
years, and had a postal address within 25 miles of one of the 22 assessment centres 
(see Figure 2-1: UK Biobank assessment centres). From these initial invitations 
503,317 participants joined the study and attended one of the assessment centres 
(participation rate 5.45%) (Fry et al. 2017). The low response rate reduces the ability 
of the study to accurately reflect the overall general population.  
 
2.1.2 Healthy volunteer bias 
A comparison of the prevalence of self-reported health conditions between the 
participants of the UK Biobank (2006 – 2010) and individuals from the Health Survey 
for England (2006, 2009 and 2010) highlighted that UK Biobank participants are 
healthier than the general population (see Table 2-1) (Fry et al. 2017). Health 
conditions such as cardiovascular disease are more prevalent in the 55-64 age range 
for both males and females in the general population, compared to the UK Biobank 
participants (18.5% and 15.2% for males and females in the Health Survey for England 
study compared to 11.5% and 5.0% for males and females in the UK Biobank cohort). 
This trend is consistent across a range of long term health conditions, with the 
exception of Chronic Obstructive Pulmonary Disease (COPD) in older females in the 
UK Biobank (0.1% in HSE compared to 0% in UK Biobank), although the difference is 
marginal. The authors noted that despite this, the assessment of exposure-disease 
relationships may be generalizable and does not require the participants to represent 
the population at large (Fry et al. 2017). 
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Table 2-1: UK Biobank healthy participant bias 
 
Men Women 
Self-Reported Disease Age 45–54 Yrs Age 55–64 Yrs Age 45–54 Yrs Age 55–64 Yrs 
UKB HSE UKB HSE UKB HSE UKB HSE 
Cardiovascular disease 4.6 10.9 11.5 18.5 2.4 10.3 5.0 15.2 
Ischemic heart disease 2.8  3.6  7.9  10.6  0.9  1.3  2.6  3.5  
Stroke  0.8  1.2  1.9  3.0  0.6  0.9  1.0  2.3  
Angina  1.8  2.4  5.3  8.0  0.7  1.2  2.1  3.2  
Myocardial infarction  1.7  2.1  4.5  6.3  0.3  0.7  0.9  1.6  
Abnormal heart rhythm  1.5  5.7  3.1  6.3  1.4  5.7  2.2  7.3  
Hypertension 21.2  27  34.4  39  15.4  16  27.4  29  
Diabetes  4.5  8.1 7.8  10.5  2.4  3.5  6.3  8.0  
Chronic kidney disease  0.2  1.1  0.3  1.5  0.2  1.2  0.2  1.9  
Asthma 11.7  12  9.9  13  13.0  16  11.8  15  
COPD 0.1  1  0.4  3  0.1  0  0.4  2  
HSE=Health Survey for England 2006/2009/2010 data; UKB=UK Biobank Self-reported health conditions; fields in green show lower incidence for each condition 




2.1.3 Population structure 
The UK Biobank mapped self-reported ethnicity of 141,670 samples against the 
results of Principal Component Analysis (PCA) of 101,284 SNPs in order to identify 
underlying population structure (Sze and Schloss 2016; Bycroft et al. 2018). 
 
 
Figure 2-2: Genetic principal components in UK Biobank 
Chart A shows the first principal component (PC1) against the second (PC2); Chart B 
shows the third principal component (PC3) against the fourth (PC4). Charts are 
overlaid with the UK Biobank self-reported ethnicity (Sze and Schloss 2016).  
Analysis throughout this thesis focused on individuals identified as European ancestry 
due to this population being the largest group in the UK Biobank cohort. This was due 
to the required statistical power to detect the large number of variants with small effect 
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sizes associated with a complex trait, such as low grip strength. Some initial 
investigation was conducted into using studies that are part of the CHARGE 
consortium with predominantly Korean participants, however the lack of a similar 
population in the UK Biobank and the small size of the Korean study made this 
unfeasible.  
In order to obtain these individuals principal components were generated using the 
1000 Genomes Cohort high confidence SNPs by Dr Andrew Wood (University of 
Exeter Medical School). The individual loadings from these variants were then used 
to project the UK Biobank data into the same principal component space, with K-
means clustering from principal components 1 to 4 (Pilling et al. 2017). Each 
participant could then be assigned to one of the five super-populations from the 100- 
genome project (European, African, East-Asian, South-Asian and Admixed) (Auton et 
al. 2015). 
 
2.1.4 UK Biobank older people cohort 
The focus of the thesis was on older adults in the UK Biobank and so only participants 
between the age ranges of 60 to 70 were included in the subsequent analysis. The 
lower bound for the age range was selected as one of the common chronological ages 
used to define the onset of old age, and 23% of the global burden of disease linked to 
people over this age (Prince et al. 2015). Individuals in this age category (60-70) are 
often referred to as “young-old” and exhibit the earliest signs of functional decline 
specific to the ageing process (K.-L. Chou and Chi 2002). By stratifying the analysis 
by this age group I aim to reduce the influence of incidence of loss of muscle function 
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and mass due to chronic illnesses that are not age-related (cachexia) and to still 
investigate the earliest detectable signs of age-related changes. 
In addition participants without values for the required fields to define either low grip 
or sarcopenia (maximum linear grip strength in either hand and skeletal muscle mass, 
calculated according to the equation by Janssen et al (Ian Janssen et al. 2000)) were 
excluded. Analysis was confined to participants falling within the 1000 Genome 
European reference population cluster as described above. 
Definitions of sarcopenia and low grip are discussed in more detail in the Introduction 
(see Section 1.2) and the specific methods sections for each of the analysis chapters. 
Briefly, the European Working Group on Sarcopenia in Older People 2010 (Cruz-
Jentoft et al. 2010) and the Foundation for the National Institutes of Health sarcopenia 
(Dam et al. 2014) definitions were used for cut-offs and analysis throughout the thesis. 
Participants who had withdrawn permission for use of their data were removed at the 
start of the project. 
 
2.2 CHARGE consortium 
The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) was 
formed by five founding members in 2008 to coordinate GWAS meta-analyses of a 
range of phenotypes associated with aging (Psaty et al. 2009). By meta-analysing 
GWAS from multiple separate cohorts the statistical power to detect significant 
associations can be increased (Zeggini and Ioannidis 2009), and the results are more 
generalizable across multiple populations. 
We submitted a study design for consideration by the constituent member cohorts, in 
2018. Twenty two studies, including our own analysis using UK Biobank, were 
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recruited from CHARGE cohorts (see Table 2-2). The CHARGE consortium cohorts 























ARIC 650 289 217 134 2,025 1,630 3,655 
BASE-II 55 19 5 4 779 752 1,531 
BPROOF 328 145 137 64 1,244 1,275 2,519 
CHS 601 201 231 88 1,855 1,206 3,061 
EPIC-Norfolk 926 503 326 219 3,962 3,546 7,508 
FHS 400 142 153 60 1,461 1,245 2,706 
HRS 2,380 1,244 1,089 665 6,164 4,650 10,814 
InCHIANTI 162 75 90 48 458 361 819 
LASA I 121 77 43 37 249 255 504 
LASA II 192 85 68 36 632 589 1,221 
Long Life Family 
Study 824 586 446 397 1,788 1,571 3,359 
MrOS 
Gothenburg 0 35 0 10 0 941 941 
MrOS Malmo 0 29 0 12 0 891 891 
ROSMAP 1 661 198 346 129 1,096 473 1,569 
ROSMAP 2 197 48 108 32 266 95 361 
Rotterdam Study I 511 234 253 121 853 587 1,440 
Rotterdam Study 
II 273 137 121 58 684 565 1,249 
Rotterdam Study 
III 146 86 41 36 844 640 1,484 
SHIP 96 35 43 8 523 513 1,036 
TSHA 844 447 525 316 1,218 882 2,100 
UK Biobank 24,229 8,807 8,966 3,941 105,597 94,968 200,565 
WLS 993 585 393 319 3,770 3,420 7,190 
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2.2.1 Atherosclerosis Risk in Communities 
The Atherosclerosis Risk in Communities (ARIC) Study is a population-based 
prospective cohort study of cardiovascular disease and includes a total of 15,792 
participants aged 45-64 years at baseline (1987-89), chosen by probability sampling 
from four US communities (The ARIC investigators 1989). Cohort members completed 
five clinic examinations, conducted approximately three years apart between 1987 and 
1998, with a fifth visit conducted from 2011 – 2013. Clinic examinations included 
assessment of cardiovascular risk factors, self-reported medical family history, 
employment and educational status, diet, physical activity, comorbidity, clinical and 
laboratory measurements.  
 
2.2.2 Berlin Aging Study II 
Berlin Aging Study II (BASE-II) is a multidisciplinary study initiated in 2009 
investigating factors related to human aging (Bertram et al. 2014). All subjects are 
recruited from the Berlin metropolitan area and underwent an extensive phenotypic 
assessment, including a 2-day internal medicine examination (follow-up will be 
completed in 2020).  
 
2.2.3 B-Vitamins for the prevention of Osteoporotic fractures 
The B-Vitamins for the prevention of Osteoporotic fractures (B-PROOF) study is a 
randomized, placebo-controlled, double-blind trial that studied the effect of vitamin B12 
and folic acid supplementation on osteoporotic fractures in 2,919 people of 65 years 
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or over, and having homocysteine levels of 12-50 µmol/L. Participants were recruited 
between 2008 and 2011 and followed during a 2-3 year period (J.P. et al. 2011).  
 
2.2.4 Cardiovascular Health Study  
The Cardiovascular Health Study (CHS) is a population-based, prospective cohort 
study of risk factors for development and progression of CHD and stroke in older adults 
ages 65 years or older (Linda P. Fried et al. 1991). A cohort of 5,201 non-
institutionalized men and women were selected and enrolled from randomly generated 
Medicare eligibility lists in 4 U.S. communities in 1989-90; an additional 687 
predominantly African American participants were recruited and enrolled in 1992-93. 
Clinic examinations were performed at study baseline, at annual visits through 1999, 
and again in 2005-2006. Participants were contact by telephone annually between 
exams, and every 6 months after the exams ended. Multiple physical and biological 
tests have been performed, including assessment of physical function.  
 
2.2.5 European Prospective Investigation of Cancer Norfolk  
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk 
study (“The EPIC (European Prospective Investigation into Cancer) Norfolk Cohort,” 
n.d.) is a prospective population-based cohort study which recruited 25,639 men and 
women aged 40-79 years at baseline between 1993 and 1998 from 35 participating 
general practices in Norfolk, UK. Individuals attended for a baseline health check 
including the provision of blood samples for concurrent and future analysis. Further 
health check visits have been conducted since the baseline visit.  Participants have 
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contributed information about their diet, lifestyle and health through questionnaires and 
health checks over two decades.  
 
2.2.6 Framingham Heart Study 
The Framingham Heart Study (FHS) is a single-site, community-based cohort study 
that was initiated in 1948 to investigate risk factors for cardiovascular disease and 
other major illnesses. The FHS includes three generations: the original cohort followed 
since 1948 (Gen1) (Dawber and Kannel 1966); their offspring and spouses of the 
offspring, followed since 1971 (Offspring or Gen2) (Feinleib et al. 1975); and children 
of the offspring  enrolled in 2002 (Third Generation or Gen3) (Splansky et al. 2007). 
The Original cohort enrolled 5,209 men and women who comprised two-thirds of the 
adult population then residing in Framingham, MA, USA. The Offspring cohort 
comprises 5,124 persons who have been examined about every 4 to 8 years. 
Examination 1 of the Gen3 occurred between 2002 and 2005 and involved 4,095 
participants. Offspring spouses not previously enrolled who were a biological parent 
of a Gen 3 participant were enrolled into the New Offspring Spouse cohort to complete 
family pedigrees. All cohorts continue under active surveillance. The FHS follows two 
multi-ethnic cohorts, Omni group 1 and Omni group 2 to reflect the current diversity of 
the town of Framingham, MA.  
 
2.2.7 Health and Retirement Study 
The Health Retirement Study (HRS) is representative American cohort with 
participants over age 50 to monitor factors related to aging and retirement (Fisher and 
Ryan 2018; Juster and Suzman 1995). A random subset of ~26,000 participants were 
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selected in three phases (phase 1 in 2006, phase 2 in 2008, and phase 3 in 2010) to 
collect biological specimen between 2006 and 2010.  
 
2.2.8 InCHIANTI 
The InCHIANTI study is a population-based epidemiological study aimed at evaluating 
the factors that influence mobility in the older population living in the Chianti region in 
Tuscany, Italy (Ferrucci et al. 2000). 1616 residents were selected from the population 
registry of Greve in Chianti (a rural area: 11,709 residents with 19.3% of the population 
greater than 65 years of age), and Bagno a Ripoli (Antella village near Florence; 4,704 
inhabitants, with 20.3% greater than 65 years of age). The participation rate was 90% 
(n=1453), and the subjects ranged between 21-102 years of age. 
 
2.2.9 Longitudinal Aging Study Amsterdam 
Longitudinal Aging Study Amsterdam (LASA) is an ongoing, population-based cohort 
of individuals 55 years and older living in the Netherlands. The design and rationale is 
described elsewhere (Hoogendijk et al. 2016; Huisman et al. 2011). In short, 3017 
participants (55-84 years old) were included at baseline (1992-1993) and two 
additional cohorts were added in 2002-2003 and 2012-2013 with respectively 1002 
and 1023 participants. Follow-up visits were conducted every 3 years. Trained 
interviewers collected data on cognitive, emotional, physical and social functioning 
during a home interview. Subsequently, all participants were invited for a medical 
interview during which further diagnostic examinations were done and blood samples 




2.2.10 Long-Life Family Study 
The Long-Life Family Study is a family-based cohort study of exceptional longevity 
that recruited families at four study centers (Boston, New York, Pittsburgh and 
Denmark) from 2006 to 2009. In brief, the LLFS recruited selected families with 
multiple exceptionally old living individuals, totaling 4559 individuals, which included 
long-lived probands and their siblings (n = 1445), their offspring (n = 2329) and spouse 
controls (n = 785). The probands were ≥79 years old in the USA, and ≥90 years old in 
Denmark. Families were selected to participate in the study based on The Family 
Longevity Selection Score (FLoSS) (Sebastiani et al. 2009) which calculated the rank 
sibships by current age or age at death of siblings, the size of the sibship and the 
number of alive individuals available for study. A proband's family was eligible if the 
FLoSS reached a score of 7 or higher, which met the following criteria: (1) the proband, 
at least one living sibling, and one of their living offspring (minimum family size of 3) 
were all able to give informed consent, and (2) were willing to participate in the 
interview and examination including the blood sample for serum and DNA extraction. 




The Osteoporotic Fractures in Men (MrOS) study is a multicenter, prospective study 
including older men in Sweden, Hong Kong and the United States. The MrOS Sweden 
study (n=3014) consists of three sub-cohorts from three different Swedish cities 
(n=1005 in Malmö, n=1010 in Gothenburg, and n=999 in Uppsala) (Mellström et al. 
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2006). Study subjects (men aged 69 to 81 years) were randomly identified using 
national population registers.  A total of 45% of the subjects who were contacted 
participated in the study. To be eligible for the study, the subjects had to be able to 
walk without assistance, provide self-reported data, and sign an informed consent. In 
this study 941 unrelated participants from Gothenburg and 891 unrelated participants 
from Malmö were included. 
 
2.2.12 ROSMAP 
The Religious Orders Study (ROS) and Memory and Aging Project (MAP) 
The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, from about 
40 groups in 12 states (A. Bennett et al. 2012). The follow-up rate of survivors exceeds 
90%. Participants were free of known dementia at enrollment, agreed to annual clinical 
evaluations, and signed both an informed consent and an Anatomic Gift Act form 
donating their brains at time of death. Participants take a neuropsychological test 
battery. DNA was extracted from whole blood, lymphocytes, or frozen post-mortem 
brain tissue. Genotyping was performed at the Broad Institute’s Center for Genotyping 
and the Translational Genomics Research Institute and the Children's Hospital of 
Philadelphia.  
The Rush Memory and AP, started in 1997, enrolled older men and women from 
assisted living facilities in the Chicago area with no evidence on dementia at baseline 
(A. Bennett et al. 2012). The follow-up rate of survivors exceeds 90%. Participants 
agreed to annual clinical evaluations, and signed both an informed consent and an 
Anatomic Gift Act form donating their brains at time of death. Participants were invited 
to take a neuropsychological test battery. DNA was extracted from whole blood, 
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lymphocytes, or frozen postmortem brain tissue. Genotyping was performed at the 
Broad Institute’s Center for Genotyping and the Translational Genomics Research 
Institute and the Children's Hospital of Philadelphia. 
 
2.2.13 Rotterdam Study 
The Rotterdam Study is an ongoing prospective population-based cohort that 
investigates occurrence, determinants, and consequences of diseases in an ageing 
population (Ikram et al. 2017). The first baseline measurement of Rotterdam Study 
started in 1990. After two expansions in 2000 and 2006, it comprised 14,926 
participants aged 45 years and over by the end of 2008. Follow-up visits were held 
every 3-5 years.  
 
2.2.14 Study of Health in Pomerania 
The Study of Health in Pomerania (SHIP) is a population-based project in West 
Pomerania, the north-east area of Germany (Volzke et al. 2011). A sample from the 
population aged 20 to 79 years was drawn from population registries. First, the three 
cities of the region (with 17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 
3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with less than 
1,500 inhabitants), were drawn at random. Second, from each of the selected 
communities, subjects were drawn at random, proportional to the population size of 
each community and stratified by age and gender. Only individuals with German 
citizenship and main residency in the study area were included. Finally, 7,008 subjects 
were sampled, with 292 persons of each gender in each of the twelve five-year age 
strata. In order to minimize drop-outs by migration or death, subjects were selected in 
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two waves. The net sample (without migrated or deceased persons) comprised 6,267 
eligible subjects. Selected persons received a maximum of three written invitations. In 
case of non-response, letters were followed by a phone call or by home visits if contact 
by phone was not possible. The SHIP population finally comprised 4,308 participants 
(corresponding to a final response of 68.8%).  
 
2.2.15 Toledo Study for Healthy Aging  
Data were taken from the Toledo Study for Healthy Aging (TSHA), a population-based 
study conducted on 2,488 individuals aged 65 years and older. Study participants were 
selected by a two-stage random sampling from the municipal census of Toledo, 
covering both institutionalized and community dwelling persons from rural and urban 
settings. Data were collected from 2006 to 2009 and then in a second wave between 
2013-2015, and included information on social support, activities of daily living, 
comorbidity, physical activity, quality of life, depressive symptoms, and cognitive 
function. In addition, a nurse collected anthropometric data, conducted tests of 
physical performance (walk speed, upper and lower extremities strength, and the 
stand-and-sit from a chair test) and obtained a blood sample.  
 
2.2.16 Wisconsin Longitudinal Study 
The Wisconsin Longitudinal Study (WLS) is a one-third sample of all 1957 Wisconsin 
high school graduates and a randomly selected sibling (Herd, Carr, and Roan 2014). 
These respondents were originally empaneled with an in-person questionnaire at age 
18 (1957), which was followed with a mail survey of parents in 1964, telephone survey 
in 1975, mail and telephone surveys in 1993 and 2004 and in-person interviews in 
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2011, where data on grip strength was collected from participants. The WLS has a 
high response rate, exceeding 80 percent in most rounds of data collection. Between 
In 2006-11, the WLS collected saliva samples from respondents using Oragene kits 
(Rylander-Rudqvist 2006). After quality control, a total of 9,012 graduate and sibling 
respondents were genotyped at ~710,000 markers (before imputation) utilizing the 
Omni-Express beadchip. 
Cohort details and definitions used for the analyses can be found in the methods 
sections for each analysis chapter (also available in Supplementary Table 2-1: 





2.3 Genotype data in the UK Biobank 
 
2.3.1 Description of microarray technology 
The concept of detecting a specific sequence of DNA by hybridization with a known 
DNA sequence, can be traced back to early colony hybridization methods of the 1970s 
(Grunstein and Hogness 1975). The original design of DNA genotyping “printed” 
arrays, where the oligonucleotide probes are printed directly onto a supporting glass 
surface have been mainly superseded by two technologies. These modern 
microarrays are more suitable for large scale genotyping and can be categorized into 
the photolithographic In Situ-Synthesized spot chips as developed by Affymetrix 
(Axiom technology, now part of Thermo-Fisher Scientific) alongside Agilent / Roche 
and the bead array technology offered by Illumina (Miller and Tang 2009). The 
genotyping for UK Biobank was undertaken using two bespoke designs based on the 
Axiom technology, as described later. 
 
2.3.2 In situ-synthesized oligonucleotide microarrays 
Microarrays produced by this technology are synthesized in-situ on the microarray 
wafer surface by the repeated exposure of the surface to ultra-violet (UV) light, using 
a lithographic mask in order to target specific areas of the wafer for the extension of 




Figure 2-3: Affymetrix Axiom oligonucleotide microarray synthesis 
(Miller and Tang 2009) 
 
The linker molecule on the base layer has a reactive hydroxyl group that is protected 
by a UV labile cap. Addition of the required nucleotide occurs when the UV light is 
focused by the lithographic mask onto an area of the wafer with the site of the probe 
to be extended. This activates the hydroxyl group which then binds covalently to the 
supplied nucleotide. After washing the process is repeated in order to extend the 
oligonucleotide probes. Each probe is typically around 25 nucleotides in length (Miller 





Due to the limited length of the probe sequence multiple probes are manufactured as 
a probe set containing 8 to 16 pairs of probes. Each pair consists of a perfect match 
to the sequence to be captured (PM) and a mismatch (MM) probe with the 13th position 
(of the 25mer probe sequence) changed to the complement nucleotide. This 
configuration helps increase the signal intensity, reduce the background noise and so 
increase sensitivity and specificity of the array (H. Liu, Bebu, and Li 2010).  
 
2.3.3 Hybridization of probe with genomic DNA 
For genotyping, genomic DNA from the participant is extracted, amplified, fragmented 
and denatured to produce single stranded DNA before being loaded onto the 
microarray chip. This process will include various quality control steps including 
quantification of the amount of DNA available (Biosystems 2018). The following is an 
overview of the process specific to the Affymetrix Axiom genotyping microarray plates 





Figure 2-4: Axiom genotyping microarray reaction 
 
(Shapero et al. 2011) 
 
After hybridization with the probes, the plate is washed to reduce background noise 
from non-hybridized fragments. Then each polymorphic nucleotide is queried through 
a multi-colour (two differently labelled sets of ligation probes, Hapten-1 and Hapten-2) 
ligation event. This is followed by staining and imaging (Shapero et al. 2011). Figure 
2-5 shows an example of an image of an Axiom genotyping microarray. In this case 
the custom design used the UK Biobank Affymetrix Axiom array as a basis (area 




Figure 2-5: Custom germline cancer Axiom microarray 
 
(Emami et al. 2020) 
 
2.3.4 UK Biobank microarrays 
The UK Biobank includes genetic data for 488,377 participants, which were genotyped 
by two different microarrays, with overlapping coverage. The initial set of 49,950 
participants were part of the UK Biobank Lung Exome Variant Evaluation (UK BiLEVE) 
cohort (Wain et al. 2015) and were analysed using the Applied Biosciences UK 
BiLEVE Axiom array. The larger set of 438,427 participants were then genotyped 
using the Applied Biosystems UK Biobank Axiom array (Bycroft et al. 2017). This array 
has been designed with specific markers to aid in HLA typing (7,348), coverage for 
eQTLs (expression Quantitative Trait Loci; 17,115 markers), autoimmune and 
inflammatory pathway associated variants (258), as well as a range of variants with 
known trait associations as found in the NHGRI GWAS catalogue (8,136) for a total 
number of 820,967 markers on the array (Affymetrix 2014). Despite the genotyping for 
UK Biobank participants being analysed on two different arrays, there is a significant 
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overlap between the two panels with approximately 95% of the probes in common 
(Bycroft et al. 2018). 
UK Biobank has recently released sequencing data, which has been used to review 
the accuracy of the microarray genotyping. The study found that for common SNPs 
(Minor Allele Frequency > 1%) the Axiom chip had an average sensitivity of 99.8%, 
specificity of 99.7% and precision of 99.0%. The BiLEVE chip had an average 
sensitivity of 99.7%, specificity of 99.7% and precision of 98.7%. However for rare 
variants (MAF < 0.001%) sensitivity falls to 29.5% for the Axiom chip and 4.4% for the 
BiLEVE chip (Weedon et al. 2019). 
 
2.3.5 Imputation (HRC v1.1) 
Although data from microarrays such as the UK Biobank Axiom array may contain 
information on over 800,000 markers, this is still only a small fraction of the variation 
present in the genome. The concept of linkage disequilibrium (the non-random 
inheritance of combinations of alleles) can be used alongside external panels of 
population matched haplotypes (which have been extensively genotyped or 
sequenced) to predict or impute the missing sites based on the available subset of 
SNPs in the raw data (Marchini and Howie 2010). 
The Haplotype Reference Consortium (HRC) produced the first version of its 64,976 
haplotypes, based in whole genome sequencing (WGS) data from twenty studies 
(32,611 samples), in 2016 (McCarthy, Das, Kretzschmar, Delaneau, Wood, Marchini, 
et al. 2016). The studies consisted mainly of samples from European ancestry, 
although the more diverse 1000 Genomes Project Phase 3 cohort has also been 
incorporated into the reference.  
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The reference allows imputation against 44,187,567 sites at a minimum Minor Allele 
Frequency (MAF) of 0.0077% or a Minor Allele Count (MAC) of equal to or greater 
than five from the combined data (McCarthy, Das, Kretzschmar, Delaneau, Wood, 
Marchini, et al. 2016). The imputation of variants by HRC reference panel resulted in 
39,235,157 SNPs for the UK Biobank participants (Bycroft et al. 2018). Imputation 
accuracy is discussed in detail in section 3.7. 
For our GWAS meta-analysis we requested that participating cohorts imputed their 




2.4 Quality control and filtering of variants 
2.4.1 Minor Allele Frequency 
Due to technical limitations it was prudent to filter variants obtained from genotyping 
and imputation. Although the UK Biobank microarray panels include genotype probes 
for rare alleles (MAF < 1%), the number of false positive calls can reach approximately 
60% for loci with a MAF of between 0.001% - 0.005% (equivalent to approximately 10 
heterozygous individuals out of the 500,000 UKB participants). At the extremely rare 
alleles (MAF < 0.0005%, approximately 5 heterozygous individuals in the UKB data), 
recent analysis has found that all variants calls were false positives (Wright et al. 




Table 2-3: Evaluation of rare alleles in UK Biobank 
MAF Bin (%) FP TP Unclear Total 
0–0.0005 511 0 11 522 
0.0005–0.001 607 8 59 674 
0.001–0.005 1,598 218 210 2,026 
0.005–0.01 138 204 73 415 
0.01–0.05 66 456 48 570 
0.05–0.1 2 129 5 136 
0.1–0.5 6 189 7 202 
0.5–1 0 40 0 40 
Total 2,928 1,244 413 4,585 
(Wright et al. 2019) 
 
Figure 2-6: False positive rate for rare alleles in UK Biobank 
(Wright et al. 2019) 
 
Rare alleles have long been thought to be a potential source of the “missing heritability” 
observed in complex traits, alongside larger structural variations and variants with 
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reduced penetrance (Maher 2008). Larger studies like the UK Biobank and techniques 
such as GWAS meta-analysis, which increase the number of participants, should 
provide a solution for rarer alleles; however as Wright et al have shown this is still an 
issue for very rare alleles (presumably with larger effect sizes) (Wright et al. 2019). 
For most cases I filtered the GWAS analyses, keeping only variants that exceeded a 
Minor Allele Frequency of 1% or 0.01. I requested that individual cohort data for the 
GWAS meta-analysis was uploaded without any MAF filter, in order to preform quality 
control checks in-house. 
 
2.4.2 Hardy-Weinberg equilibrium (HWE) 
In a randomly mating population, the frequency of a biallelic site with alleles p and q 
will reach Hardy-Weinberg equilibrium (Hardy 1908) or p2, 2pq, and q2, as long as a 
number of assumptions are  true. The assumptions are that the population size is 
sufficiently large to allow random mating (and genetic drift is negligible), an absence 
of natural selection, no gene flow or migration, no mutation of the site, the locus is on 
an autosomal chromosome and finally that mating is random. 
HWE can be used to discard variants deviating significantly from the principles of 
random selection and is generally used in GWAS to filter genotyping errors (Turner et 
al. 2011). Deviation from HWE may also highlight underlying population stratification 
and selection bias (Wigginton, Cutler, and Abecasis 2005). During the UK Biobank 
SNP quality control step variants with a significant deviation from HWE were flagged 
and set to missing for the initial interim release. For the full release these SNPs were 




For the various cohorts of the CHARGE GWAS meta-analysis full details of their 
specific filtering steps can be found in the summary appendix. However in general 
variants that showed departure from HWE were discarded in line with existing 
methodology best practice (Turner et al. 2011). 
 
2.4.3 Population stratification 
Population stratification can arise by non-random mating, possibly due to geographic 
isolation of subpopulations or bottle-neck effects. Distinct populations can be then 
observed from the genotype allele frequencies. Such distortions of genotype allele 
frequencies can confound the relationship between a variant and an observed trait 
(Hellwege et al. 2017). 
Population stratification is accounted for by the Linear Mixed Model used by BOLT-
LMM, by using principal component analysis to adjust both the phenotype and 
genotype to weighted values, which then undergo standard association testing (Sze 
and Schloss 2016). This mixed-model association method has been shown to reliably 
handle geographic population structure, family relatedness and cryptic relatedness 
(P.-R. Loh et al. 2015). 
 
2.4.4 Sex discrepancy 
Initial quality control for any GWAS includes a check for sample handling errors 
(Marees et al. 2018). One of the easiest to perform is to check for the reported sex 
against that predicted from the genotype data. Software tools for analysing genotype 
data often provide a suitable function, such as GWASTools (Turner et al. 2011) and 
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PLINK (S. Purcell et al. 2007). These checks can also reveal sex chromosome 
anomalies, such as Turner or Kleinfelter syndrome. 
 
2.4.5 Sample relatedness 
Pairwise kinship can be inferred from the genotyping data using as few as 100,000 
SNPs. By reviewing whether or not two individuals share alleles at a specific locus that 
are identical by descent (IBD), and the overall ratio of IBD alleles, the family 
relationships can be revealed. For example, parent-child pairs should share one IBD 
allele at every locus (within a margin of error for technical artefacts and random 
mutations). In a similar method the sharing of alleles between siblings should overall 
show a ratio of shared alleles of 25% for zero shared alleles, 50% for one shared allele 
and 25% for two shared alleles. This information can then be used to inform the 
analysis plan (Turner et al. 2011). 
The UK Biobank used the KING algorithm, as it is resistant to falsely identifying 
relatedness due to confounding by population structure (Manichaikul et al. 2010). 
 
2.4.6 Low call rate (Missingness) and heterozygosity 
Storage of DNA and technical issues can result in a low genotyping efficiency or call 
rate. SNPs exhibiting an overall call rate of less than 98-99% are generally considered 
poor quality and should be removed from the analysis (Turner et al. 2011).  
Sample contamination can be checked by examining the heterozygosity over common 
(MAF ≥ 0.05) autosomal markers, with a high heterozygosity (>3 Standard Deviations 
above the mean) being indicative of contamination. Plots of the B allele frequency 
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(BAF) fluorescence intensity and the log(R) ratio (LRR – a normalised measure of 
overall signal strength) against the chromosomal position, can also show abnormal 
clustering of values in the case of contamination (Igo et al. 2016). Runs of 
Homozygosity (ROH) or long tracts of homozygous genotypes, caused by the 
inheritance of identical haplotypes from a common ancestor, as well as a mixed ethnic 
ancestry can also confound the measures of heterozygosity and so these plots should 
be examine with the study population in mind (Ceballos et al. 2018). 
2.4.7 Imputation quality 
Although modern genotyping arrays consist of millions of probes capable of providing 
the direct genotype for these SNPs, this information can be expanded by imputation 
to provide greater genome wide coverage and statistical power for the following GWAS 
(Marchini and Howie 2010). 
Imputation accuracy is dependent on the size of the imputation panel (combination of 
population specific panels can boost the performance especially with regards to rare 
alleles), the algorithm used to impute the missing variants (for example BEAGLE (B. 
L. Browning and Browning 2009) or IMPUTE (B. N. Howie, Donnelly, and Marchini 
2009)), minor allele frequency (with rarer alleles being more difficult to accurately 
model) and the degree of genetic diversity between the study population and the 




2.4.8 Imputation of HLA alleles 
HLA*IMP:02 software (Dilthey et al. 2013) was used to impute 11 loci within the MHC 
region with a multi-population reference panel. Reference panels were constructed 
specifically for each of the loci from a number of datasets (Table 2-4) (Bycroft et al. 
2018). 
Table 2-4 : UK Biobank HLA loci imputation references 





HLA-A CEU+58,GSK,YRI,1000G,T1DGC 661 8,085 
HLA-B CEU+58,GSK,YRI,1000G,T1DGC 927 9,120 
HLA-C CEU+58,GSK,YRI,1000G,T1DGC 908 7,732 
HLA-DRB1 CEU+58,GSK,YRI,1000G,T1DGC 626 8,869 
HLA-DRB3 GSK,KC,SW 849 880 
HLA-DRB4 GSK,KC,SW 849 865 
HLA-DRB5 GSK,KC,SW 801 808 
HLA-DQA1 CEU+58,GSK,YRI,T1DGC,PA 747 6,242 
HLA-DQB1 CEU+58,GSK,YRI,1000G,T1DGC 623 8,491 
HLA-DPA1 T1DGC,PA,SW 794 6,067 
HLA-DPB1 GSK,T1DGC,PA,SW 691 6,176 
CEU+58 = British 1958 cohort, HapMap CEU and CEPH CEU+; GSK = GlaxoSmithKline dataset; YRI 
= HapMap YRI; 1000G = 1000 Genomes project; T1DGC = Type 1 Diabetes Genetics Consortium; KC 
= King’s College African-American individuals; SW = Karolinska Institutet Swedish individuals; PA = 





2.5 Genome wide association software 
2.5.1 BOLT-LMM 
The BOLT-LMM algorithm using a modified form of the linear mixed models that have 
become the most common method for association testing in Genome-Wide 
Association Studies (GWAS) (P.-R. Loh et al. 2015).  
Due to the standard linear mixed model assuming that, for a complex trait, all variants 
are causal with small effect sizes (Goldstein 2009), the algorithmic complexity 
approaches O(MN2) or O(M2N) – where M is the number of samples and N is the 
number of SNPs - this becomes prohibitively expensive in computational requirements 
when applied to the large biobanks, such as the UK Biobank (P.-R. Loh et al. 2018).  
Even although recent meta-analysis GWAS have identified thousands of significant 
loci for complex traits such as height and BMI (Yengo et al. 2018), this is still a limited 
set of variants and so BOLT-LMM adapts the standard linear model to account for 
non-Gaussian prior distributions of effect size to better model the contributing genetic 
architecture to a phenotype (P.-R. Loh et al. 2015). 
The BOLT-LMM algorithm has four main steps (P.-R. Loh et al. 2015), each reducing 
the complexity to O(MN) or to linear complexity from the exponential complexity of the 
standard approach, O(M2N). 
1a. Estimation of variance parameters 
1b. Computation of infinitesimal mixed-model association statistics 
2a. Estimation of Gaussian mixture-model parameters 
2b. Computation of Gaussian mixture-model association statistics 
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BOLT-LMM was used to provide the GWAS results for Chapter 4 and 5.  
 
2.5.2 LMOR adjustment 
The Linear Mixed Model utilized by BOLT-LMM uses principal component correction 
along with logistic regression in order to account for population stratification (J. Yang 
et al. 2014). When used with binary traits this results in estimates of genetic effect on 
a different scale to the odds ratio derived from logistic regression. This makes direct 
comparison between studies, for example in meta-analysis of GWAS, problematic 
(Cook, Mahajan, and Morris 2017). 
Prior to meta-analysis by METAL studies that had used BOLT-LMM for association 
testing (UK Biobank, HRS and WLS were transformed by using the LMOR function 
(Lloyd-Jones et al. 2018b) to odds ratios.  
 
2.5.3 Case-Control balance 
Due to the reliance of BOLT-LMM on basing the calculation of p-values on a chi-
squared distribution, inflated Type 1 errors (false positives) can occur when the case-
control ratios are severely imbalanced. The impact of the Type 1 error inflation for 
binary traits depends on the sample size, case fraction and minor allele frequency 
(MAF). Simulation studies have shown that for case fractions > 10% and MAF > 0.1%, 
in the UK Biobank data (N=459K), BOLT-LMM p-values are correct and not 
significantly affected by the Type 1 error inflation (P.-R. Loh et al. 2018). The 
prevalence of the low grip phenotypes within the UK Biobank, stratified into the 60-70 
age cohort, has a suitable number of cases. 
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 For a smaller sub-sample (N=150K) Type 1 error inflation is an issue at higher p-value 
thresholds than 5 x 10-8, for example the occasionally used “suggestive” p-value 
threshold of 1 x 10-6. However the inflation is not significant at case fractions > 10%, 




The PLINK toolset (S. Purcell et al. 2007) was used for additional analysis and 
confirmation of results. Analysis of allosomes (chromosomes X and Y) and 
mitochondria SNPs to the development of low grip strength was preformed using 




2.6 GWAS Meta-analysis 
2.6.1 METAL 
Meta-analysis was preformed using the METAL software from the Center for Statistical 
Genetics, at the University of Michigan (Willer, Li, and Abecasis 2010a).  
Meta-analysis was performed by one of two methods, the sample size method (the 
default method in METAL and for our analyses) which uses the direction of effect and 
the P-value to produce a signed Z-score (extremely negative Z-scores therefore 
indicate a small P-value). The allele specific Z-scores are then combined using a 
weighting scheme based on the effective sample size – either provided in the 
configuration or data files.  
The Standard Error method was also used for exploratory analysis, and in this 
approach the β-coefficients were weighted by their estimated standard errors (Willer, 





2.7 Linkage disequilibrium 
2.7.1 LDlink 
Calculation of linkage disequilibrium for interpretation of the relationship between 
genomic risk loci was occasionally performed as a secondary analysis. LDlink was 
used for this purpose (Machiela and Chanock 2015). 
LDpair was the most commonly used module, with the reference population set to 
GBR (1000 Genomes population reference – European ancestry – British in England 
and Scotland) (Auton et al. 2015). 
 
2.7.2 Linkage disequilibrium metrics 
In order to assess correlation between variants LDlink calculates a number of statistics 
including R2, D’ and goodness-of-fit (Chi-square and p-value). If R2 is greater than 0.1 
then linkage disequilibrium is present, with 0.6 being an indicator of moderate LD and 
0.8 a measure of high LD. 
D’ is an indicator of allelic segregation for two genetic variants, essentially whether or 
not two alleles at different sites are inherited together. With a range between 0 and 1, 
a value of 0 indicates alleles are not linked while a value of 1 means that at least one 
of the expected haplotype combination has not been found. 
R2 measures the correlation of alleles for two variants, giving a value between 0 and 
1. R2 of 0 indicates that the alleles are independent, while a value of 1 shows that the 
allele of one variant predicts an allele in a second variant, they are therefore in linkage 
disequilibrium. R2 accounts for the Minor Allele Frequency while D’ does not. 
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2.7.3 Heritability estimates 
The LD Score Regression software, LDSC, was used to provide heritability estimates 
for the GWAS meta-analysis traits, for example EWGSOP low grip strength. LDSC 
overcomes confounding bias due to population stratification or relatedness, and 
accounts for the issue of polygenicity common in complex trait analysis (heritable 
component is due to many variants with individual small effect sizes) by utilizing 
linkage disequilibrium to control for these. European LD scores from the 1000 
Genomes project were used as the LD reference (B. K. Bulik-Sullivan, Loh, Finucane, 
Ripke, Yang, Patterson, et al. 2015). Further details are available in the specific 




2.8 Annotation of results 
2.8.1 FUMA 
Annotation and functional mapping of variants was undertaken using FUMA 
(Watanabe, Taskesen, Van Bochoven, et al. 2017). Summary statistics from both the 
GWAS and Meta-analysis GWAS for low grip strength and sarcopenia was annotated 
using a range of modules available through FUMA. 
FUMA’s default settings were used for lead SNP and candidate SNP identification, 
see Table 2-5. 
Table 2-5 : FUMA settings 
Meta-analysis GWAS 
 
Sample size - combined 254894 
Sample size - female only 133222 
Sample size - male only 119123 
  
Maximum P-value of lead SNP (<) 5.00E-08 
Maximum P-value cut-off (<) 0.05 
r2 threshold to define independent significant SNPS (≥) 0.6 
2nd r2 threshold to define lead SNPs (≥) 0.1 
Reference panel population UKB release2b 10K European 
Include variants in reference panel  
(non-GWAS tagged SNPs in LD) 
Yes 
Minimum Minor Allele Frequency (≥)  0 
Maximum distance between LD blocks 
 to merge into a locus (< kb) 
250 
  
MHC region Included 






MAGMA (v1.08) (de Leeuw et al. 2015) was used by FUMA for gene and gene-set 
analysis. MAGMA uses a multiple regression approach (multiple linear principal 
components regression) in order to incorporate linkage disequilibrium between genetic 
markers for a gene. MAGMA uses a linear regression model even when the phenotype 
to be analysed is binary; although the F-test used to compute the gene p-value 
assumes a continuous trait, testing has shown that the results remain accurate (de 
Leeuw et al. 2015). 
 
2.8.3 GTEx 
FUMA uses data from the Genotype-Tissue Expression (GTEx) project in order to 
annotate lead SNPs with quantitative trait loci (QTL) that are significantly associated 
with a measurable phenotype. For eQTLs the associated phenotype is the expression 
of a gene and GTEx provides tissue specific eQTLs for a large number of variants 
(Lonsdale et al. 2013; “The GTEx Consortium Atlas of Genetic Regulatory Effects 
across Human Tissues” 2020). Initial exploratory annotation of GWAS meta-analysis 




2.9 Multiple testing 
The large number of simultaneous tests in Genome-Wide Association Studies, results 
in a multiple testing problem which has to be taken into account when drawing 
inferences from the results. 
The following methods were used for correction of multiple testing: 
2.9.1 Bonferroni 
The aim of the Bonferroni correction is to control the probability of obtaining at least 
one false positive result. The p value is adjusted by dividing the statistical threshold of 
0.05 by the number of tests conducted – in the case of GWAS this is the number of 
SNPs.  
A genome-wide significance threshold was proposed by the International HapMap 
Consortium based on an estimation of the “effective number of independent tests” of 
150 per 500 kbp (kilo base pairs) in the CEU (Utah residents with European ancestry), 
CHB (Han Chinese) and JPT (Japanese) populations at a MAF ≥ 0.05 (5%). The 
additional diversity of the African population, YRI (Nigerian), increased the test 
numbers to 350 per 500 kbp (Belmont et al. 2005). For the Non-African populations 
this results in a significance threshold of 5.5 x 10-8 for a 3 Gb human genome, which 
has become the de facto standard for GWAS significance. For African populations a 
more stringent threshold is required, with 1.0 x 10-8 being proposed (Hoggart et al. 
2008). 
The significance threshold for GWAS was estimated by Dudbridge et al using a 
permutation procedure on GeneChip 500K Affymetrix array data from the Wellcome 
Trust Case-Control Consortium. They found that a genome-wide significance 
threshold to be approximately 7.2 x 10-8 in the UK population of European ancestry, 
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based on 359,491 available SNPs (Dudbridge and Gusnanto 2008), which confirms 
the estimation by the HapMap consortium. 
However due to Linkage Disequilibrium (LD) many SNPs are correlated and so cannot 
be considered as independent tests (Vergara-Lope et al. 2019). Bonferroni correction 
can therefore be considered conservative and may discard real associations. 
 
2.9.2 Benjamini-Hochberg 
The Bejamini-Hochberg false discovery rate (FDR) (Benjamini and Hochberg 1995) 
controls for the proportion of Type 1 errors (incorrectly rejecting the null hypothesis), 
or false positives in an analysis. I used this method to provide adjusted p-values for 
the Two-Sample Mendelian Randomisation analysis, over the more stringent 
Bonferroni correction. Applying Benjamini-Hochberg FDR adjustment to GWAS is 
problematic since the method assumes that the tests (in this case the SNPs) are 
independent of each over (Marees et al. 2018). 
 
2.10 Genetic correlation 
Cross-trait Linkage Disequilibrium score regression can be used to test whether two 
traits share any genomic variants representing underlying pathways or mechanisms.   
The LDSC software (B. K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, Patterson, et 
al. 2015) was used to investigate genetic correlation between muscle strength or 
function traits, and a range of phenotypes of interest. LDSC uses reference linkage 
disequilibrium data in order to help reduce bias due to cryptic relatedness and 
population stratification (B. K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, Patterson, 
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et al. 2015). GWAS summary statistics can then be used to compare the underlying 
genetic correlation between two traits of interest. 
LD score regression intercept provides a measure of the bias due to population 
stratification and cryptic relatedness. The heritability of a trait is expressed on a liability 
scale so that it is comparable across studies (h2).  
 
2.11 Mendelian randomisation 
Mendelian randomization allows the inference of causal associations between 
heritable complex traits, such as low grip strength and diabetes, by using genetic 
instruments (D. M. Evans and Davey Smith 2015; Burgess, Foley, and Zuber 2018; 
Pingault et al. 2018). Genetic Instruments are Instrumental Variables or variables 
associated with the risk factor of interest, which are not related to any confounders 
and affect the outcome only through the risk factor. In the case of Genetic Instruments, 
genomic variants associated with the risk factor are used since these are set at birth. 
By using genetic instruments from our previous multi-cohort, community based 
Genome-Wide Association Study (GWAS) meta-analysis of low grip strength in older 
people (256,523 Europeans aged 60 years and over ) (G. Jones et al. 2020)  
Mendelian randomization can be used to infer causal relationships with a potentially 
modifiable biomarker, such as increased levels of circulating vitamin D being 
associated with lower risk of multiple scelorosis (OR=0.963; 95%CI=0.945-
0.981)(Jiang, Ge, and Chen 2019), without the confounding of outcome and exposure 
that can be problematic in observational studies. The methodology used is discussed 
in greater detail in Chapter 6. 
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2.11.1 Two Sample MR 
Two sample Mendelian randomization (MR) can be used to perform MR using GWAS 
summary results, where the SNP-exposure effects and the SNP-outcome effects are 
obtained from separate studies(Pierce and Burgess 2013). This allows the use of large 
pre-existing GWAS analyses to infer casual inferences between two traits, which are 
not measured in the same set of samples(Hemani et al. 2018). For Chapter 6 the R 
package TwoSampleMR (https://mrcieu.github.io/TwoSampleMR/) was used, further 
specific details are available in Chapter 6 methods. 
 
2.12 GWAS Catalogue 
The NHGRI-EBI GWAS Catalog of published genome-wide association studies was 
used to manually annotate and investigate related traits for lead SNPs from the GWAS 





2.13 Statistical and general programming languages 
Throughout this thesis I have used STATA 15.1 and R 3.4.9 to 3.5.1 for statistical 
analysis. STATA was used for the majority of the regression analysis and 
interpretation of data. R was used for more specialised packages such as 
TwoSampleMR, as well as visualisation and reformatting of data. 
Linux shell scripts were used to run various software and packages on the ISCA Linux 
cluster. In addition shell scripts were used to format data for input into these packages 
and to filter results on given parameters. When greater error control or specialised 
libraries were required I also occasionally used Python scripts. Examples of scripts 
and code used in the main parts of the GWAS Meta-analysis and associated studies 
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The underlying mechanisms which result in the state of sarcopenia in older adults is 
thought to include an autoimmune component. In this analysis we show that 
sarcopenia is associated with alleles of six genes from the Human Leukocyte Antigen 
region, this is independent of a wide range of known autoimmune conditions, including 
Rheumatoid Arthritis.  
My contribution to this article included analysis and interpretation of the data – 







Aging is characterized by chronic inflammation and loss of muscle mass and strength, 
termed sarcopenia. Human Leukocyte Antigen (HLA) types are major drivers of 
autoimmune disease, although with limited penetrance. We tested whether HLA types 
and related genetic variants are associated with sarcopenia in autoimmune disease 
free older people.  
Methods 
Data from 181,301 UK Biobank European descent volunteers aged 60 - 70 with 
measured hand-grip strength and impedance. Logistic regression analysis estimated 
HLA types sarcopenia associations, adjusted for confounders and multiple testing.  
Results 
Of 100 HLA types (allele frequency >1%), six increased sarcopenia likelihood, after 
multiple statistical testing correction. Participants with two HLA-DQA1*03:01 alleles 
had 19.3% increased sarcopenia likelihood (Odds Ratio 1.19, 95% Confidence 
Intervals 1.098-1.295, p=2.84*10-5), compared to no alleles. HLA-DRB4*01:03 
homozygotes had a 15.4% increased likelihood of sarcopenia (OR 1.1539, CI 1.079-
1.234, p=2.66*10-5). Participants with at least 6 of the possible 12 HLA alleles 
associated with sarcopenia had 23% increased likelihood of sarcopenia (OR 1.23 CI 
1.123-1.346, p=7.28*10-6).  
 Of 831 non-coding genetic variants in the HLA region previously implicated in disease, 
4 were associated with sarcopenia, including rs41268896 and rs29268645 (ORs = 




Variation in specific HLA types and non-coding SNPs are associated with sarcopenia, 
in 60 to 70 year old carriers free of diagnosed autoimmune diseases, with cumulative 
risks having substantial effects. More work is also needed on whether some patients 









Immuno-senescence and ‘Inflammaging’ are characterized by a low grade chronic pro-
inflammatory state associated with ageing, which results from an imbalance between 
the inflammatory and anti-inflammatory networks (Franceschi et al. 2007)(Bektas et 
al. 2017). The Human Leukocyte Antigens (HLA) have a major role in mediating the 
chronic inflammatory pathway in autoimmune disease via antigen presentation to the 
CD4+/8+ T cells (Dendrou et al. 2018). The HLA complex has long been associated 
with autoimmune disorders and infectious disease (Shiina et al. 2009). Examples of 
associations between certain HLA types and autoimmune disease include HLA-B*27 
and spondyloarthritis (SpA), HLA-B*51 and Behcet’s disease (Bodis, Toth, and 
Schwarting 2018), and HLA-DRB1*15:01 and multiple sclerosis (Goodin et al. 
2018)(Moutsianas et al. 2015). However, autoimmune diseases are generally not 
monogenic or fully penetrant, but rather are complex polygenic diseases influenced by 
environmental factors (despite having over 110 linked genes, excluding HLA types, 
the heritability of multiple sclerosis is approximately 28% (Goodin 2016)).  
Sarcopenia, loss of muscle mass and strength during ageing, is associated with 
reduced physical functioning and is associated with increased risks of morbidity 
(including falls and fractures) and mortality (Cruz-Jentoft et al. 2010) (Brown, Harhay, 
and Harhay 2016). The European Working Group on Sarcopenia in Older People 
(EWGSOP) defines age-related Sarcopenia to include both low muscle mass and low 
muscle function (Cruz-Jentoft et al. 2010). The Baltimore Longitudinal Study of Aging 
(BLSA) found evidence that this can occur as early as age 40 in both men and women 
(Metter et al. 1997), with progressive decline over time. Previous studies have 
presented evidence for the role of inflammation in sarcopenia (Dalle, Rossmeislova, 
and Koppo 2017)(Westbury et al. 2018), and it is becoming apparent that contributors 
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to disease vary in penetrance from Mendelian disorders to complex diseases 
(Bastarache et al. 2018).  
While muscle loss is a classical feature of multiple sclerosis and some other 
autoimmune conditions, little is known of whether the carrier status genetic 
predisposition to autoimmunity accelerates muscle loss in later life. We aimed to 
investigate the impact of HLA types on susceptibility to sarcopenia in individuals 




3.4 Methods  
We used data from 451,447 UK Biobank participants of European descent, confirmed 
by principal components analyses of genome-wide genetic information from a 
selection of participants who self-identified as ‘white European’ (Pilling et al. 2017). 
The UK Biobank is a volunteer study where participants visited one of 22 assessment 
centres across the UK. A range of physiological and questionnaire data was collected, 
including genetic data from blood draws (Sudlow et al. 2015). Genotyping data was 
generated on the initial ~50,000 participants using the Affymetrix UK BiLEVE Axiom 
array and the ~450,000 participants of the remaining cohort were genotyped using the 
Affymetrix UK Biobank Axiom array - the two arrays sharing over 95% similarity 
(http://www.ukbiobank.ac.uk).  
 
3.4.1 Phenotype definitions 
Sarcopenia was classified using the EWGSOP definition (Cruz-Jentoft et al. 2010), 
based on having both low hand grip strength and skeletal muscle mass index (SMI). 
For grip strength the highest value from hand grip strength, left and hand grip strength, 
right was taken as the selected metric. Low grip strength was defined as under 30kg 
in Males and under 20kg in Females, as measured by Jamar J00105 hydraulic hand 
dynamometer.  
Skeletal muscle mass (SMM) was calculated using the following equation from 
Janssen et al (I Janssen et al. 2000); 
SMM (kg) = [(Ht2 ∣ 𝑅 × 0.401) + (gender × 3.825 + (age × −0.071)] + 5.102 
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Where Ht is standing height in centimetres measured at the initial assessment; R is 
BIA resistance in ohms for the whole body taken by Tanita BC418MA body 
composition analyser at the initial assessment visit; for sex, men = 1 and women = 0; 
and age is in years. A Skeletal muscle mass index (SMI) was then calculated from the 
SMM. 
SMI = SMM/Ht-in-meters2 
Low SMI was defined by Janssen et al. as under 8.87 in Males and under 6.42 in 
Females. Analysis was restricted to the age range of 60-70. We excluded a small 
number participants with max grip strength or lean mass (from BIA) greater than 4 
standard deviations from the mean (SMI > 46.61; max grip > 73.91). 
 
3.4.2 Auto-immune disease exclusions 
The HLA region has been associated with a wide range of autoimmune diseases 
(Matzaraki et al. 2017; Dendrou et al. 2018), and a number of these diseases impact 
the measurements used by this study in order to define sarcopenia, such as muscle 
weakness (through the proxy of grip strength) and lean muscle mass. In order to 
resolve any association between the HLA region and sarcopenia in later life, 
participants with diagnosed autoimmune disease were excluded. One additional factor 
to consider is that treatment of many autoimmune conditions may involve anti-
inflammatory steroids, such as glucocorticoids (Fullerton and Gilroy 2016). 
Glucocorticoids being one of the most common causes of drug-induced myopathy 
(Gupta and Gupta 2013). 
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A list of 57 (including subtypes) autoimmune diseases were generated from previous 
review articles (Cárdenas-Roldán, Rojas-Villarraga, and Anaya 2013) and the ICD-10 
codes used to exclude participants from the initial analysis (Supplementary Table s3-
1). This list was not exhaustive and certain autoimmune conditions not included are 
mentioned in the discussion. In addition, UK Biobank self-reported data was also used 
based on the autoimmune conditions in the ICD-10 list. Following the initial analysis 
any additional autoimmune diseases associated with the HLA types shortlisted, were 
added to the exclusion criteria and formed the basis of the secondary analysis. 
 
3.4.3 HLA imputation 
Imputation of HLA types was performed centrally by the UK Biobank team. In brief, 
HLA*IMP:02 (Dilthey et al. 2013) was used to impute the four-digit HLA types from 
genotype information, with a number of modifications: localization feature turned off; 
graph sampling error (mS) and graph building error (mB) probabilities were both set 
to 0.001; and the number of sampled haplotype pairs was set to 5 (Motyer and Leslie 
2016). Individuals are therefore coded as 0, 1 or 2 depending on the number of HLA 
alleles carried for each gene. The methods allow for imprecise coding (e.g. 1.92) to 
indicate the confidence in HLA type imputation. Some HLA type codes indicate 
unknown or other HLA types (e.g. *99:01), and these were not included in analyses. 
HLA-types below 1% frequency were excluded from analyses. 
 
3.4.4 Statistical Analysis 
Logistic regression analyses were performed for each HLA type against sarcopenia, 
adjusted for age, sex, genotype array, and the first five principal components for 
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ancestry.  Cohorts were restricted to the age range 60 to 70 and of European descent. 
Participants with known autoimmune disease were excluded as previously described, 
based on Hospital Episode Statistics data (ICD-10 codes) and self-reported fields. 
HLA types were modelled first assuming an additive effect, and secondly comparing 
participants with 2 alleles to those with 0. This was in order to model the effect of 
recessive modes of inheritance of the HLA types within the cohort. 
Participants with imprecise HLA imputations were recoded for the second, categorical 
analysis (i.e. estimated allele dose between 0 and 0.25 set to 0, values between 0.75 
and 1.25 set to 1, and finally between 1.75 and 2 to 2; other doses were set to missing 
due to imprecise imputation). Correction for multiple testing was applied using the 
Benjamini-Hochberg method. Statistical analyses were performed in STATA (v14.1) 
and R (v3.3.2). Charts and figures were generated with package metafor (v2.0). 
After analysing each HLA type for its association with sarcopenia we performed a 
literature search to identify any autoimmune diseases implicated by the significant HLA 
types not already included in the autoimmune exclusion criteria. A second analysis 
was performed after participants with diagnoses of the autoimmune diseases identified 
had been added excluded; these are the final results presented. 
 
3.4.5 Non-coding SNPs previously linked to a phenotype in previous Genome-Wide 
Association Studies.  
The HLA types assessed so far were based on the protein-coding sequence of the 
HLA protein expressed. We also investigated non-coding SNPs within the HLA region 
that have previously been associated with traits in the GWAS catalogue; SNPs in the 
HLA region (Shiina et al. 2009) between GRCh.v38: Chr6:29545629 (start of GABBR1 
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transcript ENST00000355973.7, minus 10Kb) and GRCh.v38: Chr6:33419924 (end of 
KIFC1 transcript ENST00000428849.6, plus 10 Kb) were downloaded from the 
NHGRI-EBI GWAS Catalogue(Burdett, T; Hall, PN; Hastings, E; Hindorf, LA; Junkins, 
HA; Klemm, AK; MacArthur, J; Manolio, TA; Morales, J; Parkinson H; Welter 2018). 
SNPs labelled with one or more of the following contexts were excluded stop_gained, 
synonymous_variant, missense_variant, non_coding_transcript_exon_variant, 
frameshift_variant or inframe_deletion, in order to prioritise variants with a possible 
regulatory role over variants involved in changes to protein coding. Only SNPs with 
genome wide significance with a reported trait (p-value < 5*10-8) were included in the 
analysis. These were tested for their association with sarcopenia using the methods 
described above for HLA type analysis. P-values < 1*10-5 were deemed to be 
significant (a commonly used cut-off for suggestive associations in GWA studies). 
Associations between these SNPS and sarcopenia-associated HLA types were also 
calculated. The GTEx database (“GTEx Analysis V7 (DbGaP Accession 
Phs000424.v7.P2) Single-Tissue Cis-EQTL Data” 2018) was used to identify genes 




We selected 196,099 UK Biobank participants of European descent aged 60-70 with 
complete phenotype, diagnosis, and genotype data for investigation. Of these, 14,798 
participants had at least one diagnosed autoimmune disease (including type-1 
diabetes, multiple sclerosis, and rheumatoid arthritis, see methods for details) and 
were excluded from analyses. The remaining 181,301 participants were included in 
the analysis. The mean age was 64.1 years and 95,340 were female (Table 1). Of 
85,961 men included in the analysis 3,510 were defined as having sarcopenia 




Table 3-1: UK Biobank participant characteristics 
    n min-max mean (SD) 
Age of study participant 
(years) 181,301 60-70 64.11 (2.85) 
BMI (Kg/m2) 181,301 12.81-68.41 27.52 (4.46) 
Grip strength (Kg) 181,301 0-73 31.09 (10.71) 
Skeletal muscle mass (Kg) 181,301 8.57-46.13 21.96 (6.00) 
 
  
   




Female 95,340 52.59 
 








None 48,224 26.94 
 
Secondary 28,870 16.13 
 
College-level 26,810 14.98 
 







Never 90,242 50.01 
 
Previous 75,618 41.9 
 
Current 14,602 8.09 
 
EWGSOP Sarcopenia   
 No 166,251 91.70 
 Yes 15,050 8.30 
 
Note: UK Biobank participants aged 60-70 of European descent with complete grip strength, skeletal 
mass, genotype (HLA), and autoimmune diagnosis data. Participants with a diagnosis of autoimmune 




Of 100 HLA types with allele frequency >1%, six were associated with sarcopenia 
(EWGSOP definition) in logistic regression models adjusted for age, sex, genotyping 
array type, and population structure (genetic principal components 1-5), after 




Figure 3-1: Forest plot of HLA types associated with Sarcopenia phenotypes. 
Note: Additive logistic regression analysis of 97 HLA-types associated with sarcopenia (Benjamini-Hochberg correction for multiple testing applied). OR=Odds 
Ratio per allele of HLA-type, CI=Confidence Interval, EWGSOP=Combined sarcopenia definition: low grip and muscle mass. HLA types passing the FDR cut-




We compared participants with two alleles of each HLA-type to those with zero alleles, 
with the assumption of larger effects with a recessive mode of inheritance; participants 
homozygous for HLA-DQA1*03:01 have 19.3% (Odds Ratio 1.19, 95% Confidence 
Intervals 1.098-1.295, p=2.84*10-5) increased likelihood of sarcopenia, compared to 
those without HLA-DA1*03:01 (Supplementary Table s3-1) and HLA-DRB4*01:03 
homozygotes had a 15.4% increased likelihood of sarcopenia (Odds ratio 1.15, CI 
1.079-1.234, p=2.66*10-5). When the six HLA-types were combined, participants with 
at least six alleles (of a possible 12 - each person can have up to two alleles of each 
HLA type) had 23% increased likelihood of sarcopenia (n= 5,685 participants of 
181,301; OR 1.23, 95% CI 1.123-1.346, p=7.28*10-6).  
Seven HLA-types were associated with the sarcopenia definition based on grip 
strength alone, and six were associated with the sarcopenia muscle mass definition, 
with no overlap between the alleles associated with the two phenotypes (Figure 3-1) 
(Supplementary Table s3-2). All of the top HLA type associations for the EWGSOP 
definition of sarcopenia were also present in the low grip phenotype, with the exception 
of HLA-C*15:02 which did not reach significance after correction for multiple testing in 
the low grip phenotype analysis. Conversely, the HLA types associated with low 
muscle mass (HLA-B*27:05 OR 1.079, 95% CI 1.042-1.117, p=1.64*10-5; HLA-
C*01:02 OR 1.093, 95% CI 1.054-1.134, p=1.65*10-6 and HLA-C*02:02 OR 1.059, 
95% CI 1.022-1.096, p=1.46*10-3) were distinct from those associated with the 
EWGSOP definition of sarcopenia. 
In sensitivity analyses we investigated the effect of adjusting for height and weight; all 
the reported risk increasing associations between HLA-types and sarcopenia 
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remained significant, with nominal changes to effect sizes (Supplementary Table s3-
3). However, the three protective HLA-types associated with the sarcopenia grip 
definition were non-significant after adjusting for height and weight (p > 0.05). 
 
3.5.1 Non-coding Single Nucleotide Polymorphisms in HLA region 
We analysed 831 non-coding SNPs within the HLA region previously implicated in 
human traits at genome wide significance (p<5*10-8) available in the UK Biobank 
genotype data (frequency ≥1%). We found 216 SNPs nominally (p<0.05) associated 
with the EWGSOP definition of sarcopenia (Supplementary Table s3-4). 10 were 
associated with p-value <1*10-5 (commonly used cut-off for suggestive associations in 
GWA studies). Of these, we identified 4 independent signals (Table 3-2), after 
removing those in linkage disequilibrium (R2 >0.4, see Supplementary Table s3-5). 




Table 3-2: Non-coding SNPs within the HLA region associated with EWGSOP definition of sarcopenia (p ≤ 1.0 x 10-5) with gene 
expression information. 
RS id A1/A0 CHR:POS Trait OR 95% CI  p-value Expressed gene(s) Tissue type* 
rs41268896 ¥ A/G 6:32070069 Atopic 
dermatitis 
1.08 1.05-1.11 1.06E-08 ATF6B, CYP21A1P, BAG6, HLA-
DQA2, PRRT1 
MS, AS, AT, 
WB, SN 
rs2844479 C/A 6:31572956 Height 1.07 1.04-1.09 6.11E-07 BAG6, ATF6B, CSNK2B, LY6G5C, 
CYP21A1P 
AT, MS, HLV, 
TH, EM 
rs9268645 † G/C 6:32408527 T1 diabetes 1.06 1.04-1.09 1.50E-06 HLA-DQA2, HLA-DQB2, HLA-DQB1, 
HLA-DRB6, HLA-DRB9 
MS, WB, WB, 
MS, TH 
rs2072633 G/A 6:31919578 Coronary 
artery disease 
1.06 1.03-1.08 3.58E-06 CYP21A1P, ATF6B, HLA-DQA2, 
PSORS1C1, C2 
AS, MS, WB, 
TH, TE 
 
Note: Additive model; A1=Effect allele, A0=Reference allele, POS=build 37 base pair, OR=Odds Ratio, CI=95% Confidence Intervals. Trait = the top identified 
trait from the GWAS catalogue. * Tissue type: Adipose Subcutaneous=AS; Artery Tibial=AT; Colon Sigmoid=CS; Esophagus Muscularis=EM; 
Muscle_Skeletal=MS; Nerve Tibial=NT; Skin Not Sun Exposed Suprapubic=SN; Thyroid=TH; Whole Blood=WB; Heart Left Ventricle=HLV; Testis=TE. † 





We interrogated the GTEx eQTL (expression quantitative trait loci) database of SNP-
expression associations to determine the likely genes affected by these 4 genetic 
variants (Table 3-2, see Supplementary Table s3-6 for full details). This included 
specific HLA genes (HLA-DQA2, HLA-DQB2, HLA-DQB1, HLA-DRB6 and HLA-
DRB9), in addition to other genes with plausible mechanisms of action in sarcopenia 
(ATF6B, CYP21A1P, CYP21A2, BAG6, PRRT1, CSNK2B, LY6G5C, PRRC2A, 
PSORS1C1, C2). We also searched for protein QTLs in a recent paper by Sun et al. 
(Sun et al. 2018) and found that rs41268896 is highly correlated (R2=0.8 in UKB) with 
rs8111, a pQTL for ATF6A. 
We also investigated the combined effect of the 4 non-coding SNPs; participants with 
at least 4 effect alleles (of a possible 8), showed an increased likelihood of sarcopenia 








To the best of our knowledge, this is the first large human population study of HLA 
effects on sarcopenia in older people without autoimmune disease. We identified 6 
HLA types associated with sarcopenia in 181,301 UK Biobank participants of 
European descent aged 60-70. Although these have modest effect sizes (per allele 
odds ratios from 1.054 to 1.15) they are common in the study population, ranging in 
frequency from 3.7% to 24.8%. In combination, participants with more than six of the 
HLA-types had markedly increased likelihood of sarcopenia (27%). These results 
suggest that lifetime exposure to mild chronic pro-inflammatory state may contribute 
to risk of sarcopenia. 
We also identified 4 non-coding genetic variants in the HLA region of chromosome 6 
associated with sarcopenia. These are known to affect the expression of multiple 
genes, including HLA genes, in multiple tissues including skeletal muscle. Although 
more evidence is required for a clear causal link, this suggests that regulation in 
expression of HLA genes may also be an important driver of sarcopenia, not just the 
protein sequence (HLA-types). When taken in combination participants with more than 
four of the effect alleles, had an 11% increased likelihood of sarcopenia. 
The EWGSOP definition of sarcopenia, which combines low grip strength and low 
muscle mass, shares many of the associated HLA alleles with those seen in low grip 
strength definition alone. In contrast, there is little overlap with the low muscle mass 
definition. Often, grip strength alone is used to identify “frail” participants in population 






HLA-types associated with sarcopenia are also associated with conditions linked to 
joint pain and loss of function, such as rheumatoid arthritis (DRB1*04:01), ankylosing 
spondylitis (C*15:02), Behcet’s  disease (B*51:01, joint swelling and pain prevalence 
in 45-60% of cases (Zeidan et al. 2016)), and neuropathic pain (DQB1*03:02, although 
a meta-analysis (Veluchamy et al. 2018) only showed association to the two-digit allele 
DQB1*03). Other HLA alleles associated with sarcopenia include DQA1*03:01, which 
has been linked to pemphigus vulgaris, a painful autoimmune condition which can 
affect the skin, mouth and groin with blisters. DQB1*03:01 has only been shown to 
have an association previously as a protective allele against primary biliary cholangitis, 
although this study provides evidence of a novel association with sarcopenia. In this 
analysis we excluded participants with a self-reported or hospital diagnosis of 
autoimmune conditions, including those mentioned here, suggesting that the 
associations observed here are not due to diagnosed conditions. More work is needed 
on whether these associations are due to a general pro-inflammatory effect or 
represent sub-clinical manifestations of specific autoimmune processes. More work is 
also needed on whether some patients with sarcopenia have evidence of autoimmune 
processes and might benefit from targeted treatment. 
Some HLA types were protective for sarcopenia: increasing copies of DQB1*06:02, 
DRB5*01:01 and DRB1*15:01 were all associated with reduced likelihood of 
sarcopenia, and have previously been implicated in a number of studies in the 
development of multiple sclerosis (Goodin et al. 2018), although mainly as part of an 
extended haplotype including all three types. 
When we compared participants carrying two alleles of each HLA to those with zero 
we found far greater effect sizes; for example the likelihood of being sarcopenic for 





been reported as appearing with  increased frequency in a limited study of Brazilian 
patients with polyarteritis nodosa (de Lira Freire et al. 2009). Association of 
DRB4*01:03 with rheumatoid arthritis has mixed evidence in the literature with recent 
studies showing no association (K. Kim et al. 2016), while slightly older and smaller 
studies in a different population showing a link (Louthrenoo et al. 2015). HLA-
DQA1*03:01 has been previously shown to increase the risk of type 1 diabetes (Noble 
and Valdes 2011), when present as part of the DR4 haplotype or in conjunction with 
DQB*02:01 (Tollefsen et al. 2012). 
The analysis of low grip strength alone reinforced the associations seen in the 
EWGSOP sarcopenia definition analysis, with only a single additional association for 
DQA1*01:02. This type was protective against low grip strength and reported as 
associated with a multiple sclerosis-like condition in transgenic mice (Kaushansky et 
al. 2015). HLA alleles were only associated with low muscle mass using the additive 
model, C*01:02 and B*27:05, both of which have previously been linked to forms of 
arthritis – psoriatic arthritis (Chandran et al. 2013) and spondyloarthritis (Ma et al. 
2017). Neither type appeared in the associations for the combined EWGSOP 
phenotype of sarcopenia, suggesting potential independent effects. 
In our analysis of non-coding genetic variation in the HLA-region we identified 4 
genetic variants associated with sarcopenia. These SNPs also affect expression of 
genes other than HLAs, including ATF6B, which encodes a transcription factor in the 
unfolded protein response (UPR) pathway during endoplasmic reticulum (ER) stress 
and there has been speculation that ER stress may impair autophagy and myogenesis 
activity resulting in sarcopenia (Potes et al. 2017) (Deldicque 2013). rs41268896 is 
strongly correlated with the rs8111 (R2=0.8), known to affect protein levels of ATF6A 





increases ATF6B expression, whilst the rs8111 T allele (co-inherited) decreases 
ATF6A protein levels, suggesting a complex relationship; more work is required to 
understand this. The BAG6 protein product is also involved in elimination of misfolded 
proteins, including class-I HLA products (Yamamoto et al. 2017) (Y. Xu et al. 2013).  
CYP21A2 has a role in producing cortisol and aldosterone as part of the hypothalamic-
pituitary-adrenal (HPA) axis, disruption to the HPA has been linked to decline in 
physical function and aging (Gaffey et al. 2016)(Doleschall et al. 2014). 
The exclusion of autoimmune conditions, based on a previous literature, was not 
exhaustive. Further exclusions, for example polymyalgia rheumatica (ICD-10 M35.3), 
would help reinforce the evidence that sarcopenia has an auto-immune component 
separate from any other underlying autoimmune condition. Polymyalgia rheumatica 
(and the closely related condition, giant cell arteritis, GCA) in particular has been 
shown to involve muscle weakness, stiffness and functional impairment (Buttgereit et 
al. 2016), which would impact the low grip measurements used in the study. 
In addition GCA susceptibility has previously been associated with HLA-DRB1*04 
(odds ratio = 2.69, P = 1.5×10−11), while HLA-DRB1*15 and HLA-DRB1*16 have 
been noted to have a protective effect (OR = 0.65, P = 8.2×10−6)(Mackie et al. 2015). 
The common treatment for GCA are steroids, such as the glucocorticoids (Simon, 
Ninan, and Hissaria 2021), however glucocorticoid-induced myopathy is one of the 
most common causes of drug induced muscle weakness (Gupta and Gupta 2013) and 
so a sensitivity analysis of self-reported drug use could help to resolve any bias in the 
results due to treatments that impact muscle function and therefore the definitions of 





The strengths of this study include the large number of older participants with 
consistent sarcopenia measurements and medical records data available for analysis. 
However, it is a volunteer study and will therefore be healthier than the general 
population: effects of HLA types on sarcopenia may therefore be underestimated in 
this study. Additionally, autoimmune diagnoses may be under-reported as diagnoses 
are either self-reported or from hospital in-patient records only; further studies will be 
required. Future work should clarify the associations between HLA-types, circulating 







In this large study of older participants we identified 16 HLA-types associated with 
sarcopenia, especially with low hand grip strength, in the absence of autoimmune 
diagnoses. Chronic, low-grade autoimmune phenotypes may be present in these 
individuals, predisposing them to sarcopenia. Additional analysis of non-coding 
variants showed that SNPs involved the regulation of HLA, ER stress response and 
immune function genes are also associated with sarcopenia. Further studies into the 
long-term effects of HLA variation are required. More work is also needed on whether 
some patients with sarcopenia have evidence of autoimmune processes and might 






4 Analysis 2: Genome-wide meta-analysis of muscle 
weakness in older adults 
 
Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci 
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Low grip strength is a good predictor of overall muscle function and is a commonly 
measured metric, making a multi-cohort Genome-Wide Association Study meta-
analysis possible. By using the low grip cut-offs as defined by the European Working 
Group on Sarcopenia and genotyping data from members of the CHARGE consortium 
I have shown that there are fifteen genomic risk loci with low grip strength, 12 of which 
have not previously been associated with a continuous measure of grip strength, in 
older adults (age > 65) of European ancestry. 
 This analysis highlights the multiple pathways to the physical components of frailty 
and sarcopenia. 
 
My contribution included leading the writing of the paper and primary analyst for the 
multi-cohort study. In addition I coordinated the meta-analysis and helped draft the 
analysis plan. The resulting paper has been accepted for publication at Nature 
Communications: Jones, G., Trajanoska, K., Santanasto, A.J., Stringa, N., Kuo, C.L., 
Atkins, J.L., Lewis, J.R., Duong, T., Hong, S., Biggs, M.L. and Luan, J.A., 2021. 
Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci in 







Low muscle strength is an important heritable indicator of poor health linked to 
morbidity and mortality in older people. In a genome-wide association study meta-
analysis of 256,523 Europeans aged 60 years and over from 22 cohorts we identified 
15 loci associated with muscle weakness (European Working Group on Sarcopenia in 
Older People definition: n=48,596 cases, 18.9% of total), including 12 loci not 
implicated in previous analyses of continuous measures of grip strength. Loci include 
genes reportedly involved in autoimmune disease (HLA-DQA1 p=4*10-17), arthritis 
(GDF5 p=4*10-13), cell cycle control and cancer protection, regulation of transcription, 









Age-associated loss of muscle strength (termed dynapenia) (Brian C Clark and Manini 
2012) is one of the characteristic changes occurring with advancing age, and muscle 
weakness is considered a fundamental component of frailty and sarcopenia (Manini 
and Clark 2012). Individuals over 70 years old typically demonstrate up to 20% lost 
muscle mass compared with individual in their twenties (Mitchell et al. 2012) Although 
definitions of reduced muscle function in older people have focused on loss of muscle 
mass (“sarcopenia”) evidence now shows that muscle weakness itself is often more 
predictive of negative health outcomes (Cawthon et al. 2019). Muscle weakness 
causes difficulties in daily functioning (i.e. disability) and low muscle strength 
(measured as hand grip strength, considered a biomarker of general dynapenia) is 
predictive of future morbidity and mortality (Mitchell et al. 2012) over the long term 
(Taina Rantanen et al. 1999). Despite intensive research, causes of and contributors 
to muscle weakness in later life remain to be fully elucidated (Cruz-Jentoft et al. 2019). 
Importantly, muscle strength is heritable, and can thus be studied using genetic 
analysis. 
Previously a genome-wide association study (GWAS) by the CHARGE (Cohorts for 
Heart and Aging Research in Genomic Epidemiology) consortium identified two loci 
associated with maximum hand grip strength (as a quantitative trait) in 27,581 
Europeans aged 65 and over (Matteini et al. 2016). Another study on maximum hand 
grip strength (divided by weight) in mostly middle-aged UK Biobank participants 
(334,925 people aged 40 to 70, mean aged 56) identified and replicated 64 loci, many 
of which are known to have a role in determining anthropometric measures of body 
size (Tikkanen et al. 2018; Willems et al. 2017). These previous studies that 





may not provide insights into the age related loss of muscle strength that leads to a 
magnitude of weakness sufficient to call it a disease. 
Given the limited data on genetic contributions to a clinically meaningful level of 
muscle weakness in older adults, we aimed to determine the genetic variants and 
investigate causal pathways associated with low measured grip strength in 256,523 
older adults (aged 60+ years) of European ancestries from the CHARGE consortium. 
The primary analysis was based on the established 2010 European Working Group 
on Sarcopenia in Older People (EWGSOP) definition of low grip strength (Chapter 4), 
and results were compared to an analysis of the alternative Foundations of the 
National Institutes of Health (FNIH) definition based on its association with functional 






4.4.1 GWAS of low grip strength in older people 
I conducted a GWAS meta-analysis of low grip strength in participants aged 60 years 
or older of European ancestry from 22 studies yielding a combined sample of 254,894 
individuals. Individual studies used different genotyping platforms and imputation was 
predominantly performed using the Haplotype reference consortium (HRC) v1.1 panel.  
Over 70 year olds were not specifically excluded from the meta-analysis, with the 
analysis plan criteria being individuals over the age of 60. However due to the nature 
of the recruitment for the largest dataset, the UK Biobank, the upper age in this 
particular sample subset was 70.  
We excluded individuals below the age of 60 with low grip strength due to potential 
confounding with conditions causing Cachexia (such as cancer), or similar. In doing 
so we hoped to highlight age-specific associations to low grip strength, and their 
impact on healthy ageing. 
Two definitions of low muscle hand grip strength were utilized at the time of analysis. 
The primary analysis was of the 2010 EWGSOP criteria for sarcopenic grip strength 
(Grip strength < 30 Kg Male; < 20 Kg Female).  
GWAS was performed by each cohort individually using regression models, adjusted 
for age, sex (except in sex-specific models), and population substructure, accounting 
for relatedness and technical covariates as required by the individual study. No 
adjustment for anthropometric measures was made in the primary analysis, but the 
effects were explored in sensitivity analyses. Fixed-effects inverse variance weighted 
meta-analysis was performed using METAL (Willer, Li, and Abecasis 2010b) using the 





population structure (see Supplementary Methods for details, available online at 
https://www.nature.com/articles/s41467-021-20918-w and in Appendix). The following 
quality control filters were applied: minor allele frequency (MAF) > 0.01, imputation 
info score of > 0.4, and the variant present in at least two studies (UK Biobank – the 
largest included cohort - plus at least one other). The final analysis therefore included 
9,678,524 genetic variants. Associations that achieved a p<5*10-8 were considered 
statistically significant, with those reaching the more stringent threshold of p<5*10-9 
highlighted.  
Distinct loci were initially defined as two significant variants separated by >500kb. To 
identify independent signals at each locus we used FUMA (Functional Mapping and 
Annotation of Genome-Wide Association Studies) (Watanabe, Taskesen, van 
Bochoven, et al. 2017), which uses Linkage Disequilibrium (LD) information to 
determine independence (r2 threshold = 0.1 for independent significant single 
nucleotide polymorphisms (SNP)). We used Linkage Disequilibrium Score Regression 
(LDSC, v1.0.0) to estimate the level of bias (i.e. from population stratification and 
cryptic relatedness) in the GWAS, and the SNP-based heritability of low grip strength 
(B. K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, Consortium, et al. 2015). 
 
4.4.2 Locus overlap with diseases and anthropometric traits 
The GWAS catalog of published locus-trait associations (Buniello et al. 2019b) was 
searched to identify whether low grip strength-associated loci determined from our 
meta-analysis are known to influence other traits or diseases. In addition, we 
performed sensitivity analyses in the UK Biobank sample to determine whether 





were robust to adjustment for the following traits or diseases: height, weight, body 
mass index, osteoarthritis, rheumatoid arthritis, and osteoporosis (prevalent diseases 
were from the self-reported data at baseline or in the Hospital Episode Statistics). 
Analyses were performed in STATA (v 15) using logistic regression models adjusted 
for age, sex, principal components 1 to 10, assessment center, and genotyping array 
(the UK Biobank using two different Affymetrix microarrays that shared >95% of sites 
- Supplementary Methods). 
4.4.3 Gene Ontology Pathways, Tissue Enrichment, and eQTL analyses  
I utilized FUMA to perform functional interpretation of the GWAS results (Watanabe, 
Taskesen, van Bochoven, et al. 2017). In particular, FUMA performs gene-set analysis 
(using Multi-marker Analysis of GenoMic Annotation (MAGMA)(de Leeuw et al. 
2015a)) to identify pathways enriched amongst the significant genes (weighted by the 
SNP-associations in proximity to them), in addition to searching eQTL databases to 
identify SNPs that significantly alter the expression of genes in various tissues.  
We used MetaXcan to determine whether gene-level transcriptomic associations in 
GTEx v7 skeletal muscle data were enriched in the GWAS summary statistics for low 
grip strength (Barbeira et al. 2018). The analysis included 7,512 genes with measured 
expression in the dataset; we applied Benjamini-Hochberg multiple-testing correction, 
with adjusted p-values < 0.05 deemed to be significant. 
LD Score Regression applied to specifically expressed genes (LDSC-SEG) allows the 
identification of enriched tissue activity associated with GWAS results (Finucane et al. 
2018). We applied LDSC-SEG (v1.0.0) to the GWAS summary statistics using the 
datasets `Multi_tissue_gene_expr` and `Multi_tissue_chromatin` provided by the 





(n gene expression = 205, n chromatin = 498), with adjusted p-values < 0.05 deemed 
to be significant. 
 
4.4.4 Data Availability 
The GWAS summary statistics and supporting information on low grip strength in older 
people are available on the Musculoskeletal Knowledge Portal 
(http://musculoskeletalgenomics.org/). All relevant additional data is available on 
request from the authors.  
Supplementary result tables and methods available online at 








4.5.1 Study description 
The meta-analysis comprised 256,523 individuals of European descent aged 60 years 
or older at assessment from 22 independent cohorts with maximum hand grip strength 
recorded - including the UK Biobank, the US Health and Retirement Study (HRS), the 
Framingham Heart Study (FHS), and others. 46,596 (18.9%) of all participants had 
muscle weakness (dynapenia) based on hand grip strength (EWGSOP definition: grip 
strength < 30 Kg Male; < 20 Kg Female). Individual study characteristics are described 
in the Supplementary Information and in Supplementary Table s4-1.  
This chapter describes the primary analysis of EWGSOP definition low grip strength. 
Subsequent additional analyses described in later chapters: these include analysis of 
males and females separately, and investigation of casual pathways using mendelian 
randomisation. 
 
4.5.2 GWAS of low muscle strength identifies 15 loci 
We found 15 genomic risk loci to be associated (p<5*10-8; 8 loci p<5*10-9) with 
EWGSOP definition low hand grip strength in our GWAS meta-analysis of 22 cohorts 
(N=256,523, n=48,596 cases), adjusted for age, sex, and technical covariates (Figure 






Figure 4-1: Manhattan plot of low grip strength genome-wide association study -log10 
p-values 
 
The p-values are from a fixed-effects meta-analysis of 256,523 Europeans aged 60 or older from 22 
cohorts. The outcome was low hand grip strength grip strength cutoff (males <30 kg, females <20 kg). 
The x-axis is the chromosomal location, and the y-axis is the –log10 p-value for each genetic variant. 
The horizontal red line is the threshold for genome-wide significance (p<5*10-8). Fifteen genomic loci 
cross the threshold, and the lead variant (most significantly associated with low strength) is described 






Table 4-1: Genomic risk loci associated with low grip strength in 256,523 older men and women 
RSID Chr BP (b37) EA OA EAF OR p-value Nearest 
gene 
GTEx increased GTEx decreased 
rs34415150 6 32560477 G A 0.18 1.087 4.4*10-17 HLA-DRB1 HLA-DQA2(Snse) †; HLA-
DRB6; HLA-DQB2; HLA-DOB 
HLA-DQA1(Snse) †; HLA-DRB1; 
HLA-DQB1; HLA-DQB1-AS1 
rs143384 20 34025756 A G 0.59 1.056 4.5*10-13 GDF5 UQCC1(Musk/Cfib) †;  
FAM83C; CPNE1 
GDF5; RPL36P4 
rs62102286 18 46592408 T G 0.56 1.050 5.5*10-11 DYM 
 
DYM(Wb) † 
rs3118903 13 51099577 A G 0.22 1.059 6.7*10-11 DLEU1    RNASEH2B-AS1 
rs13107325 4 103188709 T C 0.07 1.094 7.4*10-11 SLC39A8 
 
UBE2D3 
rs11236213 11 74394369 G A 0.69 1.052 3.0*10-10 RN7SKP297 KCNE3; POLD3 RP11-864N7.4; CHRDL2 
rs34464763 12 15032860 A T 0.39 1.056 3.2*10-10 C12orf60 RP11-233G1.4 ERP27; SMCO3; C12orf60; MGP 
rs143459567 16 24600412 T C 0.04 1.126 3.4*10-10 RBBP6 
  
rs2899611 15 58327347 G T 0.50 1.044 6.0*10-9 ALDH1A2 
 
ALDH1A2 
rs958685 2 70703847 C A 0.49 1.044 6.5*10-9 TGFA TGFA (Ts)† TGFA (Bcor, Bcau, Bhyp, Bacc)† 
rs7624084 3 141093285 T C 0.56 1.044 8.5*10-9 ZBTB38 ZBTB38 (Skse, Esom, Snse)† ZBTB38 (Wb, Thy, Adips, Ts)† 
rs79723785 19 55818225 C T 0.02 1.182 1.2*10-8 BRSK1 HSPBP1(Art)* 
 
rs10952289 7 150524681 T C 0.66 1.044 2.1*10-8 AOC1 AOC1 (Haa, Hlv, Liv); 
TMEM176B (Haa)† 
AOC1 (Esom, Adipv, Thy, Esog)† 
rs8061064 16 53912364 A T 0.46 1.042 3.6*10-8 FTO 
  
rs12140813 1 227776827 T C 0.19 1.052 4.8*10-8 ZNF678 JMJD4 SNAP47 
 
Chr= chromosome; BP= base pair position, genome build 37; EA= effect allele; OA= other allele; EAF= effect allele frequency; OR= Odds Ratio of having low 





increased/decreased= Top four genes with known expression associations with the lead SNP in GTEx v8, ordered by p-value. *rs79723785 is a splicing QTL 
for HSPBP1. † GTEx v8 differential expression by tissue; Gene names in bold indicate that the SNP is the lead eQTL for that gene in the stated tissue (note: in 
many cases although the lead SNP is not the lead eQTL, it is often correlated with it) – Ts = Testis; Bput = Brain - Putamen (basal ganglia); Bcor = Brain – 
Cortex; Bcau = Brain - Caudate (basal ganglia); Bhyp = Brain – Hypothalamus; Bacc = Brain – Anterior cingulate cortex; Asub = Adipose – subcutaneous; Wb 
= Whole blood; Esom = Esophagus – mucosa; Skse = Skin sun exposed lower leg; Snse = Skin non-sun exposed lower leg; Thy = Thyroid; Adips = Adipose – 
Subcutaneous; Adipv = Adipose - Visceral (Omentum); Esog = Esophagus - Gastroesophageal Junction; Haa = Heart - Atrial Appendage; Hlv = Heart - Left 





The strongest associations were with variants close to HLA-DQA1 (rs34415150, 
beta/log-OR per G allele=0.0833, p=4.4*10-17), GDF5 (rs143384, beta per A 
allele=0.0545, p=4.5*10-13) and DYM (rs62102286, beta per T allele=0.0487, 
p=5.5*10-11). Twelve of the fifteen lead SNPs from the GWAS have not previously 
been identified in studies of continuous grip strength in all ages (Buniello et al. 2019b) 
(see Table 4-2 and Supplementary Table s4-2).  
This included the three most strongly associated variants near HLA-DQA1 (previously 
implicated in rheumatoid arthritis: see Table 2), GDF5 (‘Growth differentiation factor 
5’: previously implicated in height, waist hip ratio, muscle mass, and osteoarthritis) and 
DYM (‘Dymeclin’: implicated in in height). Six other variants were previously linked to 
height and four to osteoarthritis. None were significantly (p<5*10-8) associated with 
lean muscle mass, although rs10952289 near AOC1 is nominally associated with 
appendicular lean muscle mass (p=6*10-4) (Zillikens et al. 2017). The test of cohort 
heterogeneity in METAL for all 15 lead SNPs was not statistically significant (nominal 








Table 4-2: Low grip loci that appear in the GWAS catalog of published variant-trait associations 
Genetic variant p-value Nearest 
Gene 
Height BMI WHR Bone Grip 
strength 
OA RA Neuro 
rs34415150 4.42*10-17 HLA-DRB1 













rs62102286 5.49*10-11 DYM rs9967417 
(R2=0.83) 
       







   
rs1262778 
(R2=0.81) 






rs11236213 3.01*10-10 RN7SKP297 
  
rs11236213 
     
rs34464763 3.15*10-10 C12orf60 








rs143459567 3.41*10-10 RBBP6 
   
rs34365165 
(R2=0.93) 
    
rs2899611 6.01*10-9 ALDH1A2 
        
rs958685 6.52*10-9 TGFA 











   
rs9846396 
(R2=0.91) 
rs79723785 1.16*10-8 BRSK1 




rs10952289 2.10*10-8 AOC1 rs2110001 
(R2=0.85) 





rs8061064 3.55*10-8 FTO 
        





     
 
Data from the GWAS catalog (www.ebi.ac.uk/gwas) extracted in March 2020. BMI = Body Mass Index; WHR = Waist-Hip ratio or Hip circumference adjusted 
for BMI; Bone=includes bone mineral density and bone size (e.g. neck of femur) traits; Grip=Increasing Handgrip Strength (linear); OA = Osteoarthritis; RA = 
Rheumatoid Arthritis; Neuro = Neurological disease; R2=correlation with lead low grip Genetic Variant – information from LDlink-pair GBR population. * SNP 






Overall, three of the fifteen identified lead variants (or proxies) have not previously 
been implicated in anthropometric or musculoskeletal phenotypes in the GWAS 
catalogue (see Table 2). This included: RBBP6 (‘RB binding protein 6, ubiquitin ligase’: 
a tumor suppressor gene), ALDH1A2 (‘Aldehyde Dehydrogenase 1 Family Member 
A2’: involved in the synthesis of retinoic acid), and a variant near FTO (‘FTO Alpha-
Ketoglutarate Dependent Dioxygenase’: involved in the oxidative demethylation of 
different forms of RNA). Although the lead ALDH1A2 SNP itself has not been identified 
in previous GWAS, other independent variants (R2<0.6) at the same locus (e.g. 
rs3204689) have been found to be associated with osteoarthritis (Table 4-2). 
The LDSC regression intercept was not significantly greater than 1, suggesting no bias 
due to population stratification or cryptic relatedness (B. K. Bulik-Sullivan, Loh, 
Finucane, Ripke, Yang, Consortium, et al. 2015). The single nucleotide polymorphism 
(SNP) based heritability (h2) of low grip strength was 0.044 (SE 0.0027), i.e. 4.4%, by 
LD Score Regression.  
 
4.5.3 Subset of overall grip strength variants are associated with low grip strength 
After reviewing the 64 published variants associated with continuous measures of grip 
strength in the UK Biobank cohort (Tikkanen et al. 2018), for all ages (40 to 70 years), 
we found that only three of these SNPs were significant genome-wide (p<5*10-8) in 
the EWGSOP low grip strength GWAS (Supplementary Table s4-3). The top 
association was rs13107325 (SLC39A8 linear grip p=4.4*10-23, T effect allele = 0.006 
unit decrease in linear grip strength; low grip strength meta-analysis p=7.4*10-11, T 
effect allele = 0.0897 unit increase in risk of low grip strength with age), then 





linear grip strength; low grip strength meta-analysis p=2.6*10-9, G effect allele = 0.045 
unit increase in risk of low grip strength with age) and finally rs11236203 (POLD3, 
linear grip p=8.4*10-10, G effect allele = 0.002 unit decrease in linear grip strength; low 
grip strength meta-analysis p=2.8*10-8, G effect allele = 0.043 unit increase in risk of 
low grip strength with age ). Two less-significant associations (< 1*10-6) were seen 
with rs3821269 (TGFA linear grip p=3.5E*10-15, A effect allele = 0.002 unit decrease 
in linear grip strength; low grip strength meta-analysis p=8.0*10-8, A effect allele = 0.04 
unit increase in risk of low grip strength with age) and rs1556659 (ENSG00000232985 
linear grip p=1.1*10-11, C effect allele = 0.002 unit decrease in linear grip strength; low 
grip strength meta-analysis p=3.5*10-7, C effect allele = 0.04 unit increase in risk of 
low grip strength with age). 
A previous GWAS by the CHARGE consortium identified two loci associated with 
maximum hand grip strength recorded in 27,581 Europeans aged 65 or older (Matteini 
et al. 2016). We found that neither locus was associated with low grip strength in our 
analysis (rs752045 EWGSOP p=0.67, rs3121278 EWGSOP p=0.15). 
 
4.5.4 GWAS of low grip strength based on FNIH criteria 
In secondary analysis we performed GWAS using the low grip strength definition 
published by the FNIH (S. A. Studenski et al. 2014). This criterion uses lower grip 
strength cut-offs (<26Kg for males and <16Kg for females) than the EWGSOP 
definition (Cruz-Jentoft et al. 2010), resulting in fewer cases (n=19,345, 7.6% of total). 
Five loci were significant in the analysis (p<5*10-8), only one of which was not identified 
in the EWGSOP low grip strength analysis described previously (see Table 4-3, either 





rs3771501 and rs958685 R2=0.90). This single base-pair deletion (rs1403785912 - 
chr9:4284961:T:-) mapped to GLIS3 (“GLIS family zinc finger 3” - a repressor and 
activator of transcription), and may be specifically associated with more “extreme” 






Table 4-3: Genomic risk loci associated with low grip strength FNIH definition 
RSID Chr Position EA  OA EAF Effect P-value Nearest gene* GTEx gene expression 
increased ‡ 
GTEx gene expression 
decreased 






rs3771501 2 70717653 A G 0.47 0.0697 5.04E-11 TGFA TGFA (Ts)† TGFA (Bcor, Bcau, Bhyp, 
Bacc)† 
rs1403785912* 9 4284961 AT A 0.52 0.0765 4.32E-09 GLIS3 RP11-358M14.2* 
 
rs12456780 18 46947541 T A 0.33 0.0633 1.29E-08 DYM 
 
DYM 
rs191252760 4 61454905 G A 0.02 0.1863 3.17E-08 AC095061.1 
 
ADGRL3 
Gene names in bold indicate that the SNP is the lead eQTL for that gene in the stated tissue (note: in many cases although the lead SNP is not the lead eQTL, 
it is often correlated with it). † GTEx v8 differential expression by tissue – Ts = Testis; Bcor = Brain – Cortex; Bcau = Brain - Caudate (basal ganglia); Bhyp = 
Brain – Hypothalamus; Bacc = Brain – Anterior cingulate cortex; Asub = Adipose – subcutaneous; Wb = Whole blood; Esom = Esophagus – mucosa; Skse = 
Skin sun exposed lower leg; Snse = Skin non-sun exposed lower leg; Thy = Thyroid; Adips = Adipose – Subcutaneous; Adipv = Adipose - Visceral (Omentum); 
Esog = Esophagus - Gastroesophageal Junction; Haa = Heart - Atrial Appendage; Hlv = Heart - Left Ventricle; Liv = Liver. 





4.5.5 Mitochondrial variants and low grip strength 
Analysis of 116 mitochondrial genetic variants (MAF>0.01) available in the UK 
Biobank directly genotyped microarray data identified two associated with EWGSOP-
defined low hand grip strength (p<0.00043, i.e. Bonferroni-adjustment for 
mitochondrial variants). rs41518645 is a missense variant (p.Asp171Asn) in MT-CYB, 
identified in Plink logistic regression analysis (p=0.0003). rs201950015 is intronic, 
located between genes CO1 and ATP6/8 (p=0.00042). No variants achieved 








Table 4-4: Mitochondrial variants associated with EWGSOP low grip strength in UK Biobank participants 
AffxID BP A1 A2 MAF OR SE P RSID Annotation Nearest Gene(s) 











4.5.6 Gene Expression and Pathways 
I used data from the Genotype-Tissue Expression project (GTEx) v8 to identify 
whether the variants associated with low grip strength affect expression of genes 
(Table 4-1; Supplementary Table s4-4).  Of the top 15 EWGSOP-associated variants 
12 are eQTLs for at least one gene. For 8 of these, the nearest gene to the variant by 
chromosomal location is known to have altered expression, but other genes in the 
locus may also be affected. This is consistent with a recent study showing that the 
“nearest gene” is often a good candidate for being a causal pathway (Stacey et al. 
2019). For the top two loci (HLA-DQA1 and GDF5) the variants are eQTLs for these 
nearest genes, however for the SLC39A8 locus the lead SNP (rs13107325) is not an 
eQTL for SLC39A8, but is an eQTL for UBE2D3 (‘Ubiquitin Conjugating Enzyme E2 
D3’) in the aorta. 
In MAGMA analysis I found 80 GO processes enriched in low grip strength-associated 
genes (see Supplementary Table s4-5 for details), mainly involved in the immune 
system and antigen presentation. 
MetaXcan (Barbeira et al. 2018) identified 24 genes with expression in skeletal muscle 
significantly enriched in the low grip strength GWAS, after Benjamini-Hochberg 
adjustment for multiple testing (Supplementary Table s4-6). The International Mouse 
Phenotyping Consortium database (www.mousephenotype.org) was used to 
investigate the possible phenotypes associated with the genes highlighted by 
MetaXcan, with many having clear effects on relevant phenotypes such as “growth”, 
“lean mass”, “body weight”, “angiogenesis”, “thymus involution”, and “lipid metabolism” 





We used LDSC-SEG to determine tissue-specific gene expression and chromatin 
modification enrichment in the low grip strength  GWAS results (Finucane et al. 2018). 
We found no significant enrichment for the genetic determinants of low grip strength 
in expression profiles and epigenetic changes after adjustment for multiple testing, 
although genes expressed in the tibial nerve were borderline enriched (Benjamini-
Hochberg-adjusted p-value 0.1). See Supplementary Table s4-8 for details. 
 
4.5.7 Low grip strength loci independence from musculoskeletal traits and diseases 
To determine whether the genetic variants associated with low grip strength identified 
in the GWAS were independent of anthropometric traits or musculoskeletal co-
morbidities I performed regression analyses in the UK Biobank cohort with adjustment 
for the following covariates: height, weight, skeletal muscle mass (determined using 
bioimpedance analysis), osteoarthritis, Rheumatoid arthritis, osteoporosis, Dupytrens 
contracture (one or more fingers permanently bent), and rhizarthrosis (arthritis of the 
thumb). The association between eight of the fifteen EWGSOP loci and low grip 
strength was attenuated after adjusting for height, including rs143384 (initial UKB 
p=3.7*10-11; adjusted UKB p=3.8*10-2) and rs7624084 (initial UKB p=9.3*10-7; 
adjusted UKB p=4.9*10-1). Adjustment for weight or BMI did not substantially attenuate 
any of the associations. Overall, the associations were not attenuated by adjustment 
for osteoarthritis, Rheumatoid arthritis, osteoporosis, Dupytrens, or rhizarthrosis. See 









In this study of 256,523 Europeans aged 60 years and over we identified 15 genetic 
loci - 3 novel - associated with the EWGSOP definition of low grip strength, plus two 
additional loci for the FNIH definition that used a more extreme definition for muscle 
weakness. Only three of these were previously implicated in previous analyses of 
continuous strength measures, suggesting that the genetic causes of clinically 
meaningful weakness at older ages are partly distinct. We found prominent overlaps 
with osteoarthritis and Rheumatoid arthritis, but also with cardiovascular disease and 
type-2 diabetes. Additional links to asthma and allergy were also found. The novel 
pathways implicated appear to include hallmark mechanisms of ageing (López-Otín et 
al. 2013), for example cell cycle control related to the cancer control retinoblastoma 
pathway. However other ageing pathways such as telomere length (Kuo et al. 2019), 
and many lifespan-associated loci including APOE (Timmers et al. 2019), were not 
associated. Three of the low grip strength-associated genetic signals identified have 
not appeared in GWAS prior to the time of analysis, further demonstrating that low 
strength in older people may have distinct genetic underpinnings. 
 
The strongest association found was rs34415150, near the HLA-DQA1 gene (Figure 
4-2). Genetic variants at this locus have been implicated in a wide range of conditions, 
including autoimmune diseases such as Rheumatoid arthritis (Cortes et al. 2019), and 
continuous grip strength (Tikkanen et al. 2018). HLA haplotypes HLA-DQA1*03:01 
and HLA-DRB1*04:01, have been previously linked to sarcopenia in older UK Biobank 








Figure 4-2: HLA-DQA1 risk loci for low grip strength (rs34415150) 
 
HLA-DQA1 is associated with chronic inflammation in muscle of untreated children 
with juvenile dermatomyositis (inflammatory myopathies in children, which one of the 
characteristics is muscle weakness) (Y.-W. Chen et al. 2008). Additionally, in a multi-
trait analysis of age-related diseases HLA-DQA1 was confirmed and it may therefore 
contribute to underlying ageing mechanisms as a “geroscience locus” (Melzer, Pilling, 





Overall five of the fifteen genomic risk loci for EWGSOP low grip strength have been 
previously associated, or in linkage disequilibrium with variants associated with 
osteoarthritis (rs143384 – GDF5, rs13107325 – SLC39A8, rs34464763  – C12orf60, 
rs958685 – TGFA and rs79723785 - BRSK1), of which two are also linked to adiposity, 
a known risk factor for arthritis (Murphy et al. 2008). We found that rs143384 in the 5’ 
untranslated region of growth/differentiation factor 5 (GDF5) was the second most 
strongly associated variant with low grip strength, see Figure 4-3. GDF5 is a protein in 
the transforming growth factor beta (TGF-β) family, with key roles in bone and joint 
development (Francis-West et al. 1999; Capellini et al. 2017). 
 
Figure 4-3: GDF5 risk locus for low grip strength (rs143384) 
 
 It was the first locus identified for osteoarthritis (Miyamoto et al. 2007), with a reported 
odds ratio of 1.79, as well as one of the first identified for height (Sanna et al. 2008). 





enzymes in human primary chondrocytes (Uhalte et al. 2017), thereby may be an 
potential intervention target for avoiding weakness at older ages, although work is 
needed to determine when intervention would be most effective. In follow-up analyses 
we found that the association between rs143384 and low grip strength was 
independent of prevalent osteoarthritis in UK Biobank participants, although we cannot 
rule out an effect of sub-clinical osteoarthritis. However, the association was 
completely attenuated after adjustment for standing height, suggesting the effect of 
the variant is mediated by developmental traits such as bone length. Mice with loss of 
Gdf5 function exhibited severely impaired knee development, and the regulatory 
region pinpointed to mediate this effect in humans includes osteoarthritis-associated 
genetic variants (Pregizer et al. 2018). Although the observed association between 
variants mapping to GDF5 and low strength might be mediated by hand osteoarthritis 
pain compromising grip strength, there is evidence of a direct effect of GDF5 on 
muscle (Traoré et al. 2019). 
 
The locus on Chr 18 is proximal to the DYM gene (see Figure 4-4).  Loss of function 
mutations in this gene are associated with Dyggve-Melchior-Clausen syndrome and 
Smith-McCort dysplasia respectively.  Mice lacking this gene present with 
chondrodysplasia resulting from impaired endochondrial bone formation and 
abnormalities of the growth plate that begin to manifest shortly birth (Osipovich et al. 
2008). In homozygous mutant mice, and in patients with loss of function mutations in 
this gene, both the axial and the appendicular skeleton are affected. As is noted in 
Table 4-2, this gene is also associated with height in the GWAS catalogue.  
Interestingly, this gene is highly expressed in skeletal muscle in humans (Paupe et al., 







Figure 4-4: DYM risk locus for low grip strength (rs62102286) 
 
SLC39A8 encodes for the metal ion transporter ZIP8 which has been shown to be 
upregulated in chondrocytes present in osteoarthritic cartilage (J.-H. Kim et al. 2014). 
The lead SNP rs13107325 is a missense variant within SLC39A8 which has been 
previously associated with osteoarthritis (Tachmazidou et al. 2019).  
On chromosome 12 genetic variants known to affect expression of MGP (Matrix Gla 
Protein) in the tibial nerve (among other tissues) are associated with osteoarthritis of 
the hand but not of the hip or knee (den Hollander et al. 2017). MGP is an inhibitor of 
arterial and soft tissue calcifications, with links to atherosclerosis (Herrmann et al. 
2000). Consistent with this, older women with severe abdominal aortic calcification 





recently a study suggested MGP may also regulate muscle development and atrophy 
(Ahmad et al. 2017). Variants that result in non-functional MGP have been shown to 
result in the autosomal recessive condition, Keutel syndrome (Munroe et al. 1999). 
Keutel syndrome is characterised by brachytelephalangism, hearing loss, peripheral 
pulmonary stenosis and abnormal cartilage calcification (Cormode, Dawson, and 
Lowry 1986). The variable shortening of the terminal phalanges may influence grip 
strength, whether or not this phenotype is found in carriers of variants associated with 
the rs34464763 genomic risk locus would require further research. 
We also identified variants known to affect Transforming Growth Factor Alpha (TGFA) 
expression (increased in the testis, decreased in the brain), which is implicated in cell 
proliferation, differentiation and development. This locus has previously been 
identified for overall strength (Willems et al. 2017), and suggestive evidence from a 
study of 1,323 participants linked rs2862851, a variant in linkage disequilibrium with 
the lead SNP rs958685 (R2=0.90, D’=1.0), with increased risk of osteoarthritis in the 
knee (OR=1.4, p=3.1*10-4) (Cui et al. 2017).  
The low grip strength locus on chromosome 15 is near ALDH1A2, which has a key 
role in the pathogenesis of osteoarthritis (Styrkarsdottir et al. 2014). Low grip strength-
associated variants at this locus have previously been identified for severe 
osteoarthritis of the hand (Styrkarsdottir et al. 2014) The lack of this gene in mice is 
perinatally lethal, however at embryonic day 18.5 mice lacking this gene do present 
with numerous cartilage gene defects (Vermot et al. 2003). We also identified variants 
that affect expression of CHRDL2 (Chordin Like 2) in the thyroid, known to interact 
with mouse Gdf5, which is upregulated in human osteoarthritic joint cartilage cell line 





linked to the progression of severe osteoarthritis in the knee joint (C.-H. Chou et al. 
2015), suggesting a role for CHRDL2 in cartilage repair. 
Two of the identified loci (RBBP6 ‘RB Binding Protein 6, Ubiquitin Ligase’ and ZBTB38 
‘Zinc Finger And BTB Domain Containing 38’) form an axis involved in DNA replication 
and chromosomal stability (Miotto et al. 2014). RBBP6 ubiquitinates the transcriptional 
repressor ZBTB38, destabilizing it and reducing its action on the replication factor 
MCM10. In mice, Zbtb38 is highly expressed in skeletal muscle, loss of this methyl-
CpG-binding protein (which is also known as Cibz), promotes myogenic differentiation. 
Conversely, expression of Zbtb38 is decreased in satellite cells during muscle 
regeneration (Oikawa et al. 2011), suggesting that like other members of this gene 
family, this gene is involved in cellular differentiation. Variants associated with low grip 
strength in our analysis are known to decrease ZBTB38 expression in whole blood 
and skeletal muscle (among others) and increase expression in the skin. 
Mitochondrial dysfunction is a hallmark of aging, yet we found no variants associated 
with low strength at genome-wide significance levels. Variants in MT-CYB were 
nominally significant (p=0.0003): MT-CYB (mitochondrial cytochrome b) is part of the 
mitochondrial respiratory chain, and essential for Complex III formation. Monogenic 
diseases associated with MT-CYB include exercise intolerance and “Additional 
features include lactic acidosis, muscle weakness and/or myoglobinuria” (UniProt 
n.d.). Recent work by Cohen et al. have highlighted the importance of mitochondrial 
peptides such as humanin in many age-related diseases (Yen et al. 2013), however 






We observed minimal overlap between loci associated with low grip strength and 
general anthropometric traits such as height and continuous measures of strength. 
The SNP-based heritability estimate for EWGSOP low grip strength in older adults 
was 4.4% (SE 0.3%). This compares to 13% (SE 0.4%) SNP-based heritability for 
continuous grip strength in UK Biobank participants aged 40 to 70 (Tikkanen et al. 
2018). This may be partly explained by our using a binary cut-off for low grip compared 
to the quantitative grip analysis. Additionally, we observed only limited negative 
genetic correlation between low grip strength and lean muscle mass (~30%): taken 
together, these results emphasize that the genetics of weakness and overall strength 
are distinct. 
We chose to not adjust for body size in our primary analysis in case interesting or 
novel effects were masked, but in follow-up analysis determined that all except two of 
the loci identified were predominantly independent of participant height and weight. 
There are a number of limitations to our analyses. The data included are 
predominantly from subjects at the younger end of the age 60 plus demographic, and 
is not enriched for frail individuals. Our analysis was limited to relatively common 
variants (prevalence > 1%) in subjects with European ancestries only. The analyses 
of the FNIH strength cut-points also have limited power, given the low prevalence of 
the phenotype, although studying the extremes of a continuous trait can provide 
increased power if stronger associations are uncovered. We did not include additional 
analysis of the revised EWGSOP2 low grip cut-points (Cruz-Jentoft et al. 2019) as 
these are almost identical to the FNIH criteria, which many cohorts had already 
analysed; we future analyses should include this. Analysis of rare and structural 
variants, and analyses in other ancestral groups will give a more complete picture of 





To conclude, genetic variation in 15 loci are related to muscle weakness in people 
aged 60 plus, of European descent, with limited overlap with loci associated with the 
full range of muscle strength in 40 to 70 year olds. Novel loci implicated may be 
involved in hallmark pathways of ageing including cell cycle control and inflammation, 
along with loci implicated in arthritis and pathways involved in the development and 
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5 Analysis 3: Stratified analysis of muscle weakness in 
older people 
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Low grip strength is a commonly used proxy for measuring overall muscle function, 
particularly in regards to the age-related condition, sarcopenia (Aadahl et al. 2011; 
Bohannon et al. 2012; S. H. Lee and Gong 2020). The prevalence of sarcopenia, or 
loss of muscle mass and function primarily due to age varies considerably from 
population to population, age and sex (S. A. Purcell et al. 2020; Shafiee et al. 2017). 
It is known that skeletal muscle protein turnover differs between men and women with 
age (G. I. Smith and Mittendorfer 2016; G. I. Smith et al. 2012), as is the influence of 
sex on different substrate utilization in skeletal muscle mitochondria (Montero et al. 
2018; Mark A. Tarnopolsky 2008; Horton et al. 1998). We hypothese that the 
mechanisms leading to weakness due to ageing may differ between men and women 
and so we investigated the genomic risk loci associated with low grip strength in older 
adults in a large community based meta-analysis with cohorts separated by sex. 
Using sex-stratified analysis of the GWAS meta-analysis from 22 cohorts (135,468 
females and 121,055 males) including genotyping data from members of the CHARGE 
consortium and the low grip cut-offs as defined by the European Working Group on 
Sarcopenia I have shown that there are eight genomic risk loci associated with low 
grip strength in older women (age > 60 of European ancestry). Although there is 
substantial overlap with our previous analysis on both sexes, there is one unique risk 
locus intronic to PKD1. 







My contribution included leading the writing of resulting paper and primary analyst for 
the multi-cohort study. In addition I coordinated the meta-analysis and helped draft the 
analysis plan. A substantial part of this chapter has been published as a section of our 
paper “Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility 







Prevalence of age-associated loss of muscle strength varies considerably between 
sexes, age ranges and population setting. We undertook sex-stratified analysis of low 
grip strength, as a proxy for overall muscle weakness, in participants from 22 studies 
(n=256,523) of European ancestry, in order to investigate the underlying differences 
in age related muscle weakness between the sexes. 
Eight genomic risk loci were found to be associated with muscle weakness in the 
female only (n=135,468) cohort. Of these seven risk loci were shared by those 
associated with low grip strength in our previous analysis of 256,523 older adults of 
European ancestry over the age of 60. This includes genes involved in arthritis, 
autoimmune disease and development of the muscloskeletal system. 
One locus appears to be unique for low grip strength in older women, when compared 
to either the analysis of both sexes together or men on their own, and is an expression 
quantitative trait locus for the gene PKD1, or Polycystin 1. This transmembrane protein 
has a role in multiple signaling pathways and is associated with the kidney disease, 
Autosomal Dominant Polycystic Kidney Disease (ADPKD). However the lead SNP, 
rs7185040, has not previously been associated with this disease.  
The separate analysis of the male only cohort found three variants associated with 
muscle weakness in older adults. Two had at least nominally (p < 0.01) been 
associated with muscle weakness in the combined cohort, while the third rs774787160 
which is intronic to DSCAM (Down syndrome cell adhesion molecule) had not 
previously been associated and was novel to the male only analysis. 
Further analysis of the allosomes or sex chromosomes and mitochondrial variants 





mitochondrial candidate SNPs previously seen in the combined study (Chapter 4). 
 
In conclusion, there were a small number of genetic variants associated with 
weakness at other ages in either males or females, highlighting specific pathways that 
may be sex-specific. These included hallmarks pathways of ageing including cell cycle 
control and inflammation, along with loci implicated in arthritis and pathways involved 
in the development and maintenance of the musculoskeletal system. However, the 








The prevalence of sarcopenia and age related muscle weakness is highly variable 
based on the criteria used to define sarcopenia (S. A. Purcell et al. 2020), and the 
population characteristics (Shafiee et al. 2017). Some studies have shown differences 
in prevalence between the sexes. For example, the risk of developing sarcopenia has 
been shown to be higher in women compared men of a similar age (age adjusted 
OR=1.20, 95% CI 0.98 to 1.47)(L. Yang, Smith, and Hamer 2019), in a large 
community based study (n=3404; 54.1% women; mean age 63.4 ± 7.7, low grip 
strength as defined by EWGSOP 2010 as the main criteria).  
The underlying mechanisms for these observations does have evidence in the current 
literature with differences in skeletal muscle physiology and atrophy been noted 
between the sexes (Rosa-Caldwell and Greene 2019), including higher sensitivity of 
muscle cells in males to inflammation-mediated atrophy compared to female muscle 
cells (Wallengren et al. 2015; Cosper and Leinwand 2011), which in turn are more 
susceptible to atrophy from disuse(Callahan et al. 2014). This heterogeneity between 
the responses of skeletal muscle to challenges in a sex specific manner, may help 
explain some of the variation in prevalence rates amongst different study populations. 
Pre-frail elderly (>60 years of age) have been showed to accrue impairment of 
mitochondrial function in skeletal muscle, when compared to active elderly people 
(Andreux et al. 2018). Mitochondrial dysfunction has long formed the basis for one of 
the main theories of aging, through the resulting Reactive Oxidative Stress (ROS) and 
cellular damage (Denham Harman 1992). 
Montero et al, observed higher levels of fat oxidation over carbohydrate in female 





confirmed earlier studies on lipid versus carbohydrate / protein oxidation during 
exercise in males and females (M. A. Tarnopolsky et al. 1995; L. J. Tarnopolsky et al. 
1990; Blatchford, Knowlton, and Schneider 1985). 
Although previous studies have investigated the genetic basis for hand grip strength 
(Willems et al. 2017; Tikkanen et al. 2018; Matteini et al. 2016) as a quantitative trait, 
there has been less focus on low hand grip strength (as a proxy for loss of overall 
muscular function) in older adults and in particular any underlying differences between 
the sexes. 
The evidence for underlying differences in major mechanisms for loss of muscle 
function with age, as well as the lack of previous investigations into the casual 
pathways associated with sex and definitions of low muscle function, are to be 
examined by this study. We aim to investigate the genomic risk loci associated with 
low grip strength in older people stratified by sex, using a large community based 
cohort with 135,468 females and 121,055 males of European descent aged over 60 
years old. In addition we will analyse the allosomal and mitochondrial genotypes from 








5.4.1 GWAS of low grip strength in older people 
Initially I conducted a GWAS meta-analysis of low grip strength in participants aged 
60 years or older of European ancestry from 22 studies yielding a combined sample 
of 254,894 individuals. Individual studies used different genotyping platforms and 
imputation was predominantly performed using the Haplotype reference consortium 
(HRC) v1.1 panel. Details on methods used for individual studies is available in the 
supplementary methods. Following the original GWAS meta-analysis on both sexes, 
sex-stratified analysis was undertaken on the 135,468 females and 121,055 males. 
 
 The primary analysis was of the 2010 EWGSOP criteria for sarcopenic grip strength 
(Grip strength < 30 Kg Male; < 20 Kg Female). In secondary analysis we considered 
a more data-driven definition with more extreme thresholds by the Foundation for the 
National Institutes of Health (FNIH) sarcopenia project 2014 (Grip strength < 26 Kg 
Male; < 16 Kg Female) for comparison.  
 
GWAS was performed by each cohort individually using regression models, adjusted 
for age, and population substructure, accounting for relatedness and technical 
covariates as required by the individual study. For UK Biobank cohort GWAS was 
performed using BOLT-LMM, with co-variants for age, sex (if applicable), microarray 
used, and assessment center. For each CHARGE cohort methods used are included 
in the supplementary information, however the GWAS was minimally adjusted for age, 





No adjustment for anthropometric measures was made in the primary analysis, due to 
possible collider bias. Fixed-effects inverse variance weighted meta-analysis was 
performed using METAL (Willer, Li, and Abecasis 2010b) using the GWAS summary 
statistics generated by each cohort, with genomic control for population structure (see 
Methods for details). The following quality control filters were applied: minor allele 
frequency (MAF) > 0.01, imputation info score of > 0.4, and the variant present in at 
least two studies (UK Biobank – the largest included cohort - plus at least one other). 
The final analysis therefore included 9,678,524 genetic variants. Associations that 
achieved a p<5*10-8 were considered statistically significant, with those reaching the 
more stringent threshold of p<5*10-9 highlighted.  
Distinct loci were initially defined as two significant variants separated by >500kb. To 
identify independent signals at each locus we used FUMA (Functional Mapping and 
Annotation of Genome-Wide Association Studies) (Watanabe, Taskesen, van 
Bochoven, et al. 2017), which uses Linkage Disequilibrium (LD) information to 
determine independence (r2 threshold = 0.1 for independent significant single 
nucleotide polymorphisms (SNP)).  
 
5.4.2 Gene Ontology Pathways, Tissue Enrichment, and eQTL analyses  
I utilized FUMA to perform functional interpretation of the GWAS results (Watanabe, 
Taskesen, van Bochoven, et al. 2017). In particular, FUMA performs gene-set analysis 
(using Multi-marker Analysis of GenoMic Annotation (MAGMA) (de Leeuw et al. 2015)) 
to identify pathways enriched amongst the significant genes (weighted by the SNP-
associations in proximity to them), in addition to searching eQTL databases to identify 






5.4.3 Analysis of variants on sex-chromosomes and mitochondria 
Additive association testing with the two low grip definitions (FNIH and EWGSOP) in 
the sex- chromosomes X and Y, as well as the mitochondrial chromosome was 
performed in PLINK 1.9.3 (S. Purcell et al. 2007) on the UK Biobank dataset. The 
analysis was stratified by sex and as a combined (all participant) cohort, of participants 
of European ancestry and 60 years of age, or older. 
Mitochondrial genotypes were direct from microarray data and not imputed, whereas 
the sex chromosomes X and Y were imputed. Only variants with a Minor Allele 
Frequency (MAF) of greater than 1% were considered, due to loss of genotyping 
accuracy at lower allele frequencies and the low heterozygosity generally exhibited by 
rare variants (MAF < 1%) – this is especially important for the analysis as higher 
heterozygosity has been associated with healthy ageing (K. Xu et al. 2019). In addition 
imputation panels are still focused on variants with MAF > 1%, although incorporation 








5.5.1 Sex stratified analysis identifies different risk loci 
In sex-stratified analysis there were eight significant genomic risk loci associated with 
EWGSOP low grip strength in females only (total N=132,443 with n=33,548 cases, 
25.3%; see Figure 5-1, Table 5-1). Seven of the eight loci were either present in the 
main analysis or were correlated with corresponding variants, for example rs201754 
(chr13:51078446, Female only) and rs3118903 (chr13: 51099577, both sexes) with 
D’=0.97 and r2=0.91. rs7185040 (chr16: 2145787), mapped to gene PKD1, was only 
significant in the analysis of females only, although the association is borderline in the 
analysis of males and females together (females p = 3*10-8; combined analysis p = 
5.5*10-8). 
 
Figure 5-1: Manhattan plot of low grip strength female only genome-wide association 
study  
 
The p-values are from a fixed-effects meta-analysis of 135,468 females of European 





grip strength cutoff (females <20 kg). The x-axis is the chromosomal location, and the 
y-axis is the –log10 p-value for each genetic variant. The horizontal red line is the 
threshold for genome-wide significance (p<5*10-8). Eight genomic loci cross the 
threshold, and the lead variant (most significantly associated with low strength) is 





Table 5-1: Genomic risk loci associated with EWGSOP low grip strength in 135,468 women 
 
EWGSOP Female EWGSOP All EWGSOP Male 
 
RSID Chr BP P-value EA  OA EAF Log OR P-value Log OR P-value Log OR Nearest gene* 
rs34415150 6 32560477 1.2E-16 G A 0.18 0.1001 4.42E-17 0.0833 1.02E-03 0.0582 HLA-DRB1 
rs143384 20 34025756 5.87E-13 A G 0.59 0.0657 4.47E-13 0.0545 2.45E-03 0.0401 GDF5 
rs201754 13 51078446 4.43E-10 C T 0.22 0.0668 3.30E-10 0.0554 3.97E-02 0.0321 DLEU1 
rs4764133 12 15064363 3.9E-09 T C 0.38 0.054 1.92E-09 0.0454 2.42E-02 0.03 ERP27 
rs2899611 15 58327347 1.03E-08 G T 0.51 0.0515 6.01E-09 0.0431 5.33E-03 0.0363 ALDH1A2 
rs11236213 11 74394369 2.72E-08 G A 0.69 0.054 3.01E-10 0.0504 3.13E-04 0.0508 RN7SKP297 
rs7185040 16 2145787 3.36E-08 C A 0.18 0.0642 5.57E-08 0.052 3.91E-02 0.0348 PKD1 
rs550258 18 46860643 4.81E-08 T C 0.35 0.0511 8.51E-10 0.0473 2.23E-03 0.0414 DYM 
 
Chr= chromosome; BP= base pair position, genome build 37; EA= effect allele; OA= other allele; EAF= effect allele frequency; Log OR= Log Odds Ratio of 







The analysis of males only (total N=118,371 with 13,327 cases, 11.3%) identified three 
genomic loci associated with the EWGSOP low grip strength definition. One of these 
variants, rs35225200, was in linkage disequilibrium with a lead SNP from the 
combined analysis (rs13107325 R2=0.89, D’=1.0), which means that this is not an 
independent signal. While the two remaining lead variants appeared to be distinct 
signals (see Table 5-2): rs774787160 is a common deletion variant (Effect allele 
frequency 0.73) mapped to gene DSCAM and was not associated with low grip 
strength in females (males p = 1*10-8; females p = 0.9) and rs145933237 mapped to 
MIR466 (MicroRNA 466, short non-coding RNA involved in post-transcriptional 
regulation of gene expression), which was only nominally associated in females 
(males p = 2*10-8; females p=0.01). The reduced number of cases in males could 
contribute to the fewer associations observed, and the borderline significance (p-
values close to 5*10-8).  
The results from sex-stratified analyses need to be interpreted with caution. The 
largest cohort in our analysis, UK Biobank, has been shown to have a sex-differential 
participation bias for a number of traits, including BMI, which may impact the sex-
stratified analysis of muscle weakness with age (Pirastu et al. 2021). Pirastu et al 
suggest adjusting the analysis either utilising the Heckman correction, or due to 
limitations the authors have also proposed a new genomic structural equation model 
that corrects for collider bias induced by sample selection.  
The sex-differential participation bias appears to be specific to the participant selection 
criteria for each study, for example the iPSYCH showed the lowest heritability estimate 
and the least participation and survival bias out of the cohorts in the paper. This is a 





blood spots born between 1981 and 2005 in Denmark (C. B. Pedersen et al. 2018). 





Table 5-2: Genomic risk loci associated with EWGSOP low grip strength in 121,055 men 
 
EWGSOP Male EWGSOP All EWGSOP Female 
 
RSID Chr Position P-value EA  OA EAF Effect P-value Log 
OR 
P-value Log OR Nearest 
gene* 
rs774787160 21 41996684 1.39E-08 A ACACATCCAAAAG 0.73 0.0983 2.99E-03 0.0275 9.27E-01 -0.001 DSCAM 
rs145933237 3 31188133 2.05E-08 C G 0.02 0.2688 2.04E-06 0.1344 1.06E-02 0.0898 hsa-mir-466 
rs35225200 4 103146888 2.91E-08 C A 0.08 0.1289 1.67E-10 0.0859 8.46E-05 0.0647 SLC39A8 
 
Chr= chromosome; Position= base pair position, genome build 37; EA= effect allele; OA= other allele; EAF= effect allele frequency; p-value= fixed-effects meta-





5.5.2 Sex stratified analysis using FNIH definition 
Using the FNIH low grip strength definition (<26Kg for males and <16Kg for females), 
on the sex-stratified cohorts found that while 4 genomic risk loci were associated with 
low grip strength in females (n=13,601), there were no significant associations 
observed for the males (n=6,734). Of the four risk loci identified in the female FNIH 
analysis, three had previously been associated with the less stringent EWGSOP low 
grip definition in the female cohort (rs34415150 - FNIH p = 6.1*10-14, EWGSOP p = 
1.2 * 10-16; rs143384 - FNIH p = 5.3 * 10-9, EWGSOP p = 5.9 * 10-13 and rs552086 – 
FNIH p = 4.9 * 10-8, EWGSOP p = 4.8 * 10-8).   The remaining risk locus rs3771512 is 
an eQTL for TGFA and although a genomic risk loci was not identified at this location 
in the sex-stratified EWGSOP cohort, previous  analysis using the combined male and 
female participants (Chapter 4) had identified a risk locus, rs958685, correlated with 






Table 5-3: Genomic risk loci associated with FNIH low grip strength in 135,468 women 
 
FNIH Female FNIH All FNIH Male 
 
RSID Chr BP P-value EA  OA EAF Log OR P-value Log OR P-value Log OR Nearest gene* 
rs34415150 6 32560477 6.09E-14 G A 0.18 0.1343 5.61E-16 0.1168 9.68E-06 0.1095 HLA-DRB1 
rs143384 20 34025756 5.27E-09 A G 0.59 0.0796 1.04E-06 0.0526 1.15E-01 0.0294 GDF5 
rs3771512 2 70697720 3.73E-08 C A 0.70 0.0792 3.21E-08 0.0628 2.53E-02 0.0438 TGFA 
rs552086 18 46806432 4.9E-08 G C 0.33 0.0765 1.82E-08 0.0626 2.49E-02 0.0432 DYM 
 
Chr= chromosome; BP= base pair position, genome build 37; EA= effect allele; OA= other allele; EAF= effect allele frequency; OR= Odds Ratio of having low 






5.6 Analysis of sex chromosomes and mitochondrial variants 
In our previous analysis of the association between mitochondrial variants and low 
grip strength (Chapter 4), we found two variants that reached nominal significance 
(Benjamini-Hochberg adjusted False Discovery Rate) - rs41518645 and rs201950015 
– in the combined sex cohort.  
We found no variants showing significant association with muscle weakness in the sex 
chromosomes, or allosomes for either the combined sex cohort or the sex stratified 
cohorts (MAF >= 1%). 
No additional mitochondrial variants were associated (FDR adjusted p-value) with low 
grip strength in either of the sex-stratified cohorts. 
 
5.6.1 Gene Expression and Pathways 
MAGMA analysis using gene prioritization, identified 91 GO biological processes 
associated with the female only analysis (Table 5-4), with substantial overlap (51 of 
the pathways are common between the combined analysis – with 80 annotated GO 
pathways and the female only analysis – with 91 annotated GO pathways) in the 
processes seen for the combined meta-analysis (Chapter 4). This included pathways 
related to the immune system and antigen presentation. The combined analysis 
identified GO biological processes related to metal ion metabolism and homeostasis 
(Cadmium, Zinc, and Copper), which were not present in the female only analysis. 
By contrast the MAGMA analysis of the male only cohort did not find any significant 





Table 5-4: GO pathways associated with low grip strength in women (EWGSOP low grip strength) 




P-value Adjusted P-value 
Adaptive immune response 600 69 7.82E-41 5.75E-37 
Positive regulation of immune response process 1147 55 1.11E-14 4.09E-11 
Regulation of immune response 1072 52 3.98E-14 9.75E-11 
Positive regulation of immune response 871 46 6.49E-14 1.19E-10 
Regulation of immune system process 1606 65 9.97E-14 1.46E-10 
Antigen processing and presentation of peptide antigen 186 21 5.03E-13 6.16E-10 
Antigen processing and presentation 221 22 1.83E-12 1.92E-09 
Activation of immune response 692 37 1.43E-11 1.31E-08 
Antigen processing and presentation of peptide or polysaccharide 
antigen via MHC class II 
100 14 2.18E-10 1.78E-07 






Our sex-stratified meta-analysis of 256,523 Europeans aged 60 years and over 
identified differences in the genomic risk loci. For these genomic risk loci this indicates 
that the underlying casual pathways are consistent between the two analyses 
including inflammation and immune response (rs34415150, HLA-DRB1), cell growth 
(rs143384, GDF5) and conditions such as osteoarthritis (rs2899611, ALDH1A2). 
The one variant that was present in the female only results that was not correlated 
with a matching variant in the combined analysis was rs7185040. This variant is an 
eQTL for the downregulation of PKD1. Polycystin-1 (PC1, the protein encoded by 
PKD1) has been shown in the mouse model to have a role in osteoblastogenesis, with 
knock-out mutants of pkd1 causing bone defects (Lu et al. 2001) and osteopenia(Xiao 
et al. 2010). Low grip strength has previously been associated with low bone mineral 
density in women (Dixon et al. 2005). 
Mutations in PKD1 and PKD2 genes are the common cause of Autosomal Dominant 
Polycystic Kidney Disease (ADPKD) (Ong and Harris 2015), a disease with varying 
levels of severity dependent on the particular variations involved and is one of the 
most common inherited kidney disorders with an estimated prevalence of one in 2500 
individuals of European ancestry (Willey et al. 2017). ADPKD is a progressive 
systemic disorder, affecting primarily the kidney where accumulation of cysts results 
in end-stage kidney disease around the sixth decade of life, but can also involve 
hypertension, liver cysts (Hogan et al. 2015), and intracranial aneurysms (Chapman 
et al. 2015). PKD1 belongs to the TRPP (Transient receptor potential protein) 
superfamily of cation channel proteins. One member of this family, PKD1L2 (Polycystic 





impairments including neuromuscular junction degeneration, and polyneuronal 
innervation in the mouse model skeletal muscle (Mackenzie et al. 2009). 
Whether the association with muscle weakness observed at the PKD1 genomic risk 
locus is causal or due to a secondary effect from the burden of kidney disease is 
difficult to confirm and could be heavily confounded. Fine-mapping of the genomic risk 
locus could identify causal variants, as could eQTL analysis and network analysis of 
the gene pathways associated with the locus (Broekema, Bakker, and Jonkers 2020).  
Horizontal pleiotropy between the traits of muscle weakness with age and PKD1 risk, 
could be tested for using Mendelian randomization Egger and Steiger filtering methods 
(Cho et al. 2020; Bowden, Davey Smith, and Burgess 2015). 
However sarcopenia has previously been shown to be associated with renal 
dysfunction and chronic kidney disease (R. Yang et al. 2016; Ida et al. 2019; Ortiz and 
Sanchez-Niño 2019). 
Although only seven out of the fifteen genomic risk loci identified in the combined 
analysis presented previously (Chapter 4) were also found in the female only analysis, 
most of the missing associations could be due to a power issue and small effect sizes 
observed. However one association with a comparatively strong signal in the 
combined analysis, rs13107325, an eQTL for UBE2D3 was not observed in the female 
only results. UBE2D3 or Ubiquitin Conjugating Enzyme E2 D3, is involved in the 
ubiquitin-proteasome pathways, ubiquitination of regulatory molecules such as cyclin 
D1 (Mittal et al. 2011) or TP53 (Saville et al. 2004), and expression of UBE2D3 






The FNIH low grip definition is more stringent than the EWGSOP definition (<26Kg for 
males and <16Kg for females compared to < 30 Kg for males and < 20 Kg for females) 
and shares three of the genomic risk loci with the EWGSOP female only analysis. 
However further investigation of the presence of one genomic risk locus in the FNIH 
female only analysis (rs3771512, intronic to TGFA) is required. Since this SNP is found 
to be correlated with rs958685, the lead variant of the risk locus in the combined sex 
EWGSOP meta-analysis (Chapter 4), but is not present in the EWGSOP female only 
analysis. 
By contrast only one of the three genomic risk loci identified in the male only cohort 
was observed in our original meta-analysis on both sexes together. This was the 
genomic risk locus for UBE2D3 (rs13107325 combined sex, rs35225200 male only 
R2=0.89). Out of the remaining two loci rs145933237 is nominally (p=0.01) Two other 
risk loci rs774787160 and rs145933237 appear to be specific to the male cohort.  
The lead variant rs774787160 (merged with rs59596901 on October 12, 2018 - Build 
152 of dbSNP) is a deletion/insertion variant, intronic to DSCAM (Down syndrome cell 
adhesion molecule). The delins variant has not previously been reported to have a 
clinical significance (Clinvar March 2021, (Landrum et al. 2018)). DSCAM has 
previously been shown to be involved in axonal growth, via interactions with DCC and 
UNC5 (Purohit et al. 2012; G. Liu et al. 2009). Mouse models have established that 
DSCAM knock-outs have impaired motor control (Lemieux et al. 2016). 
The closest gene to the second genomic risk locus, rs145933237, is hsa-mir-466 or 
miRNA-466 (MicroRNA-466). MicroRNAs are key regulators of biological processes 
(Gebert and MacRae 2019) and are involved in skeletal muscle myogenesis (M. Xu et 





shown to be down-regulated (approximately 4-fold) in mice with high levels of physical 
activity (Dawes et al. 2015). GADL1 is also associated with rs145933237 (although it 
is not the nearest gene), glutamic acid decarboxylase–like 1 is involved in plasma 
levels of carnosine, muscle strength and age-related degenerative changes in the 
mouse model (Mahootchi et al. 2020). 
It is interesting to note that despite the issue of analysis power with regard to the male 
cohort, there appears to be little overlap with the top associations from both the female 
only cohort and the combined sex analysis. In particular the lack of signal associated 
with the immune response and the HLA region, may highlight that autoimmunity is a 
key mechanism for low grip strength in older women while other mechanisms such as 
neuronal health may have a greater role in men.  
Previous research has found sexual dimorphism in substrate utilization in skeletal 
muscle mitochondria and our sex-stratified analysis did not associate mitochondrial 
variants with low grip strength in older adults. 
Evidence for sexual dimorphism in protein turnover with aging muscle does find some 
support, with risk loci associated with low grip strength in women being proximal to 
genes involved in the Unfolded Protein Response pathways, for example ERP27 
(Galligan and Petersen 2012).   
Limitations to our analysis include the dominance of healthy responders from the 
largest contributing study, the UK Biobank, which may not be representative of the 
population. The sample size for sex-specific analysis is limited, especially for men. 
Given the largest sample population is of European ancestry, study is restricted to this 





Due to the limitations with imputed genotyping data our analysis is limited to relatively 
common variants (minor allele frequency > 1%) in European populations. Analysis of 
rare and structural variants should be possible in future at least with the UK Biobank 
data, with the release of sequencing data. This will provide greater resolution to the 
underlying casual pathways and genetic risk factors. 
In conclusion, there were a small number of genetic variants associated with 
weakness at other ages in either males or females, highlighting specific pathways that 
may be sex-specific. These included hallmarks pathways of ageing including cell cycle 
control and inflammation, along with loci implicated in arthritis and pathways involved 
in the development and maintenance of the musculoskeletal system. However, the 







5.8 Data Availability 
The GWAS summary statistics and supporting information on low grip strength in older 
people are available on the Musculoskeletal Knowledge Portal 
(http://musculoskeletalgenomics.org/). All relevant additional data is available on 





6 Analysis 4: Analysis of casual risk factors for low grip 
strength using Mendelian Randomization 
 
Genome-wide meta-analysis of muscle weakness identifies 15 susceptibility loci 
in older men and women  
Garan Jones, Katerina Trajanoska, Adam J Santanasto, Najada Stringa, Chia-Ling 
Kuo, Janice L Atkins, Joshua R Lewis, ThuyVy Duong, Shengjun Hong, Mary L Biggs, 
Jian'an Luan, Chloe Sarnowski, Kathryn L Lunetta, Toshiko Tanaka, Mary K 
Wojczynski, Ryan Cvejkus, Maria Nethander, Sahar Ghasemi, Jingyun Yang, M. 
Carola Zillikens, Stefan Walter, Kamil Sicinski, Erika Kague, Cheryl L Ackert-Bicknell, 
Dan E Arking, B Gwen Windham, Eric Boerwinkle, Megan L Grove, Misa Graff, 
Dominik Spira, Ilja Demuth, Nathalie van der Velde, Lisette C P G M de Groot, Bruce 
M Psaty, Michelle C Odden, Alison E Fohner, Claudia Langenberg, Nicholas J 
Wareham, Stefania Bandinelli, Natasja M van Schoor, Martijn Huisman, Qihua Tan, 
Joseph Zmuda, Dan Mellström, Magnus Karlsson, David A Bennett, Aron S Buchman, 
Philip L De Jager, Andre G Uitterlinden, Uwe Völker, Thomas Kocher, Alexander 
Teumer, Leocadio Rodriguéz-Mañas, Francisco J García García, José A Carnicero, 
Pamela Herd, Lars Bertram, Claes Ohlsson, Joanne M Murabito, George A Kuchel, 
Luigi Ferrucci, David Melzer, David Karasik, Fernando Rivadeneira, Douglas P Kiel, 
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Low muscle strength is an important heritable indicator of poor health linked to 
morbidity and mortality in older people. Using Mendelian randomization on genome-
wide association study meta-analysis of 256,523 Europeans aged 60 years and over 
for low grip strength (European working group on sacropenia definition), we report 
possible overlapping causal pathways, including diabetes susceptibility, 
haematological parameters, and the immune system. Our findings reinforce the 
multifactorial causes of weakness in older people, and the impact of growth and 








Musculoskeletal disorders associated with ageing, such as sarcopenia are often 
associated with disability and the occurrence of multiple co-morbidities (Duffield et al. 
2017). Sarcopenia (Santilli et al. 2014) has been associated with a diverse range of 
conditions including diabetes (Scott et al. 2016), cardiovascular disease (G. Bahat and 
Ilhan 2016) and cognitive decline (M. Kim and Won 2019; I. Lee et al. 2018), amongst 
others. 
Long-term conditions (LTCs) and their association with probable sarcopenia (as 
defined by the European Working Group on Sarcopenia in Older People low grip 
definition) has previously been investigated in an observational study using the entire 
UK Biobank cohort (age 40-70) (Dodds et al. 2020). The study found that the 
prevalence of conditions from a number of LTC categories (including 
musculoskeletal/trauma, endocrine/diabetes and neurological/psychiatric) in 
participants meant that those participants were more likely to also have low grip 
strength. Participants with multi-morbidity had almost twice the odds of being clinically 
weak (OR 1.96; 95% CI 1.91-2.02) (Dodds et al. 2020). However this study included 
the entire UK Biobank age range (40-70), and associations found by observational 
epidemiological studies could be confounded (Meuli and Dick 2018). 
 
6.2.1 Mendelian randomization 
Mendelian randomization or the random assortment of genes from parents to 
offspring, can be used to test the association between a trait and a genetic 
polymorphism that can control for some of the problems and limitations of traditional 





- where the effects of the studied exposure on an outcome have become mixed with 
the effects from an additional exposure or factor (Skelly, Dettori, and Brodt 2012)) and 
reverse causation - where the outcome influences the exposure (Zapf, Dormann, and 
Frese 1996)), are two limitations that can be addressed using Mendelian 
randomization (G. D. Smith and Ebrahim 2003). 
The genetic information or instrumental variable (IV) is inherited randomly from the 
parent’s genes, and affects the outcome through the exposure - free from influence of 
any additional confounders that can directly affect the exposure or outcome (Didelez 










Mendelian randomization does require that the instrumental variable (genetic variants) 
are: 
a. Associated with the exposure / risk factor 
b. Not associated with any confounders of the exposure or outcome (correlated 
pleiotropy if the IV is associated with a confounder) 
c. Has no effect on the outcome directly, only through the exposure (uncorrelated 
pleiotropy if the IV is acting directly on the outcome) 
 
6.2.2 Confounders 
Confounding is a typical hazard of observational studies and it can occur when there 
is an apparent causal relationship between an exposure and an outcome, which is 
actually due to the confounder.  
In such cases the confounder must be related to both exposure and outcome, it must 
not be an intermediary step in the causal pathway between exposure and outcome, 
and finally it must be distributed unequally between the study groups (Meuli and Dick 
2018). Randomised clinical trials are resistant to confounding due to the equal 
distribution of the confounding factor between the study groups, equally Mendelian 
randomization relies on the random assignment of genotypes prior to birth before any 
influence by environmental or lifestyle factors that often act as confounders. 
This therefore leads to an additional assumption for Mendelian randomization, 





This is Mendel’s second law or the “The Law of Independent assortment” (Morgan 
1915), which states that the inheritance of one trait is independent of – randomized in 
respect to – the inheritance of other traits, as long as they are not in linkage 
disequilibrium. 
 
6.2.3 Horizontal pleiotropy 
Mendelian randomization requires that a number of assumptions have to be made 
about the exposure and outcome. One essential criteria is that the genetic instruments 
used act on the outcome exclusively through the exposure being analysed. If the 
instruments do act on the outcome directly as well as through the exposure or risk 
factor, this is termed “horizontal pleiotropy” (Solovieff et al. 2013; Ebrahim and Davey 
Smith 2008).  
Egger regression can be used within a Mendelian randomization analysis in order to 
detect horizontal pleiotropy, and treats the bias resulting from such pleiotropy in a MR 
study as similar to small study bias in a meta-analysis (Bowden, Davey Smith, and 
Burgess 2015). The degree of this bias can be measured using the intercept from 
regression of standard normal deviates against precision (Egger et al. 1997). 
 
6.2.4 Methods for MR analysis 
The primary measure used for MR investigations was Inverse-Variance Weighted 
(IVW) regression, although for secondary analysis two other measures were also 
looked at MR-Egger and Weighted median. These methods allowed us to investigate 






Figure 6-2 : Plot of Mendelian randomization analysis of Birth Weight SNPs on low 
grip strength (EWGSOP) in females only 
 
The Inverse Variance Weighted (IVW) measure uses the ratio estimate of the causal 
effect of the exposure on the outcome for each genetic variant and their standard 
errors to calculate the estimate through a fixed effect meta-analysis model (Burgess, 
Butterworth, and Thompson 2013). 
The IVW method does have problems correctly calculating the estimate when the 
Instrumental Variables are weak, or when there are variants with small effect sizes 






6.2.5 Genetic correlation 
The problem of confounding can be addressed by using the complementary method 
of cross-trait Linkage Disequilibrium (LD) score regression whichs takes into account 
all variants in LD with the lead genomic risk loci. This method is suitable when the 
heritably of the traits is distributed across thousands of variants with small effects (B. 
K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, Patterson, et al. 2015; B. Bulik-Sullivan 
et al. 2015). This provides a measure of genetic correlation between the two traits. 
While MR tests the casual effects of genetic instruments for the exposure trait with 
regard to the outcome trait, genetic correlation provides evidence of any shared 
underlying mechanisms or pathways, with no suggestion of the direction of any casual 
effect.  Genetic correlation provides evidence of the pleiotropic action of any shared 







6.3.1 GWAS of low grip strength in older people 
I conducted a GWAS meta-analysis of low grip strength in participants aged 60 years 
or older of European ancestry from 22 studies yielding a combined sample of 254,894 
individuals, as described in Chapter 4. 
Two definitions of low muscle hand grip strength were utilized at the time of analysis. 
The primary analysis was of the 2010 EWGSOP criteria for sarcopenic grip strength 
(Grip strength < 30 Kg Male; < 20 Kg Female). Given the known differences in strength 
between males and females (on average) we also performed sex stratified analyses. 
We used Linkage Disequilibrium Score Regression (LDSC, v1.0.0) to estimate the 
level of bias (i.e. from population stratification and cryptic relatedness) in the GWAS, 
and the SNP-based heritability of low grip strength (B. K. Bulik-Sullivan, Loh, 
Finucane, Ripke, Yang, Consortium, et al. 2015). 
 
6.3.2 Genetic correlations and Mendelian randomization 
We investigated the genetic correlation between the low grip strength trait and 10 
diseases - chosen because they are common, chronic diseases of aging (Jaul and 
Barron 2017) - using LDSC (v1.0.0) (B. K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, 
Consortium, et al. 2015) and published GWAS summary statistics for the following: 
Alzheimer’s disease (Jansen et al. 2019), breast cancer (Michailidou et al. 2017), 
chronic kidney disease (Pattaro et al. 2016), coronary artery disease (van der Harst 
and Verweij 2018), osteoporotic fracture risk (Trajanoska et al. 2018), osteoarthritis  





(Okada et al. 2014), stroke (Malik et al. 2018), and type-2 diabetes (Mahajan et al. 
2018). We also calculated genetic correlations with the following anthropometric traits: 
height (Yengo et al. 2018), body mass index (BMI) (Yengo et al. 2018), waist:hip ratio 
(WHR) (Pulit et al. 2019), whole-body lean mass (Zillikens et al. 2017), and 
appendicular lean mass (Zillikens et al. 2017).  
I also undertook a phenotype-wide Mendelian randomization (MR) association study 
to examine the causal effect of 83 traits on low hand grip strength. We used the 
`TwoSampleMR` (v0.4.23) package in R(Hemani et al. 2018) to perform the analysis 
of genetic instruments from the 83 traits, which including those traits with clear 
biological rationale (for example, adiposity) and others that are more exploratory for 
hypothesis generation (for example, puberty timing). GWAS studies were selected on 
the basis of number of available associated SNPs, and the study population was of 
European ancestry. 
The process for running ‘TwoSampleMR’ included harmonisation of summary 
statistics from the provided GWAS to ensure that the effect of the SNP on the exposure 
and on the outcome corresponded to the same allele. Palindromic SNPs for which the 
effect allele strand could not be predicted from allele frequency were discarded from 
the trait Genetic Risk Score (GRS). 
Selection of a trait for analysis as an outcome also required that the summary statistics 
had at least 5 SNPs associated with that trait, after harmonization. 
Inverse Weighted Variance was used as the primary measure of association. Follow 
up sensitivity analysis of the identified traits was by the MR-Egger and using weighted 
median estimation methods provided in the package. Additional analysis by weighted 





Egger and IVW in order to manually check for agreement between the methodologies, 
and so confirm findings of the main analysis. MR Egger was used to check for 
horizontal pleiotropy, evidence of which would violate one of the assumptions required 
for the Mendelian randomization analysis. 
 
6.3.3 Data Availability 
The GWAS summary statistics and supporting information on low grip strength in older 
people are available on the Musculoskeletal Knowledge Portal 
(http://musculoskeletalgenomics.org/) and the GWAS catalogue (www.ebi.ac.uk/gwas 
accession numbers GCST90007526, GCST90007527, GCST90007528, 
GCST90007529, GCST90007530 and GCST90007531)All relevant additional data is 








6.4.1 Study description 
The meta-analysis of low grip strength in older people comprised 256,523 individuals 
of European descent aged 60 years or older at assessment from 22 independent 
cohorts with maximum hand grip strength recorded - including the UK Biobank, the US 
Health and Retirement Study (HRS), the Framingham Heart Study (FHS), and others. 
The methods and results for this study are described fully in Chapter 4. Individual study 
characteristics are described in the Supplementary Information and in Chapter 2 - 
Methods.  
 
6.4.2 Genetic correlations and Mendelian randomization 
We assessed ten common age-related diseases for their genetic correlation with low 
grip strength (Figure 6-3) using published genome-wide summary statistics and 
LDSC(B. K. Bulik-Sullivan, Loh, Finucane, Ripke, Yang, Patterson, et al. 2015). The 
largest genetic overlap (rG, or SNP genetic correlation estimate) was with 
osteoarthritis (29.7% genetic correlation, SE 6.3%), but also strong positive 
correlations with coronary artery disease (19.5%, SE 3.0%), type-2 diabetes (15.8%, 








Figure 6-3: Low grip strength genetic correlations with ten common diseases and five 
anthropometric traits 
Genome-wide genetic correlations between low muscle strength and published 
summary statistics for common age-related diseases and low muscle strength risk 






We observed no significant genetic correlation after multiple-testing correction with the 
remaining diseases examined (osteoporotic fracture risk, Alzheimer’s disease, stroke, 
chronic kidney disease, breast cancer and colorectal cancer). We also determined 
genetic correlations with five anthropometric traits (Figure 6-3) and found significant 
positive correlations with waist:hip ratio (13.0%, SE 2.7%) and BMI (9.1%, SE 2.5%), 
i.e. greater adiposity correlated with weakness in 60+ year olds. Significant negative 
correlations were observed with lean muscle mass (whole body: -30.9%, SE 6.1%; 






Table 6-1: LDSC genetic correlations 
Phenotype rg se p Reference 
Osteoarthritis 0.2972 0.0626 2.0E-06 Zengini 2018 (PMID: 29559693) 
CAD 0.1948 0.0301 9.1E-11 van der Haarst 2018 (PMID: 29212778) 
Type-2 Diabetes 0.1582 0.0307 2.7E-07 Mahajan 2018 (PMID: 30297969) 
AD 0.157 0.0787 4.6E-02 Jansen 2019 (PMID 30617256) 
RA 0.1267 0.0413 2.1E-03 Okada 2014 (PMID:  24390342) 
Ischemic Stroke 0.1078 0.0546 4.8E-02 Malik 2018 (PMID: 29531354) 
Breast Cancer 0.0453 0.0315 1.5E-01 Michailidou 2017 (PMID: 29059683) 
OFR 0.0164 0.0514 7.5E-01 Trajanoska 2018 (PMID: 30158200) 
CKD 0.0042 0.0491 9.3E-01 Pattaro 2016 (PMID: 26831199) 
Prostate Cancer 0.0037 0.0484 9.4E-01 Schumacher 2018 (PMID: 29892016) 
WHR 0.1298 0.0274 2.3E-06 Pulit 2019 (PMID: 30239722) 
BMI 0.0908 0.0249 2.7E-04 Yengo 2018 (PMID: 30124842) 
ALMM -0.265 0.0582 5.3E-06 Zillikens 2017 (PMID: 28724990) 
WBLMM -0.3089 0.0607 3.6E-07 Zillikens 2017 (PMID: 28724990) 
Height -0.3739 0.0232 2.1E-58 Yengo 2018 (PMID: 30124842) 
Grip strength  
(Linear measure) 
-0.952 0.0167 0.0E+00 Analysis in UK Biobank Europeans 
 
Phenotype = GWAS for genetic correlation with low grip strength in older people: CAD=Coronary Artery 
Disease; AD=Alzheimer's Disease; RA= Rheumatoid Arthritis; OFR=Osteoporotic Fracture Risk; 
CKD=Chronic Kidney Disease; WHR= Waist:hip Ratio (adj. BMI); BMI= Body Mass Index; ALMM= 
Appendicular lean muscle mass; WBLMM= Whole-body lean muscle mass; Grip strength shown in this 
table is the linear measurement of grip at all ages rg = genetic correlation, se = standard error of rg, p 





We examined 83 traits (Supplementary Table s6-5) in Mendelian randomization 
analysis to find evidence for shared causal pathways with weakness (low grip 
EWGSOP) at older ages: primary results presented are betas from inverse variance-
weighted regression using the `TwoSampleMR` R package(Hemani et al. 2018) 
(Figure 6-4; Supplementary Table s6-2).  
 
 
Figure 6-4: Traits sharing causal pathways with low grip strength at older ages 
identified in Mendelian Randomization analysis 
In Figure 6-4, Mendelian randomization analysis estimates whether 83 exposures may share causal 
pathways with low grip strength in people aged 60 and older. Those identified as significant (multiple 
testing-adjusted p < 0.05) in at least one analysis (all participants, or males or females separately) are 
included in the figure. *WHR (adj. BMI in Women) = Waist-Hip Ratio SNPs identified in GWAS analysis 





independent samples) aged 60 or older from 22 cohorts. Data presented as Odds Ratios + /− 95% 
Confidence Intervals. Unadjusted p value (two-sided) from IVW regression analysis of exposure SNPs 
effect on low grip strength (EWGSOP definition). Full results of Mendelian randomization available in 





Table 6-2: Mendelian randomization analysis of low grip strength in older people (EWGSOP) 
  
IVW MR - Combined IVW MR - Female only IVW MR - Male only 












upper ci ivw pval 
Menarche  298 0.9235 0.8915 0.9567 9.84E-06 0.9136 0.8780 0.9506 8.40E-06 1.0770 1.0393 1.1161 4.46E-05 
Birth weight 53 0.8042 0.7273 0.8893 2.16E-05 0.8088 0.7145 0.9156 7.98E-04 0.8151 0.6999 0.9492 8.53E-03 
Rheumatoid 
Arthritis 61 1.0316 1.0168 1.0467 2.44E-05 1.0386 1.0223 1.0551 2.66E-06 1.0224 0.9989 1.0465 6.21E-02 
WHR (adjBMI 
Women) 45 0.8455 0.7820 0.9142 2.57E-05 0.8589 0.7876 0.9367 5.89E-04 0.8237 0.7380 0.9193 5.38E-04 
Type-2 Diabetes  288 1.0488 1.0233 1.0750 1.50E-04 1.0433 1.0138 1.0737 3.79E-03 1.0770 1.0393 1.1161 4.46E-05 
Asthma and 
allergic disease  34 1.0743 1.0308 1.1195 6.76E-04 1.0841 1.0308 1.1401 1.68E-03 1.0739 1.0109 1.1408 2.07E-02 
PCT 193 0.9555 0.9262 0.9857 4.17E-03 0.9757 0.9383 1.0145 2.16E-01 0.9066 0.8638 0.9516 7.24E-05 
Depression 89 1.1510 1.0349 1.2801 9.50E-03 1.2051 1.0705 1.3567 2.02E-03 1.0469 0.8938 1.2263 5.70E-01 
Colorectal Cancer  53 1.0269 0.9917 1.0634 1.36E-01 1.0581 1.0203 1.0972 2.32E-03 0.9842 0.9309 1.0406 5.76E-01 
MCHC 51 0.9333 0.8713 0.9996 4.88E-02 0.9802 0.9065 1.0598 6.15E-01 0.8252 0.7466 0.9120 1.66E-04 
HGB 89 0.9569 0.9018 1.0153 1.45E-01 1.0118 0.9402 1.0888 7.55E-01 0.8426 0.7639 0.9295 6.23E-04 
Schizophrenia 111 0.9733 0.9459 1.0016 6.43E-02 0.9889 0.9565 1.0224 5.12E-01 0.9338 0.8955 0.9738 1.37E-03 
 
Significant associations for low grip strength for selected traits based on the EWGSOP definition for sarcopenia in older people. Inverse Variance Weighted 
(IVW) TwoSampleMR test. Menarche = Increasing age of Menarche; Birth weight = Increasing birth weight (KG); MCHC = Increasing Mature red cell Mean 
corpuscular haemoglobin concentration; HGB = Increasing Mature red cell Haemoglobin concentration; PCT = Increasing Platelet Plateletcrit; WHR (adjBMI 
Women) = Increasing Waist-Hip Ratio adjusted for Body Mass Index from GWAS for women only; All other traits = increasing incidence. nsnp = number of 





Table 6-3: IVW Mendelian randomization analysis of risk factors for ageing traits and 


















Menarche  298 5.32E-04 0.0133 9.84E-06 0.923 0.891 0.957 
Birth weight 53 5.32E-04 0.8606 2.16E-05 0.804 0.727 0.889 
Rheumatoid 
Arthritis 
61 5.32E-04 0.0002 2.44E-05 1.032 1.017 1.047 
WHR (adjBMI 
Women) 
45 5.32E-04 0.0113 2.57E-05 0.846 0.782 0.914 
Type-2 Diabetes  288 2.48E-03 0.4736 1.50E-04 1.049 1.023 1.075 
Asthma / allergic 
disease  
34 9.35E-03 0.0247 6.76E-04 1.074 1.031 1.120 
Platelet [PCT] 
Plateletcrit 
193 4.94E-02 0.2659 4.17E-03 0.955 0.926 0.986 
 
IVW=Inverse Variance Weighted TwoSampleMR test; *Benjamini-Hochberg FDR adjusted p-value; MR 
Egger p-value of intercept test (a low p-value indicates that the IVW estimate is biased and suggests 
either directional pleiotropy or failure of the InSIDE - Instrument Strength Independent of Direct Effect - 
assumption). Odds ratios = age of onset (Menarche), Kg (Birth weight), waist cm/ hip cm (WHR), % 
Volume occupied by platelets in the blood (Platelet crit), Binary traits are odds ratios of occurrence.  
 
We found significantly increased likelihood of weakness (multiple testing-adjusted p-
values<0.05) with genetically predicted rheumatoid arthritis (Odds Ratio=1.03, 
Benjamini-Hochberg adjusted p-value=5.3*10-4), presence of type-2 diabetes 
(OR=1.05, BH p =2.5*10-3), or incidence of asthma and allergic disease (OR=1.07, BH 
p=9.4*10-3) (Table 6-2). Genetic predisposition to greater age of menarche (OR=0.92, 
BH p=5.3*10-4; see Figure 6-5), increased birth weight (OR=0.80, BH p=5.3*10-4) and 
increased waist-hip ratio (WHR) adjusted for BMI in women only (OR=0.85, BH 
p=5.3*10-4) were protective of low grip strength as defined by the EWGSOP definition 






Figure 6-5: Mendelian randomization association between low grip strength and age 
of onset of menarche (EWGSOP, both sexes) 
SNP effect of age of onset of Menarche against SNP effect on low grip strength (EWGSOP – combined) 
for each variant available from the 2017 UK Biobank GWAS for age at Menarche (Day et al. 2017). 
 
For each significant analysis we also examined the results from the weighted-median 
and MR-Egger tests to check consistency and for horizontal pleiotropy. Horizontal 
pleiotropy arises when a single genetic variant or instrument influences multiple traits, 
and is one of the limitations of the Mendelian Randomization methodology (Hemani, 
Bowden, and Davey Smith 2018). 
 
Only birth weight had an MR-Egger beta that was inconsistent with the main effect (-
0.03 compared to -0.2), although the intercept did not significantly deviate from 0 





to 0.27). Additionally, the WHR association should be interpreted with caution, as the 
analysis of WHR variants associated with both sexes were not statistically significant 
(nominal IVW p=0.01, Table 6-4).  
Table 6-4: MR Egger analysis of risk factors for ageing traits and diseases are 
associated with weakness in older people (EWGSOP low grip, both sexes) 






MR Egger p-value 
Menarche  -0.124 0.883 0.050 0.0133 
Birth weight -0.027 0.973 0.154 0.8606 
Rheumatoid Arthritis 0.043 1.044 0.011 0.0002 
WHR (adjBMI Women) -0.300 0.741 0.114 0.0113 
Type-2 Diabetes  0.018 1.018 0.025 0.4736 
Asthma / allergic disease  0.128 1.137 0.054 0.0247 
Platelet [PCT] Plateletcrit -0.036 0.965 0.032 0.2659 
 
IVW=Inverse Variance Weighted TwoSampleMR test; *Benjamini-Hochberg FDR adjusted p-value; 
Odds ratios = age of onset (Menarche), Kg (Birth weight), waist cm/ hip cm (WHR), % Volume occupied 
by platelets in the blood (Platelet crit), Binary traits are odds ratios of occurrence.  
 
The analysis of females only, identified depression (OR=1.21, BH p=2.75*10-2), and 
colorectal cancer (OR=1.06, BH p=2.75*10-2) (Table 6-5, full results in Supplementary 
Table s6-3). Although the MR-Egger intercept for depression was not statistically 
different from 0, there is potential for horizontal pleiotropy confounding this result (seen 






Table 6-5: IVW Mendelian randomization of risk factors for ageing traits and diseases 













Rheumatoid Arthritis 61 2.20E-04 2.66E-06 1.039 1.022 1.055 
Menarche 298 3.49E-04 8.40E-06 0.914 0.878 0.951 
WHR (adjBMI Women) 45 1.63E-02 5.89E-04 0.859 0.788 0.937 
Birth weight 53 1.65E-02 7.98E-04 0.809 0.715 0.916 
Asthma / allergic 
disease  
34 2.75E-02 1.68E-03 1.084 1.031 1.140 
Depression  89 2.75E-02 2.02E-03 1.205 1.071 1.357 
Colorectal Cancer  53 2.75E-02 2.32E-03 1.058 1.020 1.097 
Type-2 Diabetes  288 3.93E-02 3.79E-03 1.043 1.014 1.074 
 
IVW=Inverse Variance Weighted TwoSampleMR test; *Benjamini-Hochberg FDR adjusted p-value 
Odds ratios = age of onset (Menarche), Kg (Birth weight), waist cm/ hip cm (WHR). Binary traits are 






Figure 6-6: Plot of Mendelian randomisation analysis of depression SNPs on low grip 
strength (EWGSOP) in females only 
Scatter plot of estimated SNP effects on low grip strength European Working Group 
on Sarcopenia definition against estimated SNP effects on Depression; GWAS meta-
analysis N = 132,443 female participants (biologically independent samples) with 
n=33,548 cases of EWGSOP defined low grip strength; Data points indicate SNP 






In the males, increased incidence of type-2 diabetes significantly increased odds of 
EWGSOP low grip (OR=1.08, BH p=3.0*10-3) whereas greater plateletcrit (the volume 
occupied by platelets in the blood as a percentage) (OR=0.91, p=3.0*10-3) and other 
hematological parameters appear to be protective (Table 6-6, full results in 
Supplementary Data s6-4). 
 
Table 6-6: IVW Mendelian randomization of risk factors for ageing traits and diseases 












 upper CI 
Type-2 Diabetes 288 3.00E-03 4.46E-05 1.077 1.039 1.116 
Platelet [PCT] 
Plateletcrit 
193 3.00E-03 7.24E-05 0.907 0.864 0.952 
MCHC 
 
51 4.59E-03 1.66E-04 0.825 0.747 0.912 
WHR (adjBMI Women) 45 1.03E-02 5.38E-04 0.824 0.738 0.919 
HGB 89 1.03E-02 6.23E-04 0.843 0.764 0.929 
Schizophrenia  111 1.90E-02 1.37E-03 0.934 0.895 0.974 
 
IVW=Inverse Variance Weighted TwoSampleMR test; *Benjamini-Hochberg FDR adjusted p-value 
MCHC = Increased Mature red cell mean corpuscular hemoglobin concentration; HGB = Increased 
Mature red cell hemoglobin concentration; WHR (adjBMI Women) = Increasing Waist-Hip ratio 
 
To explore the effect of genetic predisposition to low grip strength at older ages we 
created an unweighted genetic risk score (GRS) in the UK Biobank European sample 
by summing the number of low grip strength-associated alleles (15 genetic variants so 
30 alleles, mean number of alleles = 12.6, SD=2.3). We first confirmed the association 







Genetic correlation between two heritable traits provides a quantitative description of 
their relationship, and can help highlight shared underlying biological pathways and 
the causality of the relationship (van Rheenen et al. 2019). We found prominent 
genetic correlation (rG) between low grip strength and the common conditions, 
osteoarthritis and Rheumatoid arthritis, but also with cardiovascular disease and type-
2 diabetes. 
Many of these conditions were also observed in our Mendelian randomization analysis 
to share casual pathways with low grip strength with additional links to other immune 
related conditions, for example asthma and allergy, also been found.  
Our previous GWAS meta-analysis of 256,523 Europeans aged 60 years and over, 
found little overlap at the individual locus level between low grip strength at older ages 
(see Chapter 4) and other diseases. We did observe significant genetic correlations, 
especially with osteoarthritis (30% overlap). However in Mendelian Randomization 
analysis we did not observe a causal relationship between osteoarthritis and low grip 
strength: taken together, this suggests that osteoarthritis shares causal risk factors 
and biological pathways with low grip strength at older ages, such as obesity, but may 
not cause it. Although our results were robust to adjustment for osteoarthritis (including 
rhizarthrosis – arthritis of the thumb) this may suggest that arthritis in the hand needs 
to be accounted for in measures of muscle weakness, as hand grip strength may not 
always reflect muscle strength elsewhere, e.g. lower-extremity strength. 
  
Our Mendelian Randomization analyses highlighted specific traits and diseases which 





development traits such as increased birth weight, higher waist:hip ratio, and later 
pubertal timing (age at menarche) in women (highly genetically correlated – 75% – 
with age at voice breaking in men (Day et al. 2017)), where greater values were 
protective. Although puberty timing is highly polygenic, it is strongly genetically 
correlated with BMI in adults (-35%)  (Day et al. 2017). These results are consistent 
with the observation that growth and development traits are associated with strength 
trajectories in later life (Kuh et al. 2019).  
Raised red blood cell parameters - especially plateletcrit, the proportion of blood 
occupied by platelets - appear to be protective in males but associations were 
attenuated or non-significant in females. A number of studies have recently reported 
a link between raised platelet to lymphocyte ratio, inflammation, and sarcopenia cross-
sectionally (Liaw et al. 2017). However our results suggest that plateletcrit (total 
platelet mass) across the lifecourse (rather than after sarcopenia onset) may be 
different, with the binding of platelets to lymphocytes shown to regulate the 
inflammatory response (Zamora et al. 2017).  
Lastly, only four of the conditions we investigated (which included coronary artery 
disease, and some common cancers) appear to causally increase risk of weakness in 
older people: depression, asthma/allergic diseases, Rheumatoid arthritis, and type-2 
diabetes. These are diverse conditions and further underlines the multifactorial causes 
of weakness in older people. The presence of depression and asthma in our results 
suggests that treatment of these conditions, alongside treatment for muscle weakness 
and wastage may be a viable alternative for a more positive outcome. 
Some Mendelian Randomization analyses have limited power due to the lack of strong 





caution. Ideally the GWAS summary statistics used for the exposures would not 
include studies, such as UK Biobank that are also used for in the low grip GWAS meta-
analysis, due to the assumptions of Two sample MR and population stratification. 
Additional MR tests can be used to test for violations of the IV assumptions. Steiger 
filtering can be used to avoid the inclusion of SNPs that have a reverse casual effect 
(Hemani, Tilling, and Davey Smith 2017). This can be summarised as if a SNP causes 
the exposure and the exposure causes the outcome, then the effect of the SNP on the 
exposure should be larger than the effect of the SNP on the outcome. If this is not true 
then you can infer that the instrument is not influencing the exposure primarily, and 
could be evidence of reverse causality. It should be noted that measurement error 
could cause issues with this type of filtering. Co-localisation, where the same casual 
variant influences two or more traits / phenotypes, can also be investigated 
(Giambartolomei et al. 2014). Although it should be noted that testing co-localisation 
requires a similar LD structure between the exposure and outcome, also multiple 






7 Discussion and conclusions 
My thesis aims to improve on current knowledge of the role of inherited genetic 
variation in the development of musculoskeletal traits in human ageing.  
By understanding the mechanisms involved in under-studied traits, such as low grip 
strength in older people, the development of interventions to delay or prevent the pain 
and disability resulting from the common musculoskeletal changes of ageing are 
facilitated. My analysis has added to the literature surrounding muscle function and 
ageing in older people and has been used by other researchers to investigate similar 
conditions, such as the effect of exercise on gene regulation in post-menopausal 
women (“Heavy-load exercise engages about 13% of the skeletal muscle 
transcriptome in postmenopausal women”, Gautvik, K.M et al, submitted for review 
March 2021).  
The recent release of a number of large biobanks, such as the UK Biobank, has 
allowed me the opportunity to find evidence of underlying mechanisms, for example 
the influence of the inflammation and growth / development pathways on low strength 
in older people. By meta-analysing Genome-Wide Association Studies from a wide-
range of population based cohorts provided by the CHARGE consortium, I have been 
able to find associations for a greater number of variants with one of the physical 
components of both frailty and sarcopenia, low grip strength, than any previous study.  
Genetic Risk Scores (GRS) for this trait could have a clinical utility in predicting those 
most at risk of developing these debilitating conditions. However further study on the 
absolute effect in an independent population would be required. As would the 





Sex stratified analysis of the GWAS meta-analysis has highlighted differences in the 
genomic risk loci for each sex. While Mendelian randomization has shown how the 
genetic instruments derived from the low grip strength in older people has a casual 
influence from certain age-related traits, with important sex specific differences. 
Previous literature on life course epidemiology has highlighted how my analysis can 
be interpreted with relationship to environmental interactions throughout the subject’s 
life course, with particular emphasis on critical periods of risk and the accumulation of 
risk throughout life (Ben-Shlomo 2002). Due to the focus of the study on muscle 
weakness in later life, the accumulation of lifetime risk can be significant and critical 
periods may be highlighted by the traits associated by Mendelian randomization, such 
as birth weight and age of menarche. By examining the results of the analysis within 
the life course epidemiology framework, critical periods for intervention and 
observation can be identified. 
7.1 New contributions 
I have taken the knowledge in this field forward by 
 Discovery of 15 genomic risk loci associated with muscle weakness in older 
people and provided evidence for possible underlying mechanisms. 
 Conducting a sex stratified analysis using data from the 22 cohorts on muscle 
weakness in older people, and showing that there are differences in the 
genomic risk loci between the sexes. 
 Using Mendelian randomisation and genetic correlation between age related 





Rheumatoid arthritis, and diabetes. Life course traits such as age of onset of 
menarche were also implicated in later life muscle weakness.  
 Found associations between HLA haplotypes and sarcopenia. Showed that 
certain HLA haplotypes are distinct to the separate components of low grip 
strength and lean muscle mass. 
 That a combination of HLA alleles gives a 23% increased likelihood of 
sarcopenia. 
 
7.2 Sarcopenia and variation in the Human Leukocyte Antigen complex 
The underlying mechanisms which result in the state of sarcopenia in older adults is 
thought to include an autoimmune component, however the genetic contribution of 
immune system genes to sarcopenia is understudied (Tan et al. 2012). My analysis of 
181,301 UK Biobank participants of European descent aged 60-70 (95,340 women, 
12.10% defined as sarcopenic under EWGSOP criteria and 85,961 men, 4.08% 
EWGSOP sarcopenic) found an associated between the EWGSOP definition of 
sarcopenia (combined low grip strength and low lean muscle mass) and six HLA 
haplotypes. 
When these six haplotypes were combined, the presence of at least 6 alleles, out of a 
possible 12 resulted in a 23% increased likelihood of sarcopenia. 
7.2.1 Impact of findings 
My analysis of UK Biobank participants using multiple definitions of sarcopenia 





people, after accounting for common known autoimmune conditions. In addition I have 
shown that the two main clinical metrics used in the definition of sarcopenia, low grip 
strength and skeletal muscle mass, have different HLA haplotypes associated with 
them. 
My study provides evidence of the involvement of the HLA genes in these traits in 
older people, independent of other known autoimmune conditions. Whether or not this 
interaction is due to Immuno-senescence and “Inflammaging” (Franceschi et al. 2018) 
is open to debate, although this does provide a mechanism by which the progression 
of sarcopenia and loss of muscle function with age could be attributed to. 
Although I have tried to account for known auto-immune conditions, confounding with 
undiagnosed auto-immune conditions is possible. In my analysis HLA types 
associated with sarcopenia, such as DRB1*04:01, have also been previously 
associated with Rheumatoid arthritis (Viatte et al. 2015). In Chapter 6 I show that 
muscle weakness in older people shares underlying genetic correlation with 
Osteoarthritis (rG=0.30, 95% CI=0.17-0.42) and Rheumatoid arthritis (rG=0.13, 95% 
CI=0.05-0.21). I also show that rheumatoid arthritis shares a causal relationship with 
low grip strength in older people using Mendelian Randomization (p=2.44*10-5; Odds 
Ratio=1.032). Although in the MR analysis we did not exclude diagnosed rheumatoid 
arthritis or other auto-immune conditions from the low grip GWAS meta-analysis that 
provided the Instrumental Variables, these findings provide additional support for an 
auto-immune component to muscle weakness in older people. 
Although six HLA types were found associated with low skeletal muscle mass on its 
own there was no overlap with the seven HLA types associated with low handgrip 





only HLA types seen in the low grip results were found in the combined EWGSOP 
results.This does suggest that not only is low grip strength the primary informative 
measure in the combined definition, but also that there may be distinct immune system 
pathways underlying the causes for the two separate metrics.  
In addition by investigating the non-coding SNPs available in the genotyping data from 
the HLA region, 4 loci associated with the EWGSOP definition of sarcopenia were 
identified. Expression data identified that these SNPs were associated with various 
HLA types and proteins involved in the unfolded protein response. The unfolded 
protein response has previously been suggested as one of plausible mechanisms 
involved in sarcopenia (Deldicque 2013)(Gnimassou, Francaux, and Deldicque 2017), 
and the eQTLs (BAG6, ATF6B) and pQTLs (ATF6A) associated with sarcopenia by 
my analysis supports this. These preliminary results were also found in the meta-
analysis presented in Chapter 4. 
 
7.2.2 Future directions 
Future plans could include a follow up GWAS excluding known auto-immune 
conditions and a subsequent MR analysis to try and quantify the influence of 
undiagnosed auto-immune conditions such as rheumatoid arthritis. Although the UK 
Biobank provides ICD-10 codes for auto-immune conditions from Hospital Episode 
Statistics (HES) data, a similar comprehensive resource was not always available for 
CHARGE cohorts that were part of the meta-analysis. Reanalysing the meta-analysis 
could also be informative if auto-immune conditions could be accounted for.  
 





results in muscle weakness can be diagnosed by using an immunological test for the 
serum antibodies for skeletal muscle acetylcholine receptor. The sensitivity of such 
auto-antibody tests approaches 85% (Meriggioli and Sanders 2009). Late onset 
Myasthenia Gravis has an association with the HLA haplotype DRB1*15:01 (Odds 
Ratio=2.38; p=7.4*10-5; n cases=369, n controls=651), amongst a number of 
additional HLA haplotypes (Maniaol et al. 2012). By understanding the auto-immune 
mechanism involved in Myasthenia Gravis various therapies have been developed 
including complement inhibitors, or depleting the antigen producing cells (Koneczny 
and Herbst 2019).  
My analysis supports the hypothesis that there is an autoimmune component to 
sarcopenia, separate from any existing condition, in certain individuals. These 
therapies could provide the basis for treatment for a proportion of older people with 
muscle weakness and sarcopenia. With increased knowledge of the autoimmune 
targets and the antibodies involved, sensitive serum based tests could be developed. 
 
7.3 Genome-wide meta-analysis of muscle weakness identifies 15 
susceptibility loci in older men and women 
Low grip strength is a good predictor of overall muscle function and is a commonly 
measured metric, making a multi-cohort Genome-Wide Association Study meta-
analysis possible. By using the low grip cut-offs as defined by the European Working 
Group on Sarcopenia and genotyping data from members of the CHARGE consortium 





have not previously been associated with a continuous measure of grip strength, in 
older adults (age > 60 of European ancestry). 
Our analysis highlights the multiple pathways to the physical components of frailty and 
sarcopenia, including the immune response, growth and differentiation, and protein 
turnover. 
 
7.3.1 Impact of findings 
Our GWAS meta-analysis of low grip strength in older people is one of the largest 
population based studies on the primary component of sarcopenia. The genomic risk 
loci associated with low grip strength, have a range of potential casual genes which 
highlights the multifactorial nature of the underlying causes of sarcopenia.  
Given the small effect sizes observed in our study, large population based studies are 
required in order to discover such associations. The previous analysis by the CHARGE 
consortium looking at maximum hand grip strength in a smaller meta-analysis of 
27,581 Europeans aged 65 or older found two loci (rs752045 and rs3121278) (Matteini 
et al. 2016) neither of which were significant in our meta-analysis of low grip cut-offs 
according to the EWGSOP criteria.  Although the Matteini et al CHARGE study 
analysed the contribution of maximal hand grip strength in older people, rather than 
low grip cut-offs, the lack of overlap with risk loci in my GWAS meta-analysis in 
Chapter 4 (as well as the maximal grip strength study using UK Biobank participants 
of all ages for 12 of the 15 risk loci (Tikkanen et al. 2018)) is an interesting observation. 
A possible reason for this is the use of maximal linear grip trait rather than a cut-off 





 In addition to the secondary analysis using the FNIH sarcopenia cut-offs, a meta-
analysis of maximal grip strength using our cohorts (although many of the CHARGE 
cohorts are in both studies) and participant criteria would have helped to confirm this 
difference in risk loci between maximal grip strength, seen in other studies, and low 
grip cut-offs in older people. 
 
One of the risk loci, lead SNP rs13107325, was proximal to SLC39A8, a gene with 
range of pleiotropic effects on multiple conditions. For example the SLC39A8 A391T 
missense mutation has been shown to increase risk of Crohn’s disease, 
cardiovascular and metabolic diseases, as well as Parkinson’s and neuropsychiatric 
disease. SLC39A8 encodes the ZIP8 metal influx transporter and it is the disruption of 
Manganese homeostasis which is thought to be an underlying mechanism in the 
development of many of these conditions (Nakata et al. 2020). 
However our lead SNP rs13107325 is not an eQTL for SLC39A8 but instead UBE2D3. 
Fine mapping of our genomic risk loci would help to gather further evidence of casual 
genes and either support our current interpretation of multiple casual pathways to low 
muscle strength in older people or possibly help to connect these seemly diverse loci 
into a single pathway.  
 
7.3.2 Future directions 
During the design of the analysis protocol low grip strength based on EWGSOP or 
FNIH cut-offs, was selected as the outcome due to its highly informative nature with 





skeletal muscle throughout the body (Bohannon et al. 2012), and general availability 
within the CHARGE cohorts.  
Previous literature has noted that participants unable to complete grip measurement 
tests, have the highest mortality rates per 1000 person years (18.63; 11.03 to 31.46 
95% CI) (Cooper et al. 2014). Inclusion of participants unable to complete the grip 
tests due to inflammation or weakness, as opposed to accidental damage to the hand, 
may help to resolve loci involved in the loss of muscle function. 
A follow-up study on Skeletal Muscle Mass and possibly gait speed would be required 
to fulfil the full criteria for the EWGSOP 2010 version (Cruz-Jentoft et al. 2010) and 
FNIH (S. A. Studenski et al. 2014) definitions of sarcopenia. In addition to a cohort 
with cases defined by the combined criteria (low grip strength, low skeletal muscle 
mass and slow gait speed), analysing these separately in a large population based 
meta-analysis would also be informative. Although the CHARGE consortium are 
currently (march 2021) meta-analysing the Short Physical Performance Battery 
(SPPB), which incorporates gait speed as a measure of frailty, the UK Biobank only 
includes limited data on gait speed (self-reported, slow / normal / fast). This would 
mean that in order to use the UK Biobank cohort in any follow up study including gait 
speed as a trait, either the accelerometer data available for a proportion of the data 
would have to be used or the limited self-reported questionnaire data. 
Follow-up studies on the same cohorts at later time points would allow a more robust 
analysis of the progress of muscle weakness with age, and provide valuable insights 
into the ageing process. Given the large number of cohorts involved this may be 
impractical to repeat the required measurements for all of the cohorts, however for the 





available for the 100,000 participants involved in the UK Biobank imaging 
enhancement project (Littlejohns et al. 2020). 
Since the development of the meta-analysis low grip strength protocol and subsequent 
meta-analysis, the European Working Group on Sarcopenia in Older People has 
released a revised version of their sarcopenia definition(Cruz-Jentoft et al. 2019) 
(EWGSOP2). Although the low grip strength cut-offs in EWGSOP2 are very similar to 
the FNIH definition we used as our secondary analysis (and hence why we didn’t try 
and review the protocol at the last minute; FNIH Males <26 Kg, Females < 16Kg; 
EWGSOP2 Males < 27Kg, Females < 16 Kg), low grip strength is only part of the 
overall definition. When the entire algorithm for predicting sarcopenia is taken into 
account for both EWGSOP1 and EWGSOP2 the difference in prevalence within the 
UK Biobank for all ages is 8.14% and 0.36% respectively (Petermann-Rocha, Chen, 
et al. 2020). Given this significant difference in prevalence a future project using similar 
sized meta-analysis would provide further resolution of the underlying pathways in 
sarcopenia in older people. 
In addition it should be noted that the cohorts involved in the meta-analysis are 
population and community based. Replication of the findings in cohorts based on 
hospital and care home residents would be essential in order to apply our findings to 
the forms of secondary sarcopenia associated with chronic illness found in these 
populations (Welch et al. 2018).  
Replication of the results from the European population should be replicated for a 
range of different populations and ethnicities. There are different criteria for some 
ethnicities such as the Asian Working Group on Sacropenia (AWGS)(L.-Y. K. L.-K. Y. 





strength and skeletal muscle mass. Despite this a number of extremely large 
population based biobanks with deep phenotyping and genotyping similar to that of 
the UK Biobank, with greater proportion of different ethnicities are becoming 
available(“The ‘All of Us’ Research Program” 2019; Hunter-Zinck et al. 2020). Trans-
ethnic meta-analysis can identify additional candidate risk loci as well as filter out noise 
due to population specific factors (Sakaue et al. 2020). For example a recent trans-
ancestry meta-analysis of coronary heart disease (CAD) using both participants from 
the Biobank Japan and UK Biobank produced a polygenic risk score (PRS) that 
outperformed population specific PRS, identified additional risk loci and help to fine 
map the candidate genes associated with CAD across both populations (Koyama et 
al. 2020). 
 
Our GWAS meta-analysis included annotation of the lead SNPs with FUMA, which 
included a number of approaches to identify casual variants (Watanabe, Taskesen, 
Van Bochoven, et al. 2017). However there also additional approaches that could be 
used to fine map the casual variants associated with low grip strength in older people. 
These include statistical methods such as a penalised regression (only considers 
SNPs whose effect size is not reduced to zero after being penalised), an heuristic LD 
method (where variants that pass a linkage disequilibrium threshold with the peak SNP 
are considered together, this approach was used in the FUMA annotation) or a 
Bayesian fine mapping approach (Schaid, Chen, and Larson 2018).  
One common approach is to increase the SNP density and so the number of 
informative sites. The UK Biobank has recently started to release Exome sequencing 





will in time be followed by the sequencing of the entire dataset. Such data allows high 
variant density analysis of the variants associated with sarcopenia and traits like low 
grip strength. Novel approaches such as aggregating loss of function and missense 
variants for a particular gene in order to resolve any association with a trait can be 
attempted(Fuchsberger et al. 2016). In addition analysis of rarer alleles with a Minor 
Allele Frequency of less than 1% is possible, as well as better identification of 
structural variants such as Copy Number Variants (CNV). Association of CNVs with 
anthropometric traits has previously been published on, using UK Biobank genotyping 
data (Macé et al. 2017). However sequencing data will enable smaller structural 
variants to be called. 
 
 
7.4 Sex-stratified genomic analysis of low grip strength 
Low grip strength is a commonly used proxy for measuring overall muscle function, 
particularly in regards to the age-related condition, sarcopenia (Aadahl et al. 2011; 
Bohannon et al. 2012; S. H. Lee and Gong 2020). The prevalence of sarcopenia, or 
loss of muscle mass and function primarily due to age varies considerably from 
population to population, age and sex (S. A. Purcell et al. 2020; Shafiee et al. 2017). 
With the observation that sexual dimorphism in skeletal muscle protein turnover with 
age has been previously noted (G. I. Smith and Mittendorfer 2016; G. I. Smith et al. 
2012), as has the influence of sex on different substrate utilization in skeletal muscle 





investigated the genomic risk loci associated with low grip strength in older adults in a 
large community based meta-analysis with cohorts separated by sex. 
Using sex-stratified analysis of the GWAS meta-analysis from 22 cohorts (135,468 
females and 121,055 males) and the low grip cut-offs as defined by the European 
Working Group on Sarcopenia and genotyping data from members of the CHARGE 
consortium I have shown that there are eight loci associated with low grip strength in 
older women (age > 60) of European ancestry. Although there is substantial overlap 
with our previous analysis on both sexes, there is one unique risk locus intronic to 
PKD1. 
7.4.1 Impact of findings 
Although the overlap between the female only cohort risk loci and the results from the 
GWAS meta-analysis presented in chapter 4 were to be expected, the lack of 
associated risk loci overlap for the male only cohort with the original analysis is 
unexpected.  
Case numbers were substantially lower for the male only cohort for both the EWGSOP 
and FNIH definition for low grip strength (N=121,055; n cases EWGSOP=14,007 or 
1.6%; n cases FNIH=6,734 or 5.6%) when compared to the female only cohort 
(N=135,468; n cases EWGSOP=34,589 or 25.5%; n cases FNIH=13,601 or 10%). 
This was despite sex-specific cut-offs for low grip strength. 
Therefore the lower number of overall risk loci identified may be expected in the male–
only cohort due to sample size and number of cases. The non-significance of the two 
risk loci (rs774787160 and rs145933237 from the male-only results) in the female-only 





association. This highlights the importance of analysing the cohorts in a sex-stratified 
manner. 
Both the novel male-only risk loci (rs774787160 and rs145933237) have plausible 
mechanisms for low grip strength through their nearest genes DSCAM (axonal growth 
and evidence of impaired motor control in model systems (Purohit et al. 2012; G. Liu 
et al. 2009; Lemieux et al. 2016)) and MIR466 (cellular apoptosis (Cao et al. 2018)). 
However neither lead SNP has an eQTL associated with it. In the case of 
rs145933237, for example, additional interesting genes are associated with the risk 
locus, including GADL1 (glutamic acid decarboxylase–like 1 associated with plasma 
levels of carnosine, muscle strength and age-related degenerative changes) 
(Mahootchi et al. 2020). Additional fine mapping the sex-specific loci would help to 
identify the casual genes associated with the risk locus. 
Such fine mapping could lead to specific treatments for age associated muscle 
weakness. For example, GADL1 has a role in the biosynthesis of carnosine, and 
carnosine deficiency can be treated by β-Alanine supplementation(Saunders et al. 
2017). It is interesting to note that CARNS1, another gene involved in carnosine 
metabolism, has an association with maximal handgrip strength (Mahootchi et al. 
2020) and that carnosine itself has a substantial literature on its role in aging (Hipkiss, 
Baye, and de Courten 2016; Aydın et al. 2016; Chaleckis et al. 2016). 
There are seven risk loci associated with the female-only cohort, which are also 
observed in the original combined analysis. The remaining risk locus rs7185040, an 
eQTL for PKD1, which is associated with Chronic Kidney Disease (CKD). One of the 
clinical implications of my findings is that potential treatments for clinical weakness 






7.4.2 Future Directions 
Increasing the size of the meta-analysis by including other large biobanks in a 
subsequent analysis will help find additional associations with low grip strength in older 
people. This would be particularly valuable for the male only cohort were sample size 
and number of cases may be an issue. 
Trans-ethnic meta-analysis with large population based biobanks such as the 
Japanese Biobank (Nagai et al. 2017), has been used to increase the power and 
sensitivity of similar studies (Koyama et al. 2020). 
Fine mapping of the risk loci for each sex stratified analysis would help to identify the 
casual genes, and suggest additional pathways involved in muscle weakness in older 
people. 
 
7.5 Mendelian Randomization analysis of causal pathways associated with 
low grip in older people 
I used Mendelian randomization on genome-wide association study meta-analysis of 
256,523 Europeans aged 60 years and over for low grip strength (European working 
group on sacropenia definition), and found that there are a number of possible 
overlapping casual pathways, which include metabolic diseases such as diabetes, 
haematological parameters, and the immune system. These findings reinforce the 
multifactorial causes of weakness in older people, and the impact of growth and 





7.5.1 Impact of findings 
The analysis of aging related traits and chronic diseases of aging by Mendelian 
Randomization (MR) and genetic correlation confirmed the relationship with the aging 
immune system, and highlight certain measures of the human life course as important 
indicators of muscle weakness in later life.  
Indicators like birth weight, age of menarche and waist-hip ratio, can provide public 
health intervention markers, if they are reliable and consistent predictors of later ill 
health (Belbasis et al. 2016; Hsieh et al. 1990). The life course traits identified by the 
MR analysis as associated with muscle weakness in older people, have been shown 
by previous literature to be associated with each other. Birth weight has an impact on 
age of menarche (Adair 2001; Ruth et al. 2016) and reproductive aging (Tom et al. 
2010). Body Mass Index (BMI) predisposes to a range of later life diseases (Locke et 
al. 2015) and adiposity genetic loci have been associated with the timing of menarche 
onset (Fernández-Rhodes et al. 2013). In addition observational studies have linked 
waist-to-hip ratio and BMI to an earlier onset of menarche (Bratke et al. 2017; 
Żurawiecka and Wronka 2020). 
 A higher Waist-to-hip ratio or central adiposity has been shown to increase mortality 
risk in older individuals (60-69 years) who otherwise have a normal weight (Hazard 
ratio=1.41; 95% CI=1.25-1.61)(Bowman et al. 2017). MR analysis of waist-hip ratio 
has previously associated this trait with increased risk of both Type 2 diabetes and 
coronary heart disease (Emdin et al. 2017) in the UK Biobank cohort. The European 
Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study 
found an association between earlier age of menarche and a higher risk of type 2 





between BMI and type 2 diabetes (42% increase risk independent of BMI) (Elks et al. 
2013). 
This does suggest that muscle weakness in older people shares a causal pathway 
with these life-course traits, and metabolic factors may underlie at least part of the 
multifactorial nature of sarcopenia and muscle weakness with age. 
Other associations found by the MR analysis include immune system traits and 
autoimmune diseases. Rheumatoid arthritis (Smolen, Aletaha, and McInnes 2016), as 
well as Asthma and allergic disease (Han, Krempski, and Nadeau 2020) have a basis 
in the dysregulation of the immune system (Ludwig et al. 2017). In addition traits such 
as raised platelet to lymphocyte ratio have been linked to inflammation and sarcopenia 
in community-dwelling older people (Liaw et al. 2017). This does provide evidence for 
a role of immuno-senescence and “inflammaging” in the underlying pathways resulting 
in muscle weakness in older people, and in turn sarcopenia. 
7.5.2 Future Directions 
Further testing of significant associations for robustness, the effect of heterogeneity 
outliers could be investigated using software such as Radial MR (Bowden et al. 2018), 
which can indicate if directional pleiotropy is present by calculating a suitable Q 
statistic. Analysis of the factors / biomarkers that have been identified in independent 
ageing cohorts with a longer follow up period, could provide an indication of the 







With an ageing world population, it becomes increasingly important to effectively 
diagnose and treat diseases associated with musculoskeletal ageing, such as 
sarcopenia.  
My analysis of HLA types and their association with different definitions and 
components of sarcopenia has shown that there are specific risk haplotypes for 
muscle weakness in older people. By investigating low skeletal muscle mass and 
handgrip strength separately I was able to provide evidence that different HLA types 
are associated with each component. When these are looked at together, as a 
combined definition of sarcopenia, HLA types associated with low grip strength 
predominate. In addition, I was also able to show that specific HLA types in 
combination can result in 27% increased likelihood of sarcopenia. This suggests that 
a lifetime exposure to low level pro-inflammatory state contributes to the risk of 
developing sarcopenia in later life. 
The results from my meta-analysis of Genome Wide Association Studies (GWAS) for 
low grip strength of 22 cohorts from the CHARGE consortium provided fifteen genomic 
risk loci. The majority of these have not previously been associated with continuous 
measures of grip strength in previous studies, which provides evidence that these loci 
are specific to low grip strength in older people. 
The analysis of candidate genes associated with the genomic risk loci shows that there 
are a number of separate pathways involved, with previous literature on ageing 





The sex-specific analysis of low grip strength in older people highlighted the 
differences in genomic risk loci found to be significantly associated with the low grip 
definitions for each sex.  
Although the female only analysis overlapped almost completely with the previous 
combined analysis, there were far fewer risk loci associated with low grip strength in 
the male only cohort. The presence of two unique loci for the male only analysis 
(DSCAM and MIR466 / GADL1) and one for the female only analysis (PKD1) does 
allow a tentative conclusion that different pathways are casually attributable to low grip 
strength in older people, for each sex. This is further reinforced by the lack of lack of 
overlap in genomic risk loci between the combined results and the male only results. 
Mendelian randomization has allowed me to investigate the casual pathways 
associated with low grip strength and provides further evidence of the multifactorial 
nature of the underlying mechanisms at work in the development of low grip strength 
in older people.  
The genomic risk loci identified by the study do provide potential targets for treatment, 
in the same way that the ADAMTS7 loci has been identified in Coronary Artery Disease 
(CAD) as a therapeutic target (Müller et al. 2016; Reilly et al. 2011). Pathways and 
traits associated through Mendelian randomization, such as Type 2 Diabetes, also 
provide possible routes for intervention (Massimino et al. 2021). In addition, events 
earlier in the life-course such as birth weight and age of menarche provide critical 
periods where observation and possible intervention may provide alleviation of later 






7.7 Limitations  
7.7.1 Limitations of UK Biobank 
The UK Biobank constitutes the largest cohort in the meta-analysis, as well as the only 
data source for the analysis of HLA types and sarcopenia. UK biobank is known to 
have a healthy volunteer selection bias (Fry et al. 2017) (discussed in detail in Methods 
– chapter 2), which along with the young average age (approximately 64 years for the 
HLA analysis in Chapter 3) for the onset of sarcopenia and age-related reduction in 
muscle function, would reduce the number of cases and although this distorts the data 
with regards to the general UK population, it does mean a lower likelihood of false-
positives. 
In addition the underlying population structure within the UK Biobank genotyping data 
can also introduce bias into any analysis (Haworth et al. 2019). A recent study by 
Haworth et al, found that polygenic scores for traits such as BMI and height were 
influenced by geographic location of birth of UK Biobank participants (Haworth et al. 
2019).  However an analysis of birth location did not find maximum grip strength 
associated with birth location, unlike a number of traits such as walking pace, body 
mass index and various measures of limb/body fat (Cook, Mahajan, and Morris 2020). 
A follow up study on whether birth location is associated with the low grip cut-off of 
sarcopenia would provide evidence for any bias due to population structure. 
7.7.2 Limitations of meta-analysis datasets 
Despite the relatively large sample size for the GWAS meta-analysis, we have 
restricted the analysis to a single ethnicity – European ancestry. Although initially I had 





mainly Asian ancestry, the available number of cases was not enough to undertake 
the analysis. Future work may include the use of the multi-ethnic biobanks with a larger 
proportion of participants from other populations, although some possible candidates 
such as the NIH ‘All of us’ biobank does not include the measurements required (grip 
strength) (All of Us Research Program Investigators et al. 2019). 
The age range of the studies included in the meta-analysis was fairly young for the 
onset of sarcopenia and so analysis of a cohort with older ages would provide a better 
representation of the more common onset age of sarcopenia.   
7.7.3 Limitations of microarrays 
As noted in the Methods – Chapter 2, microarray technology has limitations when used 
to analyse alleles whose minor version is present in the study population at lower 
frequencies (minor allele frequency less than 1%) (Weedon et al. 2019). The UK 
Biobank has recently started to release Exome sequencing data which could be used 
instead of microarray data in order to investigate rarer alleles. 
In addition there are other types of genomic variation that can be detected by SNP 
array technology, such as structural and copy number variant, that were not 
investigated for their association with the traits in question. Although these could be 
detected using the UK Biobank data and suitable methods, this was not possible for 
the various CHARGE consortium studies without asking the analysts for each study to 
undertake this additional methodology. Given the time constraints on the meta-
analysis this was not performed, however previous literature has shown how these 
larger variants have been associated with anthropometric traits (Macé et al. 2017) and 






7.7.4 Limitations of sarcopenia definitions 
In the Introduction – Chapter 1, I discussed the various definitions for sarcopenia. The 
definitions are derived from measures that are specific to certain populations, for 
example the European Working Group on Sarcopenia (EWGSOP) used data from 
people of European ancestry. However often the baseline population used to calculate 
the cut-offs has a low sample size. For example the EWGSOP low grip definition 
(2010) was defined based on 2 standard deviations below the mean based measured 
in 1,030 (469 mean and 561 women) participants from the InCHIANTI study (Lauretani 
et al. 2003). 
With both the population specific nature and small sample size of the initial dataset 
used in the definition, bias is possible. I have tried to account for this by restricting the 
analysis to similar populations as in the original definition, community based 
participants of European ancestry. 
 
7.7.5 Limitations of sex-specific analysis 
Sample sizes for each sex-specific GWAS meta-analysis (135,468 females and 
121,055 males) is by definition smaller than the combined analysis (256,523 
participants). The number of cases in for each of the sex-specific analysis was 
imbalanced with 25.5% (34,589) cases in the female cohort, compared to 11.6% 
(14,007) cases in the male cohort despite the EWGSOP sarcopenia definition taking 
into account sex. The most likely reason could be the lower ages of participants in the 





 The sex-specific analysis, due to being a sub-set of the original meta-analysis, only 
used data from the autosomes (chromosomes 1-22) and the directly genotyped data 
for mitochondria. The allosomes, or sex-chromosomes were not analysed as 
genotyping data for the sex-chromosomes was not available for many of the CHARGE 
studies collaborating in the meta-analysis, and future work on these may provide 







The progressive loss of skeletal muscle function and mass is a common result of the 
ageing process in humans, leading to deliberating states such as sarcopenia and 
frailty. There have been a number of proposed underlying mechanisms for this loss of 
musclo-skeletal function and my thesis has provided evidence for the contribution of 
genes involved in the immune system, unfolded protein response, cell cycle control, 
transcription regulation, as well as the growth and development pathways. In addition 
I have highlighted that there are different pathways contributing to muscle weakness 
with age, for each sex. 
My analysis of the Human Leukocyte Alleles associated with sarcopenia provided 
evidence of that autoimmune pathways are contributing to clinical weakness in older 
people, with the difference between the two phenotypes of muscle mass and function 
providing two separate sets of risk alleles. Results from the investigation also showed 
that combinations of certain HLA alleles could increase an individual’s risk for 
sarcopenia by up to 23%. 
While investigating the casual pathways, I found that metabolic disease, such as 
diabetes and autoimmune conditions such as rheumatoid arthritis and allergic disease, 
had an association with muscle weakness with age.  
In addition there were well characterised differences between the casual pathways 
between the sexes. Muscle weakness in older women being influenced by life course 
traits such as age of the onset of menarche and birth weight, whereas in older men 
there was a relationship with measures of blood cell volume and concentration. Further 





number of common diseases, also found the relationship to diabetes and rheumatoid 
arthritis but also coronary heart disease and osteoarthritis.  There was also substantial 
genetic overlap with anthropometric traits like waist to hip ratio and height. 
Taken together my thesis gives insight into the mechanisms involved in muscle 
weakness in later life. This provide plausible targets for intervention as well as genetic 
markers to help characterise individual risk of muscle weakness with age. 
The association between certain HLA types and sarcopenia could provide treatment 
opportunities mediated through anti-inflammatory mechanisms, or through addressing 







Supplementary methods for Chapters 4, 5 & 6. Originally published as part of (G. 
Jones et al. 2021). Abridged version, LocusZoom plots courtesy of Dr. Luke Pilling. 
8.1 Supplementary Methods 
8.1.1 Cohorts 
22 studies with a total of 254,894 participants of European ancestries and age 60 or 
older were included in the analysis low grip strength. See Supplementary Table 8-1 
for number of cases/controls in each cohort. Here follows individual study descriptions: 
8.1.2 Atherosclerosis Risk in Communities (ARIC) study 
The Atherosclerosis Risk in Communities (ARIC) Study is a population-based 
prospective cohort study of cardiovascular disease and includes a total of 15,792 
participants aged 45-64 years at baseline (1987-89), chosen by probability sampling 
from four US communities(The ARIC investigators 1989). Cohort members completed 
five clinic examinations, conducted approximately three years apart between 1987 and 
1998, with a fifth visit conducted from 2011 – 2013. Clinic examinations included 
assessment of cardiovascular risk factors, self-reported medical family history, 
employment and educational status, diet, physical activity, comorbidity, clinical and 
laboratory measurements. The present analyses were restricted to participants of 
European descent and utilized measurements from the Visit 5 grip strength 
assessment. Grip strength in kilograms of force was assessed using Jamar Hydraulic 
Hand Dynamometer in the participant's preferred hand (usually the dominant). The 






Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 
(Affymetrix, Santa Clara, CA, USA). Exclusions at the individual level included 
removing first-degree relatives, ancestry outliers, samples with low call rate (<95%) or 
unexpected duplicates, and samples with a mismatch between called and phenotypic 
sex. SNPs were excluded due to having a low call rate for the combined sample 
(<95%), no chromosome location, being monomorphic in both the European and 
African descended genotyped individuals, and having an HWE p-value <10-6. Before 
imputation, additional quality control was completed using the “HRC/1KG Imputation 
Preparation and Checking Tool” developed by Will Rayner (version 4.2.5). SNPs with 
incorrect strand or reference/alternate allele designations were fixed accordingly and 
further SNPs were excluded due to mismatches with the 1000 Genomes reference 
panel, having allele frequency differences >0.2 from the European 1000 Genomes 
data, and being palindromic with frequencies >0.4. A total of 752,325 SNPs were 
submitted for imputation on the Michigan Imputation Server using the Haplotype 
Reference Consortium (HRC) r1.1 2016 reference panel with the following options 
chosen: phasing, Eagle v2.3; population, EUR (for quality control purposes); mode, 
Quality Control & Imputation. 
After filtering for age, phenotype, genotype availability and removing all related 
individuals, 3655 individuals remained, with a minimum age of 66 and a maximum of 
90. The number of cases and controls for each analysis/dynapenia (low grip strength 
due to ageing) definition is as follows: for FNIH, 351 cases and 3,304 controls; for 
EWGSOP, 939 cases and 2,716 controls. Logistic regression analyses were 
conducted using the ‘--logistic-snp’ option on FAST (version 2.4)(Chanda et al. 2013) 





(except in the sex-stratified analyses), study site and PCs 1-4. Only SNPs with a MAF 
≥0.02 were included in association analyses. 
 
8.1.3 Berlin Aging Study II (BASE-II) 
BASE-II is a multidisciplinary study initiated in 2009 investigating factors related to 
human aging (Bertram et al. 2014). All subjects are recruited from the Berlin 
metropolitan area and underwent an extensive phenotypic assessment, including a 2-
day internal medicine examination (follow-up will be completed in 2020). The BASE-II 
research project (Co-PIs are Lars Bertram, Ilja Demuth, Denis Gerstorf, Ulman 
Lindenberger, Graham Pawelec, Elisabeth Steinhagen-Thiessen, and Gert G. 
Wagner) is supported by the German Federal Ministry of Education and Research 
(Bundesministerium für Bildung und Forschung, BMBF) under grant numbers 
#16SV5536K, #16SV5537, #16SV5538, #16SV5837, #01UW0808, 01GL1716A and 
01GL1716B. Another source of funding is the Max Planck Institute for Human 
Development, Berlin, Germany. Additional contributions (e.g., equipment, logistics, 
personnel) are made from each of the other participating sites. 
Genome-wide SNP genotyping was performed using the "Genome-Wide Human SNP 
Array 6.0" [Affymetrix, Inc]) on the full BASE-II dataset (Bertram et al. 2014). For full 
QC and imputation procedures see (REF: PMID 26821332). Briefly, genome-wide 
imputation of unobserved genotypes was carried out on the QC’ed data using 
IMPUTE2 v2.2.2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) based on 
precompiled ‘ALL 1000G Phase1 integrated haplotypes' reference panels (December 
2013 release) [14]. A total of 27,213,648 SNPs were imputed, but only autosomal 





retained for subsequent analyses. Overall, genotype and hand grip strength data were 
available in 1,531 unrelated (i.e. IBD/IBS sharing >12.5% using –genome in PLINK1.9) 
BASE-II participants aged 60+. To calculate PCs to be used as co-variates in the 
genome-wide analyses, LD pruning was applied to pre-imputation genotype data using 
PLINK (--indep-pairwise 1500 150 0.2) resulting in 117835 SNPs. Eigenvalues and 
eigenvectors were then calculated using PLINK (–pca). Based on the resulting scree 
plot, we selected the first 10 PCs as covariates. For the actual GWAS we used 
SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html) 
v2.5.4-beta3 ( -frequentist 1 -method score -cov_names PC1 PC2 PC3 PC4 PC5 PC6 
PC7 PC8 PC9 PC10 age -cov_names sex (for combined phenotypes only)). 
 
8.1.4 B-Vitamins for the PRevention Of Osteoporotic Fractures (BPROOF) study 
The B-PROOF study is a randomized, placebo-controlled, double-blind trial that 
studied the effect of vitamin B12 and folic acid supplementation on osteoporotic 
fractures in 2,919 people of 65 years or over, and having homocysteine levels of 12-
50 µmol/L. Participants were recruited between 2008 and 2011 and followed during a 
2-3 year period (J.P. et al. 2011). Genotyping was done by using the Illumina Omni-
express array. Imputations to HRC1.1 were performed using the Michigan Imputation 
Server with standard settings. The GWAS analyses were performed using rvtest. 
 
8.1.5 Cardiovascular Health Study (CHS) 
The Cardiovascular Health Study is a population-based, prospective cohort study of 





65 years or older (Linda P. Fried et al. 1991). A cohort of 5,201 non-institutionalized 
men and women were selected and enrolled from randomly generated Medicare 
eligibility lists in 4 U.S. communities in 1989-90; an additional 687 predominantly 
African American participants were recruited and enrolled in 1992-93. Clinic 
examinations were performed at study baseline, at annual visits through 1999, and 
again in 2005-2006. Participants were contact by telephone annually between exams, 
and every 6 months after the exams ended. Multiple physical and biological tests have 
been performed, including assessment of physical function. The current analysis 
included 3,061 CHS participants of European ancestry for whom genotype and grip 
strength data were available. 
Blood samples were drawn from all participants at their baseline examination and DNA 
was subsequently extracted from available samples. Genotyping was performed at the 
General Clinical Research Center’s Phenotyping/Genotyping Laboratory at Cedars-
Sinai among CHS participants who consented to genetic testing and had DNA 
available using the Illumina 370CNV BeadChip system. CHS was approved by 
institutional review committees at each field center and individuals in the present 
analysis had available DNA and gave informed consent including consent to use of 
genetic information. 
Imputation to the HRC r1.1 2016 panel was performed on the Michigan imputation 
server. SNPs were excluded for variance on the allele dosage ≤0.01. The GWAS was 
conducted using a custom program written in R. Logistic regression models adjusted 







8.1.6 European Prospective Investigation of Cancer (EPIC) Norfolk  
The European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk 
study (https://dx.doi.org/10.22025/2019.10.105.00004) is a prospective population-
based cohort study which recruited 25,639 men and women aged 40-79 years at 
baseline between 1993 and 1998 from 35 participating general practices in Norfolk, 
UK. Individuals attended for a baseline health check including the provision of blood 
samples for concurrent and future analysis. Further health check visits have been 
conducted since the baseline visit.  Participants have contributed information about 
their diet, lifestyle and health through questionnaires and health checks over two 
decades. The Norwich Local Research Ethics Committee granted ethical approval for 
the study. All participants gave written informed consent.  Grip strength measurement 
was taken at the third (2004-2006), the fourth (2012-2016) and the fifth (2016-2018) 
health checks. To maximum the sample size, we take grip and related measures from 
a late health check visit if it is unavailable at previous visit. Related samples, ethnic 
outliers and participants whose age was less than 60 years old were excluded from 
further analysis. 
DNA has been extracted from all EPIC participants and stored blood has been 
analysed for an extensive range of classical and novel biomarkers. Samples were 
genotyped using Affymetrix Axiom array at Cambridge Genomic Services, Department 
of Pathology, University of Cambridge, UK, and samples were excluded if lower call 
rate (<95%), or heterozygosity outliers, or gender mismatch, or failed channel contrast 
(DishQC <0.82), or unusually high number of singleton genotypes, or impossible IBD 
values.  SNPs were removed if lower call rate (<95%), or MAF=0, or failed HWE (p<10-
6), or clusters failed Affymetrix SNPolisher standard tests and thresholds, or MAF 





were forwarded to imputation using HRC r1 reference panel, and using 
UK10K+1000Gp3 reference panel for additional SNPs.  
GWAS analysis was performed on 7508 participants using SNPTEST v2.5.4-beta3 (-
method newml) under an additive model with covariates age, sex, and the first 10 
principal components.   
 
8.1.7 Framingham Heart Study 
The Framingham Heart Study (FHS) is a single-site, community-based cohort study 
that was initiated in 1948 to investigate risk factors for cardiovascular disease and 
other major illnesses. The FHS includes three generations: the original cohort followed 
since 1948 (Gen1) (DAWBER and KANNEL 1966); their offspring and spouses of the 
offspring, followed since 1971 (Offspring or Gen2) (Feinleib et al. 1975); and children 
of the offspring  enrolled in 2002 (Third Generation or Gen3) (Splansky et al. 2007). 
The Original cohort enrolled 5,209 men and women who comprised two-thirds of the 
adult population then residing in Framingham, MA, USA. The Offspring cohort 
comprises 5,124 persons who have been examined about every 4 to 8 years. 
Examination 1 of the Gen3 occurred between 2002 and 2005 and involved 4,095 
participants. Offspring spouses not previously enrolled who were a biological parent 
of a Gen 3 participant were enrolled into the New Offspring Spouse cohort to complete 
family pedigrees. All cohorts continue under active surveillance. The FHS follows two 
multi-ethnic cohorts, Omni group 1 and Omni group 2 to reflect the current diversity of 





In the 1990s and early 2000s, DNA samples were collected in the Original, Offspring, 
Third Generation, and Offspring Spouse cohorts of the FHS. All individuals provided 
consent for genotyping. NHLBI funded genotyping using 550,000 SNPs (Affymetrix 
500K mapping array plus Affymetrix 50K supplemental array). Imputations were 
performed with miniMACH3 using the HRC release 1.1 reference panel for SNPs 
passing the following criteria: call rate ≥ 97%, pHWE ≥ 10-6, < 100 Mendel errors, and 
MAF ≥ 1%.  
Grip strength was recorded by trained technicians at the time of Offspring exam 7, 
exam 8 and exam 9 and Gen 3 exam 2, using a Jamar dynamometer. The maximum 
of six trials (three trial in each hand) was used. For participants with hand grip data at 
more than one examination, the first exam the individual was age 60 or older was used 
for analysis. The Boston University Medical Campus IRB approved the content of all 
examinations and participant provided informed consent at all attended exam. 
 
8.1.8 Health and Retirement Study (HRS) 
The Health Retirement Study is representative American cohort with participants over 
age 50 to monitor factors related to aging and retirement (Fisher and Ryan 2018; 
Juster and Suzman 1995). A random subset of ~26,000 participants were selected in 
three phases (phase 1 in 2006, phase 2 in 2008, and phase 3 in 2010) to collect 
biological specimen between 2006 and 2010. The DNA samples were genotyped at 
the Center for Inherited Disease Research (CIDR) on Illumina HumanOmni2.5 array, 
Phases 1-2 on HumanOmni2.5-4v1 and Phase 3 on HumanOmni2.5-8v1. Both arrays 
are designed to human genome build 37. Imputation analyses were performed using 





Genotyping data were available for 15,708 samples (6519 males and 9189 females) 
in the combined Phase 1-3 dataset.  15,454 remained after filtering related or 
duplicated samples, genotyping controls, and those with a missing call rate ≥ 2%. 
12,940 (84%) were Whites. Of which, 10,919 reached 60 years old. The grip strength 
was measured using a medley spring-type hand dynamometer. Two measurements 
were taken from each hand and the maximum at the most recent visit was used to 
conduct association analyses. Grip strength ≥ 90 kg was considered unreal and set to 
missing based on actual data distribution. Dynapenia was determined based on the 
EWGSOP or FNIH definition. 10,814 white participant (4650 males and 6164 females) 
had both genotyping and grip strength data. 3624 (34%) and 1754 (16%) met the 
EWGSOP and FNIH criteria, respectively. Women were more likely to have dynapenia 
than men by the EWGSOP (39% vs. 27%) or FNIH (18% vs. 14%). 
In genome-wide association analyses, the EWGSOP or FNIH dynapenia (low grip 
strength cut-off) was associated with SNPs, one at a time, in a linear mixed effects 
model, including additive allelic effect of the candidate SNP, sex (if not sex-specific), 
age at measurement, plus random polygenic and environment effects. The analyses 
were conducted using the BOLT-LMM version 2.2 (P.-R. Loh et al. 2015), with 
precomputed LD scores from Europeans in the 1000 Genomes.  
 
8.1.9 InCHIANTI study 
The InCHIANTI study is a population-based epidemiological study aimed at evaluating 
the factors that influence mobility in the older population living in the Chianti region in 
Tuscany, Italy. The details of the study have been previously reported (Ferrucci et al. 





Chianti (a rural area: 11,709 residents with 19.3% of the population greater than 65 
years of age), and Bagno a Ripoli (Antella village near Florence; 4,704 inhabitants, 
with 20.3% greater than 65 years of age). The participation rate was 90% (n=1453), 
and the subjects ranged between 21-102 years of age. Overnight fasted blood 
samples were for genomic DNA extraction. Maximal isometric hand grip strength was 
measured in kilograms using a hand-held dynamometer (Smith & Nephew, Agrate 
Brianza, Milan, Italy). The subject was seated in front of a bench with the tested arm 
supported on the bench and the elbow flexed to 45°. Participants were asked to 
perform the task twice with each hand, and the maximum strength attained during the 
four trials was used for the present analyses. Dynapenia was determined using the 
FNIH criteria and EWGSOP criteria. The study protocol was approved by the Italian 
National Institute of Research and Care of Aging Institutional Review and Internal 
Review Board of the National Institute for Environmental Health Sciences (NIEHS). All 
participants provided written informed consent. 
Genome-wide genotyping was conducted using Illumina Infinium HumanHap 550K 
SNP arrays (Melzer et al. 2008). Genotyping was completed for 1210 subjects with a 
sample call rate >97%, heterozygosity rates > 0.3 and correct sex specification. 
495,343 autosomal SNPs that passed quality control (MAF>1%, completeness >99%, 
HWE > 10-4) were used for imputation using as reference the Haplotype Reference 
Consortium (HRC) panel, version 1.1. The imputation was done using Minimac, and 
the process was facilitated by the Michigan Imputation server (Das et al. 2016). 
Associations between grip strength and SNP dosages was performed using logistic 
regression in PLINK 1.9, adjusting for age, sex (except sex-specific analyses), study 






8.1.10 LASA:  Longitudinal Aging Study Amsterdam 
Longitudinal Aging Study Amsterdam (LASA) is an ongoing, population-based cohort 
of individuals 55 years and older living in the Netherlands. The design and rationale is 
described elsewhere (Hoogendijk et al. 2016; Huisman et al. 2011). In short, 3017 
participants (55-84 years old) were included at baseline (1992-1993) and two 
additional cohorts were added in 2002-2003 and 2012-2013 with respectively 1002 
and 1023 participants. Follow-up visits were conducted every 3 years. Trained 
interviewers collected data on cognitive, emotional, physical and social functioning 
during a home interview. Subsequently, all participants were invited for a medical 
interview during which further diagnostic examinations were done and blood samples 
were drawn. LASA has been approved by the Medical Ethics Committee of VU 
University Medical Center. All participants gave written informed consent. 
DNA was isolated from buffy coats or full blood samples drawn at 
baseline. Genotyping was done using two arrays: Axiom-NL Array (Affymetrix Inc, 
Santa Clara, CA., USA) and Infinium Global Screening Array (GSA) (Illumina Inc, San 
Diego, CA., USA). Quality control (QC) was done separately for each array 
using Ricopili (Rapid Imputation for COnsortias PIpeLIne for GWAS), an established 
tool developed by the Psychiatric Genomics Consortium (Lam et al. 2019). After QC, 
the data was imputed using as reference the Haplotype Reference Consortium (HRC) 
panel, version 1.1 (McCarthy, Das, Kretzschmar, Delaneau, Wood, Haplotype 
Reference Consortium, et al. 2016). The imputation was done using Minimac 3, and 





Grip strength was measured during the medical interview using a dynamometer (Takei 
TKK 5001, Takei Scientific Instruments Co. Ltd., Tokyo, Japan) and it was recorded in 
the nearest 1 kg. Dynapenia was determined using the FNIH criteria and EWGSOP 
criteria. 
The analyses were performed separately per genotyping array and were adjusted for 
age, sex (except sex-specific analyses), 10 principal components and cohort (for the 
GSA array). Logistic regression in Plink v.1.9 was used. 
 
8.1.11 Long-Life Family Study 
The Long Life Family Study is a multi- centre international study on the genetics and 
familial components of exceptional survival. Between 2006 to 2009, LLFS successfully 
enrolled and rigorously phenotyped probands, their siblings, and children of families 
demonstrating exceptional survival (4,953 individuals from 539 families; N=1727 
probands; 3226 offspring). LLFS includes: Field centres at Boston University, 
Columbia University, University of Pittsburgh, and University of Southern Denmark, at 
Laboratory Core (University of Minnesota) and a Coordinating Center (Washington 
University in St. Louis). In brief, the LLFS recruited selected families with multiple 
exceptionally old living individuals, the probands were ≥79 years old in the USA, and 
≥90 years old in Denmark. Families were selected to participate in the study based on 
The Family Longevity Selection Score (FLoSS) (Sebastiani et al. 2009) which 
calculated the rank sibships by current age or age at death of siblings, the size of the 
sibship and the number of alive individuals available for study. A proband's family was 
eligible if the FLoSS reached a score of 7 or higher, which met the following criteria: 





family size of 3) were all able to give informed consent, and (2) were willing to 
participate in the interview and examination including the blood sample for serum and 
DNA extraction. The age of the 3359 participants who were aged 60 years and older 
with valid grip strength and genotyped data in the current analyses was: 77.6 ± 12.9 
(range: 60-110). 
Grip strength was measured using a JAMAR® hand-held dynamometer (Sammos 
Preston Rolyan, Bolingbrook, IL). Two trials for each were conducted, and the 
maximum value for the strongest hand was used in analyses. 
Genotype data were produced on 4,716 of the consented LLFS subjects using the 
Illumina 2.5 million HumanOmni array, with the purpose of utilizing them in genome-
wide association (GWA) analyses. Genotypes were called using Bead Studio. LLFS 
QC of the genotypes included using the package GRR (Graphical Representation of 
Relationships)(Abecasis et al. 2001) to check familial relationships and sample 
switches based on Identity-by-State genotypes. Corrections to familial relationships 
were made as warranted by the data.  After GRR, additional QC included removing 18 
samples with autosomal call rates less than 97.5%, leaving 4,693 (4,597 with EU 
ancestry) subjects for further analysis.  To determine and exclude outliers with respect 
to ancestral population, we generated principle components (PCs) with smartpca2016 
(Price et al. 2006) from 112,639 Tag SNPs in 4,597 (of 4,693) LLFS samples of 
European Ancestry and included 2,504 haplotypes from 1000 genomes Cosmopolitan 
panel to support ancestral clustering.  18 additional individuals of the 4,597 samples 
with EU ancestry were identified as PCs outliers and removed prior to imputation.  





PCA outliers) with excess heterozygosity, i.e. heterozygosity > median + 3*IQR, 
thereby leaving 4,577 samples for imputation.   
SNP QC included using Loki (Heath 1997) to identify all Mendel errors in SNPs among 
families. 3,647 SNPs were identified as outliers with respect to total number of 
detected Mendelian errors and were excluded. All other genotype calls resulting in 
Mendel errors were set to missing, which occurred 153,363 times in our data. SNPs 
with a call rate lower than 98% were also excluded (n=83,774; 1,188 of these were 
also Mendelian outlier SNPs). Applying both the call rate and Mendelian error criteria, 
86,233 autosomal SNPs were removed, leaving 2,225,478 SNPs in the cleaned 
genotyped data passing QC criteria. 
From the SNPs that passed LLFS QC procedures, we applied the following criteria, 
per the MI server, to ensure the highest quality imputation. The imputation ‘scaffold’ 
for the MI server included SNPs from our cleaned genotyped SNPs (n=2,225,478) 
which met the following additional criteria: 1) Hardy-Weinberg equilibrium (p>=1E-06); 
2) No allele mismatch when compared with 1000HG; 3) No position mismatch when 
compared with 1000HG (e.g. assembly GRCh37); 4) No association with known 
inversions between GRCh37 and GRCh38 (identified by order reversal between rs-
named SNPs in b138 and b144 from NCBI annotation downloads); and 5) 
Monomorphic markers. 
The cleaned binary files (one for each chromosome) were then uploaded to the 
imputation server for pre-phasing and imputation in VCF format (after bgzip and tabix 
in the UNIX environment).  The final number of clean autosomal SNPs used for 
imputation was 1,559,272. Autosomal Imputation was performed on the Michigan 





simultaneous jobs).  The reference panel used was HRC r1.1 2016, phasing was 
performed with Eagle v2.3, population was set to EUR., and the mode option 
employed quality control and imputation. 
GWAS was done using R package GENESIS via Bioconductor. The protocol in 
GENESIS is to first fit a null model without genotype data, which adjusts the outcome 
based on the covariates, principal components, and family correlations (GENESIS 
function ‘fitNullModel’). Genetic relatedness matrix is established using sample of 
independent genotyped SNPs, then specified as the covariance matrix in the mixed 
model. Population stratification is adjusted for by a set of principal components specific 
to the outcome, which are derived from the same sample of independent SNPs. This 
data is then used in SNP association tests (GENESIS function ‘assocTestSingle’), so 
that the mixed models only need to be run once. Tests were adjusted for Age, sex (if 
combined sex analysis), field centre, principal components (for population 
stratification). Betas, SEs, and Odds ratios were separately calculated from the Score 


















8.1.12 MrOS (Osteoporotic Fractures in Men) study 
The Osteoporotic Fractures in Men (MrOS) study is a multicenter, prospective study 
including older men in Sweden, Hong Kong and the United States. The MrOS Sweden 
study (n=3014) consists of three sub-cohorts from three different Swedish cities 
(n=1005 in Malmö, n=1010 in Gothenburg, and n=999 in Uppsala) (Mellström et al. 
2006). Study subjects (men aged 69 to 81 years) were randomly identified using 
national population registers.  A total of 45% of the subjects who were contacted 
participated in the study. To be eligible for the study, the subjects had to be able to 
walk without assistance, provide self-reported data, and sign an informed consent. 
The study was approved by the ethics committees at the Universities of Gothenburg, 
Lund, and Uppsala. Informed consent was obtained from all study participants. In this 
study 941 unrelated participants from Gothenburg and 891 unrelated participants from 
Malmö were included. 
A Jamar® hydraulic hand dynamometer (5030J1, Jackson, MI, USA), with adjustable 
handgrip, was used in the grip strength test. Participants were made to sit in a standard 
chair with the arm resting on a moveable table with the dynamometer in an upright 
position. Two trials were performed on each hand. The better of the two results 
(presented as kilograms of force) was used in the analyses. Grip strength was not 
measured if the subject had current arthritis or pain in the wrist or hand or had 
undergone fusion, arthroplasty, tendon repair, synovectomy or related surgery of the 






Genotyping, imputation and quality controls of MrOS Gothenburg were performed 
using the Illumina HumanOmni1_Quad_v1-0 B array. Genotypes were called using 
the Illumina’s BeadStudio calling algorithm. The sample quality control exclusion 
criteria were sample call rate < 97%, excessive autosomal heterozygozity, first and 
second degree relatives, genotypic sex mismatch using X and Y chromosome probe 
intensities and gross chromosome abnormalities. Genotyped SNPs with GenTrain 
scores <0.6, cluster separation scores <0.4, call rates <97%, or MAF <0.01 were 
excluded. Also, autosomal SNPs with Hardy-Weinberg Equilibrium P-value <10-4 
were excluded and genotype clusters for SNPs on chrX, chrY, chrXY and chrMT were 
reviewed manually. 714543 autosomal SNPs passed quality control.  
Genotyping, imputation and quality controls of MrOS Malmö were performed using the 
HumanOmniExpress-12v1_B build 36. The sample quality control exclusion criteria 
were sample call rate < 97.5%, missing data, excessive autosomal heterozygozity, 
familiar relationship (one sample excluded), genotypic sex mismatch, non-caucasians 
and gross chromosome abnormalities. SNPs with call rates<95% were excluded. 
725409 autosomal SNPs passed quality control. 
The genotype data for both MrOS Gothenburg and MrOS Malmö were pre-phased first 
without a reference panel, using SHAPEIT2. The imputation was done using Sanger 
Imputation Service to the Haplotype Reference Consortium release 1.1. 
Associations between grip strength and SNP dosages were obtained using logistic 






8.1.13 ROSMAP: the Religious Orders Study (ROS) and Memory and Aging Project 
(MAP) 
The ROS, started in 1994, enrolled Catholic priests, nuns, and brothers, from about 
40 groups in 12 states (A. Bennett et al. 2012). The follow-up rate of survivors exceeds 
90%. Participants were free of known dementia at enrollment, agreed to annual clinical 
evaluations, and signed both an informed consent and an Anatomic Gift Act form 
donating their brains at time of death. Participants take a neuropsychological test 
battery. DNA was extracted from whole blood, lymphocytes, or frozen post-mortem 
brain tissue. Genotyping was performed at the Broad Institute’s Center for Genotyping 
and the Translational Genomics Research Institute and the Children's Hospital of 
Philadelphia.  
The Rush Memory and Aging Project, started in 1997, enrolled older men and women 
from assisted living facilities in the Chicago area with no evidence on dementia at 
baseline (A. Bennett et al. 2012). The follow-up rate of survivors exceeds 90%. 
Participants agreed to annual clinical evaluations, and signed both an informed 
consent and an Anatomic Gift Act form donating their brains at time of death. 
Participants were invited to take a neuropsychological test battery. DNA was extracted 
from whole blood, lymphocytes, or frozen postmortem brain tissue. Genotyping was 
performed at the Broad Institute’s Center for Genotyping and the Translational 






8.1.14 Rotterdam Study 
The Rotterdam Study is an ongoing prospective population-based cohort that 
investigates occurrence, determinants, and consequences of diseases in an ageing 
population (Ikram et al. 2017). The first baseline measurement of Rotterdam Study 
started in 1990. After two expansions in 2000 and 2006, it comprised 14,926 
participants aged 45 years and over by the end of 2008. Follow-up visits were held 
every 3-5 years. The Rotterdam Study has been approved by the Medical Ethics 
Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch 
Ministry of Health, Welfare and Sport. All participants provided written informed 
consent to participate in the study and to have their information obtained from treating 
physicians. Imputations to HRC1.1 were performed using the Michigan Imputation 
Server with standard settings (McCarthy, Das, Kretzschmar, Delaneau, Wood, 
Marchini, et al. 2016; Das et al. 2016).  
 
8.1.15 Study of Health in Pomerania (SHIP) 
The Study of Health in Pomerania (SHIP) is a population-based project in West 
Pomerania, the north-east area of Germany (Volzke et al. 2011). A sample from the 
population aged 20 to 79 years was drawn from population registries. First, the three 
cities of the region (with 17,076 to 65,977 inhabitants) and the 12 towns (with 1,516 to 
3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with less than 
1,500 inhabitants), were drawn at random. Second, from each of the selected 
communities, subjects were drawn at random, proportional to the population size of 
each community and stratified by age and gender. Only individuals with German 





were sampled, with 292 persons of each gender in each of the twelve five-year age 
strata. In order to minimize drop-outs by migration or death, subjects were selected in 
two waves. The net sample (without migrated or deceased persons) comprised 6,267 
eligible subjects. Selected persons received a maximum of three written invitations. In 
case of non-response, letters were followed by a phone call or by home visits if contact 
by phone was not possible. The SHIP population finally comprised 4,308 participants 
(corresponding to a final response of 68.8%). The medical ethics committee of the 
University of Greifswald approved the study protocol, and oral and written informed 
consents were obtained from each of the study participants. Handgrip strength was 
assessed in the second five-year follow-up of the study (SHIP-2) and used for this 
project. 
Non-fasting blood samples were drawn from the cubital vein in the supine position. 
The samples were taken between 07:00 AM and 04:00 PM, and serum aliquots were 
prepared for immediate analysis and for storage at -80 °C in the Integrated Research 
Biobank (Liconic, Liechtenstein). The SHIP samples were genotyped using the 
Affymetrix Genome-Wide Human SNP Array 6.0. Hybridisation of genomic DNA was 
done in accordance with the manufacturer’s standard recommendations. Genetic data 
were stored using the database Caché (InterSystems). Genotypes were determined 
using the Birdseed2 clustering algorithm. For quality control purposes, several control 
samples where added. On the chip level, only subjects with a genotyping rate on QC 
probesets (QC callrate) of at least 86% were included. Finally, all arrays had a sample 
callrate > 92%. The overall genotyping efficiency of the GWA was 98.55 %. Imputation 
of genotypes was performed using the HRCv1.1 reference panel and the Eagle and 
minimac3 software implemented in the Michigan Imputation Server for pre-phasing 





<0.0001, a call rate <0.95, and monomorphic SNPs were removed before imputation. 
The GWAS were performed sex-stratified using EPACTS-3.2.6-patched adjusting for 
age, the (two) handgrip measurement devices, and the first 10 genetic principal 
components. 
 
8.1.16 Toledo Study for Healthy Aging (TSHA) 
Data were taken from the Toledo Study for Healthy Aging, a population-based study 
conducted on 2,488 individuals aged 65 years and older. Study participants were 
selected by a two-stage random sampling from the municipal census of Toledo, 
covering both institutionalized and community dwelling persons from rural and urban 
settings. Data were collected from 2006 to 2009, and included information on social 
support, activities of daily living, comorbidity, physical activity, quality of life, 
depressive symptoms, and cognitive function. In addition, a nurse collected 
anthropometric data, conducted tests of physical performance (walk speed, upper and 
lower extremities strength, and the stand-and-sit from a chair test) and obtained a 
blood sample. The diagnosis of the frailty syndrome was based on the Fried criteria 
(weakness, low speed, low physical activity, exhaustion, and weight loss). For this 
analysis, participants from the second wave of data collection 2013 – 2015 were 
included. 
Genotyping was performing using Illumina Infinium Global Screening Array. The call 
rate was 0.98, 3.4% of the sample presented a call rate lower than 95% and were 
excluded from the analysis. Imputation Panel: HRC (Version r1.1 2016) using 
Michigan Imputation Server. GWAS was performed using SNPTEST logistic 






8.1.17 UK Biobank (UKB) 
Between 2006 and 2010, 503,325 volunteers (aged 40 to 70 years old) were recruited 
from across the United Kingdom to the UK Biobank study. Genetic data was available 
on 488,377 UK Biobank participants after genotype calling and quality control 
performed centrally by the UK Biobank team (Bycroft et al. 2018). We selected 
451,447 participants identified as ‘white European’ through self-report and verified 
through principal components analysis based on genotypes. Briefly, principal 
components were generated in the 1000 Genomes Cohort using high-confidence 
SNPs to obtain their individual loadings. These loadings were then used to project all 
of the UK Biobank samples into the same principal component space and individuals 
were then clustered using principal components 1 to 4 (see (Thompson et al. 2019b) 
for details). Imputation of 39,235,157 genetic variants from the Haplotype Reference 
Consortium panel was performed using IMPUTE4 centrally by the UK Biobank team 
(Bycroft et al. 2018). After filtering for variants with MAF ≥0.1%, missingness <1.5%, 
imputation quality >0.1 and with Hardy-Weinberg equilibrium (HWE) P>1x10-6 within 
the European-descent participants 11,516,125 imputed autosomal variants were 
eligible for the analyses. We used BOLT-LMM v2.3.2 to model the associations 
between imputed variants (dosages) and each phenotype (P.-R. Loh et al. 2015) using 
LD Score provided with the package for European populations. Although this means 
we have not used a logistic regression model, this approach has the advantage that 
the linear mixed effects model approach robustly accounts for relatedness and 






8.1.18 Wisconsin Longitudinal Study (WLS) 
The Wisconsin Longitudinal Study (WLS) is a one-third sample of all 1957 Wisconsin 
high school graduates and a randomly selected sibling (Herd, Carr, and Roan 2014). 
These respondents were originally empaneled with an in-person questionnaire at age 
18 (1957), which was followed with a mail survey of parents in 1964, telephone survey 
in 1975, mail and telephone surveys in 1993 and 2004 and in-person interviews in 
2011, where data on grip strength was collected from participants. The WLS has a 
high response rate, exceeding 80 percent in most rounds of data collection. Between 
In 2006-11, the WLS collected saliva samples from respondents using Oragene kits 
(Rylander-Rudqvist 2006). After quality control, a total of 9,012 graduate and sibling 
respondents were genotyped at ~710,000 markers (before imputation) utilizing the 
Omni-Express beadchip. Genotyping was complete at Johns Hopkins’ Center for 
Inherited Disease Research (CIDR) and data cleaning was performed in collaboration 
with the Genetic Analysis Center at the University of Washington. The detailed 
procedures employed to generate the genetic data are available on the WLS website 
(https://www.ssc.wisc.edu/wlsresearch/documentation/GWAS). Genotype imputation 
using the Haplotype Reference Consortium (HRC) v1.1 panel was performed.  
In the sample aged 60 or over at grip assessment (n=7,190) BOLT-LMM was used to 
model associations between the imputation variants and low grip strength phenotypes. 
Covariates used were age at grip strength measurement, age at DNA collection, 10 
principal components, and sex. 
WLS Data, documentation and other material are accessible at 







8.1.19 GWAS meta-analysis methods 
Each cohort used the optimum GWAS method available at the time. Most used logistic 
regression models or equivalent to derive Odds Ratios. Some (HRS, UK Biobank and 
WLS) were able to use BOLT-LMM to maximise discovery power by including all 
related participants (appropriate adjustment made in the Linear Mixed Model methods 
but larger sample sizes are required for the method to be robust). While BOLT-LMM 
was developed for quantitative traits, it can be used for binary traits as long as they 
are sufficiently balanced (cases >10% of sample) (P. R. Loh et al. 2018). We therefore 
converted the regression coefficients from BOLT-LMM to Odds Ratios using a method 
published by Lloyd-Jones in 2018 (Lloyd-Jones et al. 2018a) prior to meta-analysis. 
This method uses the genetic effect (the beta), allele frequency, and sample 
prevalence to estimate the Odds Ratio from the Beta. We used the published R 
function to perform the transformation from the HRS, UK Biobank and WLS results 
(https://github.com/lukelloydjones/ORShiny/blob/master/shiny_lmor_func.R). Finally, 
inverse variance-weighted meta-analysis with genomic control was performed by 















8.1.20 Supplementary Figures 2A-O: LocusZoom plots for the 15 EWGSOP low grip 
loci 
The LocusZoom online tool (http://locuszoom.org) was used to plot the regions around 
the 15 loci (panels A to O) significantly (p<5*10-8) associated with low grip strength in 











Figure 8-3: rs143384 (chr20:34025756) 
 
 




























Figure 8-8:  rs34464763 (chr12:15032860) 
 













Figure 8-11: rs958685 (chr2:70703847) 
 
 






Figure 8-13: rs79723785 (chr19:55818225) 
 







Figure 8-15: rs8061064 (chr16:53912364) 
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ARIC 650 289 217 134 2,025 1,630 3,655 
BASE-II 55 19 5 4 779 752 1,531 
BPROOF 328 145 137 64 1,244 1,275 2,519 
CHS 601 201 231 88 1,855 1,206 3,061 
EPIC-Norfolk 926 503 326 219 3,962 3,546 7,508 
FHS 400 142 153 60 1,461 1,245 2,706 
HRS 2,380 1,244 1,089 665 6,164 4,650 10,814 
InCHIANTI 162 75 90 48 458 361 819 
LASA I 121 77 43 37 249 255 504 





Long Life Family Study 824 586 446 397 1,788 1,571 3,359 
MrOS Gothenburg 0 35 0 10 0 941 941 
MrOS Malmo 0 29 0 12 0 891 891 
ROSMAP 1 661 198 346 129 1,096 473 1,569 
ROSMAP 2 197 48 108 32 266 95 361 
Rotterdam Study I 511 234 253 121 853 587 1,440 
Rotterdam Study II 273 137 121 58 684 565 1,249 
Rotterdam Study III 146 86 41 36 844 640 1,484 
SHIP 96 35 43 8 523 513 1,036 
TSHA 844 447 525 316 1,218 882 2,100 
UK Biobank 24,229 8,807 8,966 3,941 105,597 94,968 200,565 
WLS 993 585 393 319 3,770 3,420 7,190 
Total 34,589 14,007 13,601 6,734 135,468 121,055 256,523 
 
EWGSOP total= 48,596 FNIH total= 20,335 





        
Table 8-2: ICD-10 and UK Biobank self-reported codes used in sensitivity analysis 
Condition UK Biobank self-reported 
fields 
ICD-10 codes OPCS codes N 
Osteoarthritis 1465 M15.0; M15.1; M15.2; M15.9; 
M16.0; M16.1; M17.0; M17.1; 
M18.0; M18.1; M19.0 
O18*; W40*; W41*; W42*; W37*; 
W38*; W39*; W46*; W47*; 
W48*; W93*; W94*; W95* 
29,380 
Rheumatoid arthritis 1464 M05; M06   3,263 
Rhizarthrosis    M18; M180; M181; M182; M183; 
M184; M185; M189 
  355 
Osteoporosis 1309 M80; M81   6,308 







Any autoimmune condition 1234; 1522; 1428; 1464; 1381; 
1313; 1382; 1261; 1456; 1463; 
1477; 1453; 11222 
D69*; D758; D141; D862; E271; 
E05; E051; E063; E100; E101; 
E102; E103; E104; E105; E106; 
E107; E108; E109; G35; G737; 
G70*; H30*; K900; K510; K512; 
K513; K514; K515; K518; K519; 
L40; L400; L401; L402; L403; 
L404; L405; L408; L409; L12*; 
L10*; L511; M023; M0230; 
M0236; M0239; M028; M0281; 
M0284; M0285; M0286; M0287; 
M029; M0290; M0293; M0294; 
M0295; M0296; M0297; M0299; 
M06*; M320; M321; M328; 
M329; M45; M350; M30*; M34*; 
M352 
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